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Abstract 
Age-related  macular  degeneration  (AMD)  is  the  most  common  cause  of  irreversible 
blindness in people over the age of 50 in the developed world. Inflammation has a central 
role in the pathobiology of AMD; complement pathway dysfunction is thought to induce 
significant damage to macular cells, leading to atrophy, degeneration and the elaboration of 
choroidal neovascular membranes. The complement component 2 (C2) and complement 
factor B (CFB) genes are among several loci implicated though basic biology and genetic 
association studies in playing a significant role in determining susceptibility to AMD. The 
precise manner by which these genes affect AMD risk is unclear and largely theoretical. 
The  purpose  of  this  study  was  to  examine  the  potential  role  of  C2/CFB  polymorphic 
genetic loci in determining the clinical severity of AMD and the manifestation of different 
AMD  subphenotypes.  Specifically,  it  was  hypothesised  that  the  C2/CFB  genes  are 
associated  with  AMD  severity,  independent  of  known  AMD  risk  factors  such  as  the 
complement  factor  H  (CFH)  Y402H  polymorphism,  smoking,  and  other  plausible 
covariates. 
This research forms part of, and contributed greatly to, the  WA Macular Degeneration 
Study  (WAMDS);  a  cross-sectional  clinic-based  case  series  of  1013  AMD  cases 
comprising  675  choroidal  neovascularisation  (CNV)  patients,  71  geographic  atrophy 
patients, and 267 “early” (Age-Related Eye Disease Study [AREDS] grades 1-3) patients. 
Case-control analyses of subphenotypes utilised either or both of the geographic atrophy 
and early AMD subsets as „controls‟. All participants were existing patients of the Lions 
Eye Institute Elsie Gadd Eye Clinic in Nedlands, Western Australia. 4 
 
DNA  samples  were  genotyped  for  C2/CFB  using  a  haplotype-tagging  set  of  19  single 
nucleotide polymorphisms (SNPs) to capture 78% of the common variation in these genes. 
Additionally, the DNA samples were also genotyped for the CFH Y402H variant. AMD 
severity was graded according to the AREDS scale by ophthalmologists upon review of 
fundus  photographs.  Smoking  and  other  relevant  environmental/medical  histories  were 
collected via a comprehensive questionnaire. The multivariate associations of tagging SNPs 
and AMD phenotypes were tested. 
Significant associations between C2/CFB genetic variants and AMD subphenotypes were 
observed. The rs7746553 (P = 0.04), rs3020644 (P = 0.008) and rs4151657 (P = 0.02) 
variants were associated with neovascular AMD; rs7746553 was also associated with legal 
blindness (P = 0.04). The rs2072633 (P = 0.002), rs1048709 (P = 0.005) and rs537160  
(P = 0.002) variants were associated with neovascular lesion composition. Models were 
adjusted for appropriate covariates and CFH Y402H, and all P values were adjusted for 
multiple testing.  
These  results  support  the  hypothesis,  suggesting  that  C2/CFB  genetic  variants  are 
associated with altered/compromised functioning of the alternative complement pathway 
and with a concomitant increased risk of developing more severe AMD independent of the 
CFH Y402H variant. Additionally, in establishing this study, I and my collaborators have 
created a comprehensive and useful resource for current and future AMD research. 
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Glossary 
Allele: One of two or more alternative forms of a gene located at the corresponding site of 
homologous chromosomes  
Association:  The  statistical  association  of  an  allele  with  a  phenotypic  trait.  Statistical 
dependence between two or more events, characteristics, or other variables. 
Bias: Deviation of results or inferences from the truth, or processes leading to such 
deviation. 
Bonferroni correction: A multiple test correction method. The false-positive rate is 
divided by the number of tests, and this modified number is used to declare any single 
change to be significant. 
Candidate Gene: A sequenced gene of previously unknown function that, because of its 
chromosomal  position  or  some  other  property,  becomes  a  candidate  for  a  particular 
function such as disease determination. 
Chromosome: A linear end-to-end arrangement of genes and other DNA, sometimes with 
associated protein and RNA. 
Complex Genetic Disorder: A disease that involves several genetic and environmental 
factors, and which does not exhibit a classic Mendelian pattern of inheritance. 
Confounding variable (confounder): An additional variable that may be responsible 
for an apparent association between a genotype and a phenotype. 
Covariate: A potentially confounding variable controlled for in analysis of 23 
 
covariance. 
Exon: The region of a gene that is present in the final mRNA transcript. 
Genome: The total complement of DNA carried by an individual. 
Haplotype: A group of nearby alleles that are inherited together. 
Hardy-Weinberg equilibrium: The stable frequency distribution of genotypes A/A, 
A/a, and a/a, in the proportions p
2, 2pq, and q
2, respectively (where p and q are the 
frequencies of the alleles A and a), that is a consequence of random mating in the 
absence of mutation, migration, natural selection, or drift. 
Heritability: The proportion of population variance in a trait attributable to 
segregation of a gene or genes. 
Heterozygous: Having two different alleles at a specific autosomal (or X chromosome 
in a female) gene locus. 
Homozygous: Having two identical alleles at a specific autosomal (or X chromosome 
in a female) gene locus. 
Intron: A non-coding sequence of DNA that is initially copied into RNA but is spliced 
out of the final RNA transcript. 
Linkage: The tendency for genes that are located close to each other on the same 
chromosome to be inherited together. 
Linkage disequilibrium: Two alleles at different loci that occur together within an 24 
 
individual more often than would be predicted by random chance. Also called 
population allelic association. 
Locus: Any genomic site, whether functional or not, that can be mapped through 
formal genetic analysis. 
Marker: A segment of DNA with an identifiable physical location on a chromosome 
and whose inheritance can be followed. 
Meta-analysis: A method for combining the results from several independent studies 
of the same outcome so that an overall P value may be determined. 
Molecular genetics: The study of the molecular processes underlying gene structure 
and function. 
Monogenic: Controlled by or associated with a single gene. 
Oligonucleotide: Short sequence of single-stranded DNA or RNA. 
P value: The probability of observing a result as extreme as or more extreme than the 
one actually observed from chance alone (i.e. if the null hypothesis is true). 
Pathophysiology: Derangement of function seen in disease. 
Phenotype: The clinical presentation or expression of a specific gene or genes, 
environmental factors, or both. 
Polygenic: Pertaining to the combined action of alleles of more than one gene. 
Polymerase chain reaction (PCR): A method for amplifying specific DNA segments that 
exploits certain features of DNA replication.  25 
 
Polymorphism: A common variation (>1%) in the sequence of DNA among 
individuals. 
Population stratification: Occurs when cases and controls have different allele 
frequencies attributable to diversity in background population, unrelated to outcome 
status. A potential confounding factor in genetic association studies. 
Power: The ability of a study to detect an actual effect or difference. 
Primer: An oligonucleotide sequence used in a polymerase chain reaction. 
Probe: Defines a nucleic acid segment that can be used to identify specific DNA 
molecules bearing the complementary sequence. 
Promoter: The part of a gene that contains the information to turn the gene on or off. 
The process of transcription is initiated at the promoter. 
Recombination: The exchange of genetic material between homologous 
chromosomes during meiosis, producing a combination of alleles at two distinct loci. 26 
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Chapter 1: Introduction 
Age-related  macular  degeneration  (AMD)  is  the  principal  cause  of  registered  legal 
blindness in those aged over 65 years in the United States of America, Western Europe, 
Australia and Japan.
2-4  AMD is characterised by progressive destruction of the retina‟s 
central region (macula), causing central field vision loss.
5 A variety of pathological changes 
in the macula of an affected eye can lead to visual disturbances, and in more extreme cases, 
loss of central vision.
5 AMD is often a diagnosis of exclusion as the diverse symptoms seen 
in AMD cases are also found in many other conditions.
5, 6 The internal diversity of AMD 
phenotypes  creates  further  uncertainty  when  considering  the  condition  as  a  discrete 
disease.
6  
Possibly the most appropriate and modern working definition of AMD is that described by 
Edwards and Malek:
6 
“AMD is a clinical phenotype. It is the typical appearance of a constellation of findings 
observed in the outer retina and choroid that is used to define the presence and severity of 
disease. AMD may or may not be a single disease. Indeed, the breadth of criteria used to 
define  the  phenotype  in  a  study  can  have  a  major  impact  on  the  number  of  different 
diseases included in a group of “AMD patients”. A working definition of AMD might be a 
maculopathy characterised by the variable presence and extent of subretinal deposits called 
drusen with or without evidence of damage to the underlying retinal pigment epithelium.”
6 
This definition captures the many diagnostic uncertainties that must be considered when 
studying AMD, uncertainties that may be resolved as research progresses. 32 
 
Adopting  Edwards  and  Malek‟s  definition,
6  AMD  is  a  clinical  phenotype  used  for  a 
collection of symptoms observed in the outer retina and choroid layers that cause visual 
disturbance  and  vision  loss  in  the  elderly.
6  These  signs  are  loosely  grouped  into 
subphenotypes; early AMD (often referred to as age-related maculopathy), and two types of 
late AMD, neovascular and atrophic.
5 The diagnosis of AMD rests on signs in the macula, 
irrespective of visual acuity.
5  AMD can be defined in a number of ways, depending on the 
hypothesis and focus of study.
5 For simplicity, it is often referred to as if it is one disease 
alone, which is potentially misleading.
6 It is still difficult to determine whether AMD and 
its  various  forms  are  one  discrete  disease,  or  several  diseases  with  various  different 
mechanisms.
6  The  only  known  common  denominator  between  all  cases  is  age,  thus 
research is being conducted in many countries in an attempt to elucidate the genetic and 
environmental factors involved.
3, 4, 7-47 33 
 
 
Chapter 2: Literature Review 
2.1  The Macula 
 
 
 
 
 
 
 
 
 
 
 
The macula (Figure 2. 1) is formally known as the macula lutea, meaning „yellow spot‟, 
but for practical purposes this is usually truncated. A circular region of the retina situated at 
the  back  of  the  eye,  the  macula  contains  the  highest  concentration  of  rod  and  cone 
photoreceptor cells, responsible for detecting light and colour respectively. The macula 
converges into the fovea, a small avascular depression in the middle of the macular region. 
Traversing from the outer regions of the macula to the fovea in the centre, there is an 
increase in photoreceptors and a decrease in vascularity; and a corresponding increase in 
visual  clarity.  The  smooth  surface  of  the  macula  and  the  fovea  required  for  detailed 
resolution is achieved by the distinct lack of blood vessels in the region. The macula and its 
Figure 2. 1: A section of the human eye showing the location of the macula
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large population of photoreceptors thus rely on a fragile and sensitive exchange of oxygen 
and wastes with the choroid layer via Bruch‟s membrane (Figure 2. 2). This offers a likely 
explanation of why the macular region of the retina is largely affected in AMD, as opposed 
to the entire retina. The macula may be likened to a canary in a coal mine; it is sensitive to 
changes in oxygen levels, and should there be a disturbance in oxygen supply, the macula is 
the first to show signs of hypoxic stress.  
 
 
 
 
 
 
 
There are two main theories to explain why the macula in particular is affected in AMD 
rather than other areas of the retina. Firstly, the gene expression patterns in the macula may 
differ significantly from those seen in non-macular retinal areas, resulting in different levels 
of  certain  gene  products.  Secondly,  the  physiological  differences  in  the  structure  and 
composition of the macula compared to the rest of the retina may cause a predisposition to 
pathological  changes  such  as  those  seen  in  AMD.  An  exploration  of  these  hypotheses 
follows, with supporting evidence provided where available.  
Figure  2.  2:  The  cross-sectional  layout  of  the  macular  portion  of  the  retina  is 
illustrated,  and  the  exchange  of  oxygen  and  waste  between  the  retinal  pigment 
epithelium (RPE) and the choroid layer via Bruch’s membrane is shown. 35 
 
2.2  General Physiology and Biochemistry 
When  investigating  any  disease,  and  especially  a  complex  disease  such  as  AMD,  it  is 
important  to  do  so  in  context  of  the  function  and  physiology  of  tissues  involved.  An 
understanding of biochemistry and differential expression of key species is also crucial. 
This section will explore the function, physiology and biochemistry of relevant tissues, 
with particular focus on the macula. Elucidation of differences between the macula and the 
more distal regions of the retina may help us understand why AMD primarily affects the 
macula, and to theorise the possible causes of AMD. 
The  combined  cooperative  layers  of  the  retinal  pigment  epithelium  (RPE),  Bruch‟s 
membrane and the choroid (Figure 2. 3) are referred to as Ruysch‟s complex, where all of 
the pathological effects of AMD take place. Bruch‟s membrane is a thin semi-permeable 
membrane between the choroid and the RPE, and is the site of oxygen and waste exchange 
between  the  blood  supply  and  the  RPE  cells.  It  is  here,  on  the  surface  of  Bruch‟s 
membrane,  debris  accumulations  called  drusen  form  in  AMD  sufferers.  Drusen  are 
discussed in further detail in section 2.5. As Bruch‟s membrane is simply an inert semi-
permeable barrier between the RPE and the choroid, the latter two structures will be the 
focus of further discussion. 36 
 
 
 
 
 
 
 
 
 
 
The Retinal Pigment Epithelium 
The RPE is a central element in the pathogenesis of AMD.
48 It is a post-mitotic, cuboidal 
monolayer of cells with a very high metabolic rate.
48 The RPE cell derives its name from 
the numerous melanosomes within its cytoplasm.
48 Of the 10 known functions of the RPE, 
the  most  important  are  regeneration  of  bleached  visual  pigments;  formation  and 
maintenance  of  two  extracellular  matrixes,  the  interphotoreceptor  matrix  and  Bruch‟s 
membrane; transport of fluids and ions between photoreceptors and the choriocapillaris; 
and phagocytosis.
48  
A pivotal function of the RPE is the regeneration of the visual pigment rhodopsin.
48 The 
absorption  of  light  by  rhodopsin  creates  a  visual  signal  and  results  in  a  change  in  the 
molecule that necessitates the reconstitution of dark-adapted visual pigment.
48 This process 
Figure 2. 3: Cross sectional illustration of a normal retina, centred on the fovea and 
macula.  37 
 
occurs largely within the RPE through many complex intermediate steps.
48 One of them 
entails RPE65, an enzyme that converts all-trans retinyl esters into 11-cis retinal, which is 
essential for the function of rods and cones.
49 
The RPE is a phagocytic system that is essential for the renewal of photoreceptors.
48 Each 
photoreceptor has an inner and outer segment, separated by an invagination, the connecting 
cilium.
48 The outer segment of each rod has about 1000 disks,
50 and the outer segment of 
every cone has a membrane that is folded 700 times, stacked like a roll of coins.
48 The disks 
are necessary for the conversion of light into electrical potentials.
48 In each disc membrane, 
the transmembrane protein rhodopsin is positioned in combination with four phospholipids 
and docosahaxanoic acid.
51 The tips of both types of photoreceptors are shed from their 
outer segments and engulfed and degraded within the RPE.
52 The shedding is balanced by 
the addition of membranes at the base of the outer segments of rods and the replacement of 
nucleic acids, proteins, and lipid throughout the cones.
48  In the rhesus monkey, about 3000 
disks are shed daily from 30 photoreceptors in each RPE cell.
53 These shed disks fuse with 
lysosomes,  forming  phagolysosomes.
48  The  contents  of  the  phagolysosomes  are 
incompletely degraded within acid lysosomal compartments and form the residual bodies 
that are the substrates for lipofuscin formation.
48 
The Choroid 
The choroid layer hosts the blood supply for the retina, seemingly paradoxically high in the 
peripheral regions of the retina and low in the critical regions of the macula and fovea. As 
inconvenient as this trend is, it serves the function of maintaining a smooth RPE surface as 
required for detailed vision. 38 
 
 
Figure 2. 4: Comparison between young and aging RPE cells.
48 
 
Figure 2. 4 Legend: RPE cell in a 3-year-old child (left-hand panel) and an 80-year-old person 
(right-hand panel). 
The outer segments of the rods and cones are embedded in the interphotoreceptor matrix (blue-gray 
areas) and partially surrounded by apical pseudopodial RPE processes (APRP). The shed disks 
(right-hand panel) become encapsulated in the phagosomes and are digested in phagolysosomes in 
the cell cytoplasm of the RPE. Macrophages and fused macrophages (giant cells) remove cellular 
debris  around  the  cell.  Light-induced  toxicity  occurs  as  light  is  absorbed  by  the  various 
chromophores  in  the  lipofuscin  granules.  This  damages  DNA  and  cell  membranes  and  causes 
inflammation  and  apoptosis.  The  right-hand  panel  shows  enlarged  lipofuscin  granules,  the 
thickened Bruch‟s membrane, and the attenuation of the choriocapillaris. The central elastic lamina 
in Bruch‟s membrane becomes more porous in old age. Figure and legend reproduced and adapted 
from de Jong et al..
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Figure 2. 4 illustrates common age-related differences between the retina of a young child 
and an elderly individual. The changes observed are particularly critical in the macula due 
to the higher concentration of photoreceptors. 
Differential Gene Expression in the Macula 
The molecular basis for the macula‟s  predisposition  to  degenerative disease is  still  not 
understood.
54  Radeke  et  al.
54  examined  the  molecular  basis  for  the  macula‟s  disease 
susceptibility by comparing the gene expression profile of the human RPE/choroid in the 
macula with the profile in the extramacular region using DNA microarrays.
54 Significant 
differences  in  gene  expression  were  found  in  genes  related  to  inflammation  (CCL19, 
CCL26, CXCL14, SLIT2), angiogenesis (CXCL14, SLIT2, TFP12, WFDC1), extracellular 
matrix components (DCN, MYOC, OGN, SMOC2, TFP12) and an RPE cell growth factor 
(TFP12) .
54 All of these processes are highly relevant to AMD pathogenesis.
54 With the 
possible exception of CX3CR1,
55 none of the genes associated with any type of macular 
degeneration were shown to be differentially expressed in the macula.
54 
Differential Physiology of the Macula 
The  macula‟s  predisposition  to  degenerative  disease  may  be  attributable  to  specialised 
structural features and/or functional properties of the underlying macular RPE/choroid and 
Bruch‟s membrane.
56 Chong et al.
56 found a significant difference in the thickness and 
elastic integrity of Bruch‟s membrane between extra-macular regions of low susceptibility 
to degeneration and macular regions with high susceptibility to degeneration, such that the 
differences in Bruch‟s membrane could be used to delineate the entire macular region.
56 40 
 
 One obvious distinction between the macula and extramacular regions is the difference in 
retinal organisation and photoreceptor distribution.
54  Accordingly, it has been suggested 
that the cone-rich macula may be subjected to elevated levels of oxidative stress, resulting 
in increased susceptibility to degeneration.
54  An alternative explanation for the macula‟s 
susceptibility may lie in the adjacent RPE/choroid, the anatomical location where the early 
histopathologic signs of degeneration are first recognised.
54 Although not as striking as in 
the  retina,  there  are  significant  differences  between  the  macular  and  extramacular 
RPE/choroid.
54 These include a substantially higher macular RPE cell density,
57 smaller 
calibre and higher density of choroidal capillaries
58 and a thinner and less dense elastic 
layer within Bruch‟s membrane.
56 
2.3  Visual disturbances 
Visual  disturbances  experienced  by  AMD  sufferers  can  range  from  slight  distortion  of 
shapes  and  colours,  to  blind  spots  and  large  areas  of  vision  loss,  qualifying  for  legal 
blindness.  These visual defects affect the central vision rather than the peripheral vision, 
though some AMD treatments such as laser therapy may sacrifice some peripheral vision in 
an attempt to preserve central vision. 41 
 
   
 
Figure 2. 5 a): An image as seen by an individual with normal healthy vision; b) An 
example of the visual distortion that may be experienced by an individual with AMD
5942 
 
 
2.4  Classification and Nomenclature 
The  stages  of  AMD  are  categorised  as  early,  in  which  visual  symptoms  are 
inconspicuous,
60  and  late,  in  which  severe  loss  of  vision  is  usual.
48  Early  AMD  is 
characterised  by  drusen  (described  in  the  following  section  dealing  with  AMD 
subphenotypes) or by hyper-pigmentations or small hypo-pigmentations, without visible 
choroidal vessels.
5  
Seven  out  of  eight  people  who  develop  sub-clinical  AMD  (early  drusen)  will  not 
experience visual impairment and will not progress to late stage AMD. The one remaining 
person  will  progress  to  late  stage  AMD,  but  as  yet  it  is  difficult  to  predict  when  the 
progression will occur, what type of late stage symptoms will present, and to which person.  
Late stage AMD generally results in progressive visual distortion and loss of central vision, 
caused by retinal bleeds, drusen, and resulting central scotomas. A central scotoma is an 
area of depressed vision that corresponds with the point of fixation and interferes with 
central vision. Presence of a central scotoma suggests a lesion between the optic nerve head 
and the chiasm. Other more complex consequences of AMD can include thickening of 
Bruch‟s membrane and hypoxia due to drusen coverage. 
The  characteristic  late  stage  symptoms  (geographic  atrophy  and  choroidal 
neovascularisation) that define each AMD subphenotype are quite different and distinctive, 
with drusen being the major overlapping symptom connecting the two. However, many 
individuals appear to have symptoms of both neovascular and atrophic AMD (sometimes 
even in the same eye) and numerous cases appear to be atrophic AMD yet later progress to 43 
 
the  neovascular  form,  and  likewise  with  neovascular  forms  becoming  atrophic.
48  This 
interesting behaviour makes it difficult to elucidate the relationship between the two forms 
of  AMD,  and  creates  confusion  over  appropriate  classifications  to  use  when  studying 
AMD.
61  AMD symptoms can often resemble other retinal diseases and conditions (for 
example,  ocular  trauma,  retinal  detachment,  high  myopia,  chorioretinal  infective  or 
inflammatory process, choroidal dystrophy, etc), and for this reason, AMD is a diagnosis of 
exclusion.
5  
Under  superceded  and  less  useful  definitions,  any  AMD  case  that  lacked  choroidal 
neovascularisation would often be classified as atrophic AMD. Only some of these cases 
would  progress  to  late  stage  atrophic  AMD,  while  some  developed  neovascular  AMD 
symptoms and would thus be reclassified. The new definition of subphenotypes classifies 
all cases with choroidal neovascularisation as neovascular AMD, geographic atrophy as 
atrophic AMD, and all remaining AMD cases as early AMD.
62 
In  general,  the  nomenclature  of  AMD  reflects  some  uncertainty  surrounding  the 
classification of the disease(s) and its various manifestations.
3,  13,  18,  19,  58,  63-68 The term 
“Aging Macular Disorder” was coined because the word “degeneration” was thought to 
cause distress to many patients told of their diagnosis. Frequently, the term “Age-Related 
Maculopathy (ARM)” is used to refer to either all cases of AMD, or early stage (often sub-
clinical)  AMD.
5  The  extension  of  this  term  to  “Age-Related  Macular  Degeneration 
(ARMD)” is usually used to describe late stage disease, involving geographic atrophy or 
choroidal neovascularisation and noticeable visual impairment. Another term that may be 
used for AMD in clinical settings is “senile macular degeneration”
63 but this term is largely 
considered  archaic  and  derogatory  to  the  patients;  thus  it  may  be  commonly  found  in 44 
 
doctors‟ notes but rarely spoken. In this review I will refer to all forms of the disease as 
“AMD”, and will specify early/late stage, neovascular/atrophic subphenotypes, and other 
features as applicable.  45 
 
2.5  AMD Subphenotypes 
2.5.1  Early AMD 
A clinical hallmark of early AMD is the presence of drusen, localised deposits of debris 
found between the basement membrane of the RPE and Bruch‟s epithelium in the layers of 
the retina.
69 The origin of drusen has remained undetermined for over a century.
70, 71 There 
is  still disagreement  as  to  whether drusen in  the absence of other ocular abnormalities 
always  point  to  early  AMD.
72,  73  The  debris  is  thought  to  be  derived  from  the 
photoreceptors (photoreceptor derived debris, or PDD).  
 
 
 
 
 
 
 
Figure 2. 6: Cross section of the retina, displaying the location of drusen.
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Figure 2. 7: a) Soft drusen as seen in colour fundus photography. b) Hard drusen as 
seen in colour fundus photography.
74 
Drusen are typically clustered in the central macula (Figure 2. 7).
75 Early drusen appear as 
semi-translucent  punctuate  dots  in  retroillumination,
75  only  visible  by  ophthalmoscopy 
when their diameter exceeds 25µm.
72 The larger the drusen, the greater area they cover, and 
the larger the areas of  hyperpigmentation and  hypopigmentation of the retinal  pigment 
epithelium (RPE), the higher the risk of late AMD.
8 
 Clinically, there are two main types of drusen; hard drusen and soft drusen. Hard drusen 
are considered to be normal hallmarks of age, while soft drusen tend to be indicative of 
AMD. The main morphologic distinction between hard and soft drusen is size; hard drusen 
are  usually  less  than  63µm  in  diameter,  while  soft  drusen  are  generally  larger  with 
indistinct edges. Hard drusen are pinpoint yellow-white spots 
75 which appear as window 
defects on fluorescein angiography. Soft drusen have a tendency to become confluent as 
they grow larger, a distinctive feature setting soft drusen apart from hard drusen.  
In  small  numbers,  hard  drusen  are  not  considered  risk  factors  for  the  development  of 
AMD,
72  but  numerous  hard  drusen  are  an  independent  risk  factor  for  visual  loss  from 47 
 
AMD.
76  With  increasing  age,  drusen  can  become  calcified  or  filled  with  cholesterol, 
appearing  crystalline  or  polychromatic.
75  Extensive  drusen  can  lead  to  more  serious 
complications such as localised detachment of the RPE which causes significant vision loss 
and requires emergency surgery.  
Drusen  are  usually  the  earliest  sign  to  appear  in  both  atrophic  and  neovascular  AMD. 
However, drusen are common in aging individuals, and the majority of those with drusen 
will not progress to late stage AMD. Small drusen may not noticeably affect vision and, as 
drusen develop relatively slowly, AMD is often not detected in the early phases. Most early 
cases  of AMD  are detected by optometrists  often before the patient  has  noticed visual 
disturbance.  
There is currently no known effective treatment for drusen, largely due to their nature and 
location. Preventing their formation would be the most ideal option, but currently the most 
widely available therapeutic option, a vitamin supplement, can potentially offer a reduction 
in the rate of AMD progression. 
2.5.2  Atrophic AMD 
Thinning of the retina, known as geographic atrophy (GA), is  the defining hallmark of 
atrophic AMD. Technically, GA refers to confluent areas (defined as 175µm in minimum 
diameter)  of  retinal  pigment  epithelium  (RPE)  cell  death  accompanied  by  overlying 
photoreceptor atrophy.
77 Often it develops in the parafoveal region, sparing the fovea until 
late in  the disease, and is  bilateral  in  more than half of the patients.
7,  77-81 Geographic 
atrophy can develop in many situations; following the fading of drusen, in an area of RPE 
attenuation,  following  flattening  of  a  RPE  detachment,  or  involution  of  choroidal 48 
 
neovascularisation  (CNV).
75  The  visible  atrophy  is  usually  accompanied  by  atrophic 
underlying  choriocapillaris,
82,  83  and  large  areas  of  atrophy  reveal  underlying  choroidal 
blood vessels seen ophthalmoscopically or angiographically. Areas of geographic atrophy 
are characterised by diffuse, irregular patches of increased autofluorescence, which precede 
the development and enlargement of geographic atrophy.
84 
Historically,  patients  with  GA  were  not  considered  to  be  at  risk  for  developing  CNV. 
However, Green et al. showed a 34% incidence of GA in a histopathologic study of patients 
with CNV.
85 Geographic atrophy and CNV both tend to develop in patients with large 
drusen and pigmentary  changes.
86,  87 CNV can  sometimes conceal  an  atrophic process, 
making it difficult to distinguish.
75 GA leads to gradual progression of vision loss, most 
likely because photoreceptors overlying areas of RPE atrophy are metabolically dependant 
on RPE cells.
75 Atrophic AMD and early AMD combined make up 90% of AMD cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 8: Geographic atrophy as seen in a colour fundus photograph of an atrophic 
AMD retina. 49 
 
2.5.3 Neovascular AMD 
The defining feature of neovascular AMD is CNV, the growth of new blood vessels in the 
choroid layer beneath the macula. The blood vessels not only distort the smooth surface of 
the retinal pigment epithelium, they also have a tendency to leak and bleed into subretinal 
layers and in extreme cases into the vitreous space. The subretinal presence of the vessels 
alone can often be sufficient to distort vision by creating irregularities in the smooth surface 
of the RPE above, especially when present beneath the fovea. Subretinal haemorrhages are 
often classified as emergency situations, as the bleeding can lead to acute and intractable 
blindness  if  not  stemmed  quickly.  Neovascular  AMD  can  cause  rapid  vision  loss  and 
potential  complications  such  as  retinal  detachment  and  RPE  tears.  The  aftermath  of  a 
haemorrhage often takes the form of a disciform scar.  
 
Figure 2. 9: Cross section of wet AMD retina, showing location of CNV-related 
haemorrhage
88 
 50 
 
Neovascular AMD is less common than atrophic and early AMD, accounting for only 10% 
of  all  AMD  cases.  However,  neovascular  AMD  patients  are  often  overrepresented  at 
ophthalmic  clinics  due  to  the  acuteness  and  relative  severity  of  this  subphenotype, 
accounting for 90% of AMD related legal blindness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.4  Bilateralism 
The  symptoms  of  AMD  exhibit  varying  degrees  of  bilateralism,  complicating  the 
classification,  diagnosis  and  treatment  of  the  disease.  The  Blue  Mountains  Study 
89 
produced a variety of statistics on the bilateralism of the study population‟s AMD signs. 
The percentage of bilateralism indicates, out of those with a particular subphenotype, the 
proportion of individuals who have that subphenotype in both eyes.  
Early  (subclinical)  AMD  showed  80%  bilateralism,  while  the  clinical  forms  of  AMD 
exhibited 57% bilateralism.
89 The specific clinical signs ranged from high to low bilateral 
Figure 2. 10: A small haemorrhage as seen in colour fundus photography of a 
neovascular AMD retina. 51 
 
prevalence; from reticular drusen and indistinct soft drusen at 91% and 79% bilateralism 
respectively, to hypopigmentation and hyperpigmentation at 28% and 38% respectively.
89 
The more severe late stage AMD symptoms of geographic atrophy and neovascularisation 
showed moderate levels of bilateralism at 56% and 40% repectively, along with distinct 
soft drusen at 47% bilateralism.
89  
Wang et al.
89 found a consistent increase in bilateral occurrences with age for most lesions, 
and all lesions except soft drusen were found to be more bilateral in women, once the data 
were  adjusted  for  confounding  factors.
89  There  was  also  an  observed  increase  in  age-
adjusted risk of AMD blindness in women, possibly due to the increased bilateralism of 
lesions in women.
89 Finally, a reported family history of AMD was found more frequently 
amongst bilateral cases.
89 
Knowledge of bilateral tendencies is significant in understanding the aetiology of AMD and 
enabling  more  accurate  classification  of  the  subphenotypes.  Furthermore,  the  ability  to 
predict the likelihood of AMD lesions developing in a patient‟s presently unaffected eye is 
useful in determining the correct course of treatment and support required for that patient.  
2.6  Current Treatments for AMD 
There  is  no  known  cure  for  AMD,  and  treatments  currently  available  are  focused  on 
treatment/prevention  of  choroidal  neovascularisation  (CNV).  Recently  a  greater  public 
awareness of AMD has led to earlier presentation and diagnoses, providing the opportunity 
to reduce the chance of haemorrhage in CNV cases through preventative treatments. Two 
types of laser therapy are frequently used; a thermal laser can be used to cauterise and 
destroy the new blood vessels, while photodynamic therapy (PDT) involves the injection of 52 
 
a chemical that becomes solid when hit with a laser, also destroying the blood vessels and 
stemming the leakage. A third type of treatment recently developed is the use of anti-
vascular endothelial growth factor (anti-VEGF) injections. Anti-VEGF is thought to slow 
or  prevent  the  growth  of  new  blood  vessels  by  antagonising  the  VEGF  protein  that  is 
responsible for encouraging new blood vessel growth. These treatments are discussed in 
greater detail below. 
Prior to 1999, the only proven treatment for subfoveal exudation in AMD was thermal laser 
photocoagulation,  which  was  advocated  to  stop  the  progression  of  vision  loss  in  this 
disease.
90, 91 Thermal laser coagulates new choroidal vessels at the cost of destroying the 
overlying  sensory  retina  and  creating  an  absolute  central  scotoma.
90  In  addition,  a 
significant fraction of patients treated with thermal laser for neovascular AMD
92 develop 
persistent or recurrent neovascularisation after laser photocoagulation,
91 a regrettable trend 
which has been observed in subjects with high-risk drusen in several large randomised 
control trials.
93, 94 Due to the undesirable collateral effects of the thermal laser treatment its 
use is currently limited to treating small extrafoveal CNV lesions.  
The need for a new CNV treatment approach was met first with photodynamic therapy 
(PDT) using verteporfin. This treatment is performed by injecting a photosensitizing dye 
(verteporfin)  intravenously,  followed  by  application  of  focused  light  to  the  area  of 
subretinal neovascularisation under direct visualisation. Photodynamic therapy reduces the 
rate of visual loss in patients with subfoveal choroidal neovascularisation but does not lead 
to significant visual improvement in most individuals.
95, 96 These limitations have led to the 
investigation  of  alternative  treatment  modes  for  subfoveal  neovascular  AMD,  such  as 
systemic interferon,
97, 98 brachytherapy,
99, 100 subfoveal membranectomy with and without 53 
 
RPE transplantation or translocation,
101-104 macular translocation
105 and pharmacological 
therapy with intravitreal triamcinolone
106 and posterior juxtascleral subTenon‟s anecortave 
acetate.
74 
The most significant advances in the management of neovascular AMD have come from 
the  recent  development  of  anti-VEGF  drugs,  such  as  the  the  anti-VEGF  aptamer 
pegaptanib, which was the first anti-VEGF compound approved for use for neovascular 
AMD, the anti-VEGF antibody fragment ranibizumab, and the widespread off-label use of 
intravitreal  bevacizumab  which  has  met  with  some  success  in  controlling 
neovascularisation in neovascular AMD as well as diabetic retinopathy and sequelae of 
central and branch retinal vein occlusions. 
Photodynamic  therapy  has  recently  been  supplemented  by  intravitreal  injection  of 
triamcinolone, which has been shown to decrease the frequency of PDT treatments. PDT or 
intravitreal injection of pharmacological agents aim to obliterate new choroidal vessels, 
inhibit their growth, cause their regression, or simply decrease plasma leakage from the 
neovascular tissue. These treatments are more effective if applied early in the course of the 
disease, and multiple treatment sessions are required to maintain continued effect. 
The anti-VEGF drug is administered via intravitreal injection to an eye deemed suitable for 
the  treatment  by  an  ophthalmologist.  Anti-VEGF  performs,  as  its  name  suggests,  by 
antagonising VEGF in the eye and thus reducing the opportunity for new blood vessels to 
grow in the retina. Unfortunately, this treatment is quite expensive and does not have a 
permanent lasting effect. Anti-VEGF must be re-administered every few weeks for best 
results in staving off blood vessel growth.  54 
 
Despite the significant advances in the management of neovascular AMD, there is a large 
unmet need for many patients who have already lost vision from this condition. More than 
50% of patients do not respond to anti-VEGF therapy, and many patients with advanced 
disease have loss of vision due to scar formation and altered cellular architecture in the 
subretinal space.
107 For these individuals, pharmacological therapy alone cannot improve 
vision significantly without reconstitution of normal subretinal architecture. These cases 
require  maculoplasty,  defined  as  reconstruction  of  macular  anatomy  in  patients  with 
advanced  vision  loss  due  to  neovascular  AMD.
108  Maculoplasty  borrows  from  many 
surgical techniques developed for managing extreme cases of AMD, and is currently too 
expensive and difficult for widespread use. Maculoplasty remains largely an experimental 
treatment, along with implantable mini-telescopes and other innovations on the horizon.  
Serious  haemorrhages  resulting  from  CNV  can  be  sometimes  treated  with  emergency 
surgery  to  stem  bleeding,  repair  any  torn  or  detached  RPE,  and  remove  excess  blood. 
However, many haemorrhages go unaddressed; in some cases the blood is removed by the 
immune system with minimal lasting impact on vision, while other cases may result in a 
disciform scar and a corresponding area of lost vision.  
Meanwhile, the most accessible, least invasive and widely used treatment is nutritional 
supplementation, incorporating antioxidants, lutein, zinc, beta carotene and a wide range of 
vitamins.  There is some modest evidence of efficacy; the most promising result thus far for 
use of antioxidants and/or zinc is reduced risk of disease progression of between 17% to 
25% when compared with placebos.
109 However, the actual  benefit  of  some nutritional 
supplements is a controversial issue due to funding partnerships with companies who have 
a vested interest in the outcomes. The mechanism of protection by antioxidants remains a 55 
 
hypothesis only, and the side effects of the above supplements in high doses for extended 
periods of time remains unknown.
110  In the absence of any other suitable treatment for an 
AMD case (particularly atrophic AMD cases), a dietary supplement is recommended. It is 
of vital importance that the patient is educated and monitored to ensure that a correct, safe 
dosage is taken and that the particular supplement combination will not harm their health; 
for example, beta carotene is an unwise recommendation for a smoker.
111-113  
Many AMD cases go untreated due to the lack of proven treatments for many facets of the 
condition. For atrophic AMD patients in particular, management of the condition involves 
yearly or biennial consultations with an ophthalmologist to essentially monitor for any new 
clinical signs (often neovascular changes) that may be treated by existing methods.  
Ultimately, an ideal treatment regime would involve prediagnosis of the condition before it 
manifests, and gene/drug therapy along with appropriate lifestyle changes to prevent the 
appearance  of  the  clinical  signs.  Current  research  is  essentially  directed  at  identifying 
appropriate  targets  for  such  treatments,  whilst  continuing  to  improve  current  treatment 
modes to benefit the AMD patients for whom prevention therapy will be too late. 
2.7  Incidence and Prevalence of AMD 
AMD is a leading global cause of vision loss and blindness.
37, 114-116 AMD prevalence has 
been  studied  in  population-based  samples  in  multiple  countries,  but  differences  in 
diagnostic  procedures  and  definitions  of  early  disease  make  it  difficult  to  compare  the 
overall prevalence in different populations. Fortunately the definition of late stage AMD 
(characterised by  geographic atrophy and/or choroidal  neovascularisation) is  reasonably 56 
 
universal, with prevalence estimated at 1.2-1.8% in the global population and increasing 
exponentially after the age of 70.
117, 118   
The age-weighted prevalence of AMD in Australia is shown in Figure 2. 11. Meta-analyses 
of prevalence studies in western countries have suggested that women experience slightly 
greater risks of all AMD types, even when adjusted for age.
30, 114, 115 However, this could 
possibly be explained by differential survival rates between men and women with AMD.
115 
The  incidence  of  vision  impairing  AMD  cases  in  Australia  was  estimated  to  be 
approximately 50,000 in 2005.
119 The number of people with AMD with any form/stage of 
AMD is predicted to reach 800,000 by the year 2025.
120 The vast majority of these 800,000 
cases will not progress to visually impairing stages of AMD, but as yet it is impossible to 
predict which cases will progress and which will not.
119  
The  prevalence  of  late-stage  AMD  and  early  AMD  in  the  American  population  were 
reported at 1.47% and 6.12% respectively.
114 Taking into account the trend of increasing 
life expectancies, the number of late stage AMD cases in America is predicted to increase 
from 1.75 million to 3 million by the year 2020.
114 
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Figure 2.8: Age-weighted prevalence of AMD in Australia 
Image taken from Access Economics (2006) 
 
The incidence of clinically significant AMD in Australia is currently about 50,000 cases 
and is expected to double or treble by the year 2025.
119 The number of people with any 
stage of AMD (including early stages not affecting vision) is predicted to reach 800,000 by 
the year 2025.
119 The vast majority of these cases will not progress to visually impairing 
stages  of  AMD,  yet  the  determinants  for  this  progression  are  currently  unknown. 
Discovering these factors may make it possible to delay or prevent progression of AMD in 
susceptible individuals. 
 
 
Figure 2. 11: Age-weighted prevalence of AMD in Australia. 58 
 
2.8  Impact of AMD 
 
Vision is a dominant sense in determining how we perceive our environment, and as such 
vision loss is feared more than any other impairment. The ramifications of AMD may be far 
reaching in the daily life of a sufferer. It is difficult to immediately appreciate the level of 
disability experienced by an individual due to the varying patterns of visual disturbance and 
blindness,  and  the  effects  of  common  coexisting  conditions  such  as  cataracts,  myopia, 
hyperopia and astigmatism. AMD patients can range from having perfect vision (usually in 
mild or early cases) to being declared legally blind. The consequences described in this 
commentary relate largely to severe or late stage AMD, but may also be experienced to 
some degree by those with milder AMD.  
The  inability  to  read  and  drive  is  devastating  to  AMD  sufferers,  particularly  those  of 
working age. Premature retirement and the resulting loss of income restricts the level of 
independence the individual can maintain. Inability to drive also restricts the individual‟s 
freedom substantially. The AMD sufferer may become dependent on others such as family, 
friends  and  professional  carers  for  transport,  and  assistance  with  managing  finances, 
personal hygiene standards, health conditions, nutrition and other personal matters. 
The  distortion  and  loss  of  central  vision  can  have  a  highly  detrimental  effect  on  the 
individual‟s  social  functioning.  Inability  to  recognise  faces  and  difficulty  in  observing 
facial expressions and body language can result in awkwardness and alienation. Combined 
with hearing difficulties common in the elderly, the individual may have trouble keeping up 
to date with various media that normally help individuals maintain a level of integration 
and familiarity with current affairs.   59 
 
The  ability  to  function  socially  and  maintain  independence  is  a  key  indicator  of  an 
individual‟s  quality  of  life.  Many  studies  report  lower  quality  of  life  and  depression 
experienced  by  AMD  sufferers.
121  Vision  impaired  AMD  sufferers  frequently  require 
carers. The majority of carers are unpaid volunteers, often friends, family or members of 
charitable  organisations.
122  The  professional  carers  employed  may  be  subsidised  and/or 
provided by government welfare, specialist health insurance, or paid entirely by the patient 
in certain circumstances.
122  
It is estimated that a great deal of volunteer caring goes unrecognised as such; for example, 
family members using personal leave to obtain time off work, and dedicating substantial 
after hours time to helping the patient.
122 A volunteer carer in a situation such as this may 
feel obliged to dedicate as much time and effort as they can, often causing the carer to 
neglect their own wellbeing. Once committed, attempts to reduce the caring workload may 
be met with feelings of guilt and even criticism from others.
121 Volunteer carers are at high 
risk of being taken for granted and allowing their own livelihoods to suffer.
121 
A visually impaired person can be a burden on the resources of the family, community and 
government welfare system, thus reducing the resources available for other members of the 
family and community.
122 The development of depression in AMD sufferers and health 
problems in overworked and neglected carers further stresses the resources and vitality of 
the family and community.
122 
AMD is thought to affect two out of every three people at some stage of their lives, and 
with the increased life expectancy of modern times the disease has a substantial effect on 60 
 
society. AMD can cause early retirement, early loss of driver licenses and independence. 
This means that more people and more money are required to care for AMD sufferers.
122 
2.9  Causes of AMD 
 
The pathogenesis of AMD is still unclear; many potential risk factors have been implicated, 
but age and smoking seem to be the only definite non-genetic risk factors to date, the latter 
being  the  most  important  and  only  agreed  upon  modifiable  risk  factor.
8,  123,  124  The 
increasing prevalence of AMD  with  age has been well documented in  epidemiological 
studies.
125  Meta-analysis  of  several  large  studies  suggests  no  statistical  difference  in 
prevalence  of  AMD  between  men  and  women.
126  Controversy  exists  over  whether 
blindness  from  AMD  is  higher  in  females,  although  this  may  be  due  to  increased  life 
expectancy and over-representation of females in these studies.
127   
At present, smoking appears to be the only clear modifiable risk factor for AMD, especially 
the neovascular form.
123 Dietary fat intake appears to influence AMD risk and progression, 
as does body mass index (BMI), but more research is required to replicate and better define 
these risk parameters.
128, 129  Nutrition is another potential risk variable; the most prominent 
research on dietary supplements was conducted by the  Age-Related Eye Disease Study 
(AREDS) research group, observing a reduced rate of progression in subjects taking an 
antioxidant/zinc  supplement.
130  However,  other  studies  of  dietary  supplements  have 
returned  negative  results,  and  the  mechanism  of  protection  by  antioxidants  remains 
hypothetical at this stage. Numerous potential risk factors are still under investigation, but 61 
 
many  of  them  are  difficult  to  study  due  to  the  degree  of  close  monitoring  and  high 
participant compliance required.  
The past decade has seen the discovery of numerous genetic factors implicated in AMD 
pathogenesis, in particular, the suspected role of the complement cascade genes. Among the 
complement  family  genes  to  be  implicated  thus  far  are  complement  factor  H  (CFH), 
complement factor B (CFB), complement component 2 (C2) and complement component 3 
(C3).
131-135 Other genetic loci are still under investigation. 
2.9.1  Genetic Risk Factors 
In order to discuss the genetics of AMD, key concepts and appropriate terminology will 
first be outlined and discussed. Terms that are not defined here for brevity may be found in 
the glossary (page 22). 
 
Genetic Epidemiology  
The  discipline  of  epidemiology  is  often  defined  as  “the  study  of  the  distribution, 
determinants  [and  control]  of  health-related  states  and  events  in  populations”.  Genetic 
epidemiology  has  a  variety  of  meanings  which  depend  on  the  context.  Genetic 
epidemiology emerged in the 1960s as a discipline closely tied to genetics and traditional 
epidemiology; „a science that deals with the aetiology, distribution, and control of disease 
in  groups  of  relatives  and  of  inherited  causes  of  diseases  in  populations‟.
136  For  the 
purposes  of  this  thesis,  “genetic  epidemiology”  is  defined  as  the  study  of  genetic  and 
potentially  heritable  determinants  of  disease,  and  the  joint  effects  of  genetic  and  non-
genetic determinants.   62 
 
Complex Diseases 
AMD  is  classified  as  a  “complex  disease”.  Complex  diseases  do  not  display  classical 
Mendelian patterns of inheritance. Instead, these diseases tend to involve multiple genes 
interacting with multiple environmental factors. The rapidly advancing field of complex 
disease genetics promises to deliver new ways of preventing and treating complex diseases. 
The convenience and compliance achievable through genetic intervention may avoid the 
need for disruptive environmental intervention and at the same time provide more direct 
results.   
Recently, new technology has provided key tools for studying the genetic epidemiology of 
diseases that cannot be pinned down to a monogenic cause. The completion of the human 
genome  project  brought  about  abundant  coverage  of  the  genome  in  regions  previously 
unexplored.  Identification  of  single  nucleotide  polymorphisms  (SNPs)  throughout  the 
human genome, combined with advances in microarray technology, gives researchers the 
ability to scan informative markers across areas of the genome searching for signals that 
suggest association with a disease. When conducted across the entire human genome, this 
technique is termed a “genome-wide association study”, potentially involving 500,000 –
1,000,000 SNPs or more. On a smaller scale, a target gene may be “tagged”, selecting an 
array of HapMap SNPs that will provide the most efficient coverage of the gene and help 
pinpoint areas of interest within the gene.  This  approach utilises knowledge of linkage 
disequilibrium (LD), which is introduced and discussed later (see page 63). Finally, it is 
also possible to conduct assays of specific SNPs of interest, enabling a number of genetic 
analyses, such as association studies and linkage analyses. 63 
 
Gene Discovery Techniques 
The techniques utilised in attempting to discover the genetic determinants of a complex 
disease  vary  greatly  depending  on  existing  knowledge,  and  the  (elusive)  actual  natural 
history of the disease.  Initially, there must be a stimulus to suggest a genetic component; 
often the observation of familial aggregation, or significant disease incidence that cannot be 
attributed to known non-genetic risk factors. Almost all human diseases, with the possible 
exception of trauma, are heritable to varying degrees. Once it is established that a genetic 
risk component is likely, we can attempt to deduce the location of the responsible genetic 
variant/s using a variety of approaches. There are two major types of investigation utilised, 
which serve different purposes. Linkage analysis is used to perform a very broad, low 
resolution  search  of  the  genome  (or  large  portions  thereof),  attempting  to  estimate  the 
locations of potential disease loci. Genetic association analysis is then used to refine the 
location of these loci and theoretical nature of association with the disease.   In some cases, 
candidate  gene  hypotheses  based  on  disease  aetiology  will  also  provide  appropriate 
analytical  targets.  Once  there  is  sufficient  evidence  to  support  the  existence  and  exact 
location of a disease locus, studies may be undertaken to determine if the locus variation 
results in altered function relevant to the disease phenotype. A deeper exploration of these 
analytical approaches follows.  
Initial observations: Familial Aggregation 
The observation of familial aggregation may be the initial indication of involvement of a 
genetic component in disease causation.
137 Familial aggregation is detected when there is a 
high occurrence of a trait within a family and evidence of transmission of the trait to the 
offspring. Although familial aggregation is a necessary criterion, it alone is not sufficient to 64 
 
infer a genetic component in a disease. This is because environmental risk factors can also 
aggregate in families, leading to excessive familial risk and apparent family clustering.
137, 
138 Comparing the concordance rate in blood relatives with that in genetically unrelated 
individuals living in the same family environment can help distinguish non-genetic shared 
environmental effects from genetic effects. For this reason, studies of twins, adoptees and 
half-siblings are examples of valuable approaches in establishing the presence of a genetic 
component in disease aetiology.
137 
Mode of Inheritance: Segregation Analysis 
Once a genetically heritable disease component is identified, segregation analyses can be 
used to determine the mode of inheritance.
137 The two major patterns of inheritance are 
Mendelian, caused by the inheritance of a single mutant gene, and non-Mendelian, which is 
the result of complex interactions of multiple genes which all contribute a fraction of the 
total disease risk. Segregation analysis can assist in determining the mode of inheritance, by 
examining  disease  transmission  rates  and  the  degree  of  penetrance  in  large  pedigrees 
containing more than one affected member.
137 
Rough Mapping: Linkage Analysis 
Armed with the knowledge that a genetic component is involved in disease causation, the 
next step is to obtain an estimated chromosomal location of the gene/s of interest. For a 
relatively  rare  singe-gene  disorder  such  as  Huntington‟s  disease,  it  is  often  possible  to 
identify the gene/s directly. Linkage studies are often used at early stages of investigation in 
an attempt to narrow down the initial field of more than 30,000 human genes to a small 
chromosomal  region  containing  several  hundred  genes.
139  Linkage  is  the  key  concept 
underpinning genetic linkage studies. Two genetic loci are said to be linked if they are co-65 
 
transmitted to the offspring more often than expected under independent inheritance.
140 The 
closer  the  two  loci  are  on  the  same  chromosome,  the  smaller  the  probability  of 
recombination occurring between the two loci, and hence the greater chance of linkage.  
Linkage  analysis  allows  researchers  to  infer  the  chromosomal  location  harbouring  the 
linked disease loci, by studying the pattern of cosegregation of a disease phenotype with 
typed genetic markers through pedigrees. Unfortunately, the application of linkage analysis 
in non-Mendelian disorders has been less successful than its use in Mendelian disorders; 
this is partially due to the large study sample sizes required to achieve substantial statistical 
power to detect multiple genes each with modest effects.
140  
Fine Mapping: Genetic Association Analysis and Linkage Disequilibrium (LD) 
Whereas linkage studies are used to perform a global search of the whole genome for the 
approximate location of a disease locus in family data, fine mapping of susceptibility genes 
for  complex  disorders  at  the  population  level  requires  genetic  association  studies.  The 
concept  of  linkage  disequilibrium  (LD)  is  heavily  used  in  genetic  association  studies. 
Unlike linkage, which deals with intrafamilial cosegregation of genetic AMD marker loci, 
LD  refers  to  the  pattern  of  non-random  association  between  specific  alleles  at  the 
population level.
141 For this reason, the phenomenon of LD has also more appropriately 
been referred to as “allelic association” .
141 Linkage is thus a technique that requires family 
data, whereas LD analysis can be done using family data or unrelated individuals.  
 The set of closely associated alleles at separate loci along a single chromosome is referred 
to as a haplotype.
142 LD amongst alleles along a single chromosome in a population is 
observed  presumably  because  they  have  descended  from  a  common  ancestor,  and  are 66 
 
closely located next to each other such that no or minimal meiotic recombination events 
have occurred between them during the evolutionary history of the variants. However, LD 
decay  does  occur slowly  over successive  generations  as  more  and  more recombination 
events  occur  between  homologous  chromosomes,  thus  gradually  breaking  up  the 
correlation  between  associated  alleles.  Other  factors  which  may  influence  LD  include 
genetic drift, population growth, admixture, population structure, mutation rates and gene 
conversion.
143 
Indirect Association Studies: Haplotype Tagging 
Known  patterns  of  LD  can  be  useful  in  mapping  causal  genetic  variants  by  using  the 
indirect association approach. If a marker variant is in LD with a nearby causal variant, 
then information about the causal variant may be obtained by typing the marker variant 
alone.  This  means  that  in  a  region  of  high  LD,  most  of  the  genetic  variation  may  be 
captured with only a small set of representative genetic markers. This eliminates the need 
for  typing  every  known  genetic  variant  and  significantly  reduces  the  genotyping  costs 
compared to interrogation of a comprehensive set of SNPs. Hence, the indirect association 
method begins with scans of whole genes for disease association using firstly a set of typed 
marker variants. Once an association is detected, the search for causal genetic variants may 
then be refined to that particular region of the gene.  
SNPs are plentiful throughout the genome, making them ideal polymorphic markers to use 
in indirect association studies to enhance gene mapping on the basis of LD. As mentioned, 
a representative set of SNPs can capture most of the genetic information within a region of 
high LD. This introduces the concept of tagging, which refers to the method of selecting a 
minimum  set  of  non-redundant  tag  SNPs  that  retain  most  or  all  of  the  haplotype 67 
 
information of the full SNP set in a given genomic region. For this reason, non-redundant 
SNPs are also often referred to as haplotype-tagging SNPs, or tag SNPs. Identification of a 
representative set of tag SNPs requires extensive knowledge of the LD pattern across the 
region of interest. 
The magnitude of LD between alleles can be measured using various methods. Lewontin‟s 
D‟ and r
2 are two most frequently used measures of LD.
144 Both can take on values between 
0 and 1. Lewontin‟s D‟ is an important measure that identifies regions in which there has 
been little ancestral recombination. D‟ takes a value of 1 to signify zero recombination 
between two loci since the last mutational event, or „complete LD‟. The square of the 
conventional correlation coefficient, r
2, measures the degree of correlation between two 
alleles and takes on the value of 1 when there is perfect tagging of one to the other, or 
„perfect LD‟. By convention, the r
2 measure is used in statistical analyses to define the 
threshold for LD as it simply reflects the predictive power of a typed marker variant to 
correctly detect an unobserved causal variant. Methods of calculating D‟ and r
2 are outlined 
in Section 3.6.2.2. 
Tagging-based  SNP  selection  is  facilitated  by  databases  of  common  human  genetic 
variation such as the International HapMap Project.
145 The International HapMap Project 
allows indirect association studies to be readily designed by making available in public 
domain a map of common patterns of genetic variation across the genome using genetic 
information from subjects with African, Caucasian and Asian ancestries.
145 Availability of 
this useful resource, together with advances in high-throughput genotyping technology, has 
made genome-wide association studies possible. Most of the whole genome variation in a 68 
 
Caucasian population can now be captured and studied with approximately 300,000 well-
chosen tag SNPs.
144 
Tag SNPs are selected generally agnostic to functional annotation, but rather, on the basis 
of their capacity to capture genetic variation within a genomic region. In practical terms, 
this  means  that  any  observed  statistical  association  between  a  tag  SNP  and  a  disease 
phenotype may be due to one of three situations: 1) the association may be due to chance or 
an artifact; 2) the tag SNP itself is causal; or 3) the tag SNP may be in LD with a nearby 
true causal variant.  
Direct Association Studies: Polymorphisms in Candidate Genes 
In contrast, the direct association approach tests putatively causal variants in biologically 
plausible  genes  for  direct  correlation  with  the  disease  phenotype.  While  this  type  of 
association  study  is  most  powerful,  identification  of  candidate  polymorphisms  can  be 
difficult. In part this is due to the limited understanding of the biological functions of many 
genetic  polymorphisms.  Further,  to  search  the  entire  genome  for  all  potential  disease-
causing variants and testing each for direct association remains expensive and impractical. 
For this reason, at present the direct approach is still used only to test limited numbers of 
variants with known function. 
Comparison of Approaches 
Each  of  the  techniques  outlined  has  different  strengths  and  weaknesses,  but  when 
appropriately used in complementary combinations they allow for thorough and systematic 
investigations. Linkage studies are generally not as powerful as association studies for the 
identification of genes‟ contribution to the risk for common, complex diseases.
146 However, 69 
 
searching  the  whole  genome  in  an  association  study  requires  typing  500,000  or  more 
SNPs,
147 which can be expensive. Technological progress has resulted in the publication of 
more than ten whole-genome linkage studies
148-158 and one whole-genome association study 
of AMD.
131 
This study utilises an indirect genetic association approach, using haplotype-tagging SNPs 
to investigate the C2/CFB genes. This research complements the prior work of others, who 
selected  these  genes  as  candidates  through  a  combination  of  linkage  analysis  and  a 
plausible biological hypothesis; which were subsequently supported by direct association 
analysis  of  select  non-synonymous  SNPs  within  the  genes.  Details  of  prior  studies  are 
discussed later in the section entitled “Genetic Aetiology of AMD” (Section 2.10.2, page 
74). 
2.10  Proposed Pathogenesis of AMD 
Several hypotheses have been proposed regarding the potential pathogenesis of AMD. A 
common theme shared by most of these hypotheses is the central role of inflammation. 
Extensive data accumulated in  the last  decade  suggest  that  AMD may involve  chronic 
inflammatory processes.
159-161 Immune mechanisms and cellular interactions in AMD are 
similar to those seen in other diseases characterised by the accumulation of extracellular 
deposits such as atherosclerosis and Alzheimer‟s disease.
162 Evidence is growing that the 
complement  system  may  play  a  significant  role  in  the  pathogenesis  of  AMD.
163 
Inflammatory  and  immune-mediated  events  involving  complement  proteins  have  been 
implicated  in  the  biogenesis  of  drusen.
161  Significantly,  several  studies  have  identified 
multiple  genetic  variants  of  CFH,  a  regulator  protein  that  can  confer  elevated  risk  of 70 
 
AMD.
131-133  Furthermore,  both  risk  and  protective  haplotypes  have  been  found  in  the 
C2/CFB genes.
134 These genes are the focus of the current study. 
 
2.10.1  Inflammation and the Complement System 
The complement system (Figure 2.12) is an integral part of innate immune defence. The 
complement system comprises of a complex of at least 30 enzymes and regulators and 
provides  an  innate  immune  defence  mechanism.  The  liver  is  the  main  source  of 
complement synthesis and the complement molecules constitute approximately 5% of the 
total  serum  proteins.  Many  extrahepatic  cells  such  as  monocytes,  endothelial  cells, 
epithelial cells, glial cells, and neurons also produce complements
164 presumably as part of 
a defence mechanism, though they can be counterproductive leading to local tissue damage. 
The  complement  cascade  performs  many  essential  activities,  such  as  controlling 
inflammatory reactions  and chemotaxis,  clearing immune complexes,  cellular activation 
and antimicrobial defence.  
Three principal pathways (Figure 2.12) are involved in complement activation, all of which 
converge on the activation of C3. These are the classical pathway which is activated by 
antibody bound to antigen, the lectin pathway activated by carbohydrates and oxidative 
stress and the alternate pathway triggered by the presence of microbial pathogens, cellular 
debris or multimolecular aggregates. The convergence of these pathways to C3 initiates the 
final common pathway that results in the formation of terminal complexes such as C5b-9 
that promotes cell lysis of the target cell whether it be an invader or bystander cell exposed 
to the complement activation. Other by-products of the complement cascade such as C3b 71 
 
and anaphylatoxins (C3a, C4a and C5a) may also serve as proinflammatory polypeptides 
further amplifying the injury or inflammation. 
CFH is a key regulator in the alternate complement pathway (Figure 2.13), inhibiting the 
levels of C3b to ensure the rate of C3b deposition does not exceed the body‟s requirements 
for immunity. CFB is required for the conversion of C3b to C3bB in the alternate pathway, 
and competes with CFH at this point. It is theorised that people with a risk variant of the 
CFH gene produce a less active CFH protein, thus reducing the inhibition of the alternate 
pathway and allowing superfluous deposition of C3b. The errant deposition of C3b could 
thus trigger the damage and destruction of host cells. 
The mRNAs of a few components of the complement system such as C3 and terminal 
complement component, C5 have been identified in the retina and RPE-choroid complex of 
adult human donor eyes and cultures human RPE cells.
73,  161,  165,  166 Although they may 
serve as a protective function in innate immunity, it also suggests the presence of chronic 
low-grade  local  complement  activation  that  is  controlled  by  complement  regulatory 
proteins.
163  
Environmental  stimuli  interact  with  the  complement  cascade;  potentially  modifying  the 
outcomes further. Whilst age leads to increased levels of CFH in the plasma, smoking is 
associated with decreased levels of plasma CFH.
167 Recent research suggests that the CFH 
Y402H (T1277C genotype) polymorphism and smoking act as independent risk factors for 
AMD,  without  interaction.
168  There  is  also  evidence  that  local  infections  such  as 
Chlamydia may be a risk factor for AMD, potentially via chronic complement activation.
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Figure 2. 12: The complement system
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Complement regulatory proteins 
The complement system is regulated by both fluid phase and membrane-bound regulatory 
proteins to prevent inadvertent damage as a consequence of complement activation. Fluid 
phase  proteins,  vitronectin  and  clusterin  (apolipoprotein  J)  bind  C5b67  complement 
complexes thereby preventing cell lysis. Membrane-bound cofactor proteins (MCP, CD46), 
decay acceleration factor (DAF, CD55), membrane inhibitor of reactive cell lysis (MIRL, 
CD59),  and  complement  receptors  (CD1,  CD35)  help  in  clearance  of  soluble  immune 
complexes.
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Figure 2.13: The alternative complement pathway 
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Both  vitronectin  and  clusterin  have  been  identified  in  healthy  donor  RPE-choroid 
complex,
73,  166 indicating their role in containing proinflammatory local stimuli. The co-
precipitation of CD46 with β1 integrin in the basolateral membrane of healthy RPE cells 
suggest that this complement regulatory protein may be useful both in adhesion of RPE 
cells and in integrin-signalling pathways.
170  
The complement system attacks diseased and dysplastic cells and normally spares healthy 
cells,  protecting  against  infection.  When  C3  convertase  is  activated,  it  leads  to  the 
production of C3a and C3b and then to the terminal C5b-9 complex. CFH, on cells and in 74 
 
circulation, regulates complement activity by inhibiting the activation of C3 to C3a and 
C3b and by inactivating existing C3b. 
Various components of the complement cascade, including the C5b-9 complex, have been 
identified in the drusen of patients with AMD.
162, 165 Deposition of activated complement 
C5b-9 was noted in Bruch‟s membrane, the intercapillary pillars, and within drusen. The 
observation of complement components in drusen in both humans
162, 165 and mice
171 have 
led  to  the  hypothesis  that  AMD  results  from  an  aberrant  inflammatory  process  which 
includes inappropriate complement activation.
159 
2.10.2  The Genetic Aetiology of AMD 
Recent progress in ophthalmic genetics has contributed to the discovery of the important 
roles  of  genetic  factors  in  the  pathogenesis,  severity  and  treatment  response  of  several 
complex eye diseases, such as primary open angle glaucoma, retinitis pigmentosa, myopia, 
retinoblastoma and anterior segment disease.
172 While over 100 candidate genes for all eye 
disease (including AMD) have been investigated, only 20 or so have been shown to have 
definite causal  effects.
172  Knowledge of such  genetic variations  is  being utilised in  the 
development of new diagnostic, prognostic and treatment techniques, and future research in 
this field will no doubt fuel more constructive developments of this nature. 
It has been firmly established that genetic susceptibility plays a significant role in AMD 
aetiology, with heritability estimates suggesting a genetic contribution to disease risk of 
approximately  45%.
173  Heritability  estimates  from  a  large  US  study  of  840  twin  pairs 
showed that genetic factors accounted for 46% to 71% of the variation in AMD severity, 
whereas  environmental  factors  contributed  only  19%  to  37%  of  the  variation  in  AMD 75 
 
grade.
174 The emerging network of genetic risk factors for AMD is still incomplete, but 
research in this area is strong and has progressed rapidly over the past decade. Meanwhile, 
the  successful  identification  of  causal  genes  in  the  development  of  heritable  macular 
dystrophies,  which  have  phenotypic  similarity  to  AMD,  has  kindled  interest  in  the 
possibility that single or multiple genetic defects may also account for the development of 
AMD.  Over  the  past  few  decades,  substantial  knowledge  has  been  gained  through  the 
progressive  genetic  epidemiological  analyses  of  family-  and  population-based  data,  not 
only confirming the existence of genetic determinants in AMD but also providing a new 
stimulus  for  further  novel  investigations  into  AMD  disease  mechanisms.  A  historical 
review of research into the genetic epidemiology of AMD follows. 
Physicians  have  reported  a  family  clustering  of  patients  with  AMD  in  as  early  as  the 
1960‟s: “nearly every patient I have seen has had other members of the family similarly 
affected”.
175 Early family studies provided compelling evidence for the existence of genetic 
factors  in  AMD  aetiology.  Prevalence  of  AMD  was  found  to  be  significantly  and 
consistently higher among relatives of AMD patients,
176, 177 demonstrating aggregation of 
disease phenotype within families.  
Familial aggregation studies have compared AMD rates in relatives of cases to AMD rates 
in relatives of controls,
176-179 or evaluated concordance rates of disease characteristics in 
proband-sibling pairs versus proband-spouse pairs.
180 Seddon et al. 
176 found higher AMD 
prevalence (OR = 2.4, 95% CI 1.2 to 4.7; adjusted for age and gender) in relatives of cases 
versus  relatives  of  controls,  using  first  degree  relatives  of  119  AMD  cases  and  72 
controls.
176 Furthermore, among relatives of exudative AMD cases, the odds ratio was 3.1 
(95% CI 1.5 to 6.7).
176 Klaver et al.
177 compared siblings and offspring of 87 late AMD 76 
 
cases  with  those  of  135  control  subjects,  adjusting  for  age,  gender,  smoking  and 
atherosclerosis.
177 They found increased prevalence of early AMD for siblings (OR = 4.8, 
95% CI 1.4 to 31.8) of cases versus controls and offspring (OR = 6.6, 95% CI 1.8 to 12.2) 
of cases versus controls.
177 
Twin  studies  have  provided  more  direct  evidence  of  AMD  heritability  by  comparing 
disease concordance rates in monozygotic versus dizygotic twins.
181 Nearly all studies of 
twin pairs have found statistically significant high concordance of AMD in monozygotic 
twins and moderate concordance in dyzygotic twin pairs.
173, 182-185 Identical twin pairs have 
also been reported for having manifested severe AMD in astonishing similarity in terms of 
time of onset, degree of visual impairment and fundus appearance, strongly suggesting that 
AMD could be influenced mainly by familial and genetic factors.
186-188   
Several smaller twins studies have been conducted in the past,
182-186, 189 but the significance 
of these is dwarfed by the results of two much larger twin studies.
173, 174 The research of 
Seddon et al. on 840 elderly male twins resulted in heritability estimates of 0.46 for the 
ordinal 5 step AMD grade assignment, 0.67 for intermediate/advanced AMD, and 0.71 for 
advanced AMD only.
174 Hammond et al. evaluated 506 female twin pairs with specific 
interest in early ARM, yielding a heritability estimate of 45% for ARM and noting the most 
heritable phenotypes were soft drusen ≤ 125µm in diameter and the presence of ≥ 20 hard 
drusen.
173 
A segregation analysis of 564 families in the Beaver Dam Eye Study cohort concluded that 
the possibility of a major environmental effect can be rejected and that the results appear 
consistent with a mendelian transmission of a major gene accounting for over 50% of the 77 
 
total  variability in  AMD  grading scores.
190 These early findings  prompted a search for 
AMD susceptibility loci using the linkage study design. 
The first disease locus for AMD, chromosomal 1q25-31, was discovered in 1998 using 
linkage  analysis  in  a  multigenerational  pedigree  involving  ten  affected  members  with 
drusen and/or geographic atrophy.
191 This locus was later found to contain a gene named 
Fibulin 6 (FBNL6), also known as Hemicentin-1, which encodes for an extracellular matrix 
protein  thought  to  be  involved  in  drusen  formation.
192  In  a  similar  manner,  the  first 
putative disease locus for neovascular AMD was detected on chromosome 16p12-13 in a 
large Northern Irish pedigree.
193   
To date, more than ten genome-wide linkage studies have together identified susceptibility 
loci on almost every single chromosome,
148-158 with the strongest evidence of linkage found 
on 1q25-31 and 10q26. In-depth study of chromosome locus 10q26 revealed three genes, 
PLEKHA1, LOC387715 and PRSS11, all of which were discovered to be potentially major 
contributors to AMD susceptibility.
157  It is clear that results from genome-wide linkage 
studies have and will continue to help prioritise genomic regions for further candidate gene 
analyses in the search for causal genes in AMD. 
As recently as 2004, candidate gene studies had not found any genetic differences that 
could  account  for  a  large  proportion  of  the  overall  AMD  prevalence.
194  Family-based 
whole-genome linkage scans had identified chromosomal regions that showed evidence of 
linkage to AMD, 
148-151, 154 but the linkage areas had not been resolved to any causative 
mutations until early 2005. Investigations of candidate genes using the genetic association 
study design have had varied success. Studies of over 40 candidate genes in the past ten 78 
 
years have mostly shown negative or inconclusive findings of association with AMD.
195 
Despite the phenotypic similarities between the heritable macular dystrophies and AMD 
none  of  the  causative  genes,  such  as  VMD2  (Best  disease),  RDS  (Pattern  dystrophy), 
ABCA4  (Stargardt  disease),  ELOVL4  (autosomal  dominant  Stargardt-like  macular 
dystrophy),  EFEMP1  (dominant  drusen)  and  TIMP3  (Sorsby  fundus  dystrophy),  were 
found to be responsible for a significant percentage of AMD cases.
195, 196 Newer findings of 
genetic  association,  such  as  the  VEGF  gene  with  AMD  development,
197  are  yet  to  be 
replicated in larger studies.   
To date, CFH
131-133, 198-207 and PLEKHA1/LOC387715/PRSS11
157, 199, 206-210 are considered 
the two major susceptibility loci for AMD, for both have been most strongly associated 
with  disease  and  consistently  replicated  in  large  study  samples.  These  reside  in 
chromosomes 1q31 and 10q26 respectively, the exact sites of previously replicated linkage 
signals. The Y402H variant of the CFH gene has been associated with ORs of 2.45–3.33 
for all stages of AMD, increasing to 3.45–7.40 for the advanced stages of AMD. Similarly, 
the  rs10490924  variant  of  the  PLEKHA1/LOC387715  locus  had  been  associated  with 
significantly increased ORs of up to 8.21.  Homozygosity for risk alleles at both CFH and 
LOC387715 conferred an astounding OR of 57.6 when compared with the baseline in a 
study of over 2000 German subjects.
208 Another variant, rs11200638, within PRSS11 has 
been associated with highly increased ORs of 7.29–11.1 in homozygous Caucasian and 
Chinese subjects.
211, 212 PRSS11 is also known as HTRA1, and has recently been found to 
encode for a serine peptidase that appears to regulate the degradation of extracellular matrix 
proteoglycans. 79 
 
Recently,  studies  have  also  detected  significant  association  between  AMD  and  genes 
encoding complement factor B (CFB)
134,  213 and complement components C2
134,  213 and 
C3,
214, 215 all of which act along the same biological pathway as CFH. Given the putative 
involvement  of  the  complement  system  in  AMD  pathogenesis,  genes  which  encode 
regulatory proteins of the human complement cascade appear to be promising areas for 
study. Complement reactive protein (CRP), a nonspecific systemic inflammatory marker, is 
also a regulator of the complement pathway and has been highlighted in both observational 
epidemiological studies
117,  216,  217 and genetic association studies.
201 I review the current 
evidence supporting the involvement of C2/CFB in AMD development in the next section, 
followed by the research aims and hypotheses of this study. 
While several studies have used a genome-wide linkage approach to detect regions of the 
genome which potentially contain genes involved in the aetiology of AMD, 
148-158, 218 to 
date only one genome wide association study of AMD has been published.
131 The field of 
genes  suspected to  be involved has  been narrowed significantly in  the past  four  years. 
Initial results of the genome-wide scans pointed to areas of chromosomes 1 and 10, and to a 
lesser  extent,  to  regions  of  almost  every  other  human  chromosome. 
148-158,  218  Recent 
developments have led to the identification of specific genes such as CFH, C2/CFB and 
HTRA1/LOC387715, all thought to contain significant risk loci for AMD. The C2/CFB 
genes in particular were chosen for a candidate gene study once it became apparent that 
complement family member CFH was a locus for AMD risk.   
In the first  half of 2005, four independent  groups  almost  simultaneously  reported their 
findings detailing the role of CFH as a major risk factor in the pathogenesis of  
AMD.
131-133,  205  Various  techniques  were  used  yet  delivered  the  same  finding  in  a 80 
 
remarkable example of research convergence. Haines et al. had identified in their previous 
studies that 1q32 was harbouring a susceptibility locus for AMD, hence their approach 
involved using SNPs to interrogate the 1q32 region in two independent data sets.
132 
Numerous genes have been implicated in the development of AMD, with the most solid 
evidence  levelled  at  CFH  in  Caucasians,  followed  by  HTRA1/LOC387715  in  Asians 
particularly, and to a lesser extent, Caucasians. A further investigation into the role of other 
complement pathway genes C2 and CFB by Gold et al.
134 suggested these genes may also 
influence the development of AMD.
134 The C2 and CFB genes and their potential role in 
determining AMD subphenotypes will be the focus of this thesis. 
There are ethnic differences in AMD risk factors, and each risk factor must be examined 
carefully in multiple ethnic groups before assuming it is a generic risk factor. Each ethnic 
group may potentially tell a different story, which in turn may elucidate more obscure 
genetic risk factors implicated in many ethnicities but overshadowed in some by one or two 
seemingly more significant results.  In Caucasians the genetic causes of AMD may differ 
from the causes of AMD in Asians, such as the Japanese population. For example, the CFH 
Y402H polymorphism has been shown to be a risk factor for AMD in Caucasians, but not 
in  the  Japanese.
219  This  may  contribute  to  the  findings  in  ethnic  differences  of  AMD 
phenotypes.  Other  polymorphisms,  such  as  the  HTRA1  promoter  polymorphism  and 
LOC387715 polymorphism, appear to induce neovascular AMD risk in both Caucasians 
and the Japanese.
210, 220 The HTRA1 SNP appears to be in high linkage disequilibrium with 
the LOC387715 (also known as ARMS2, age-related maculopathy susceptibility 2) SNP; 
this warrants closer examination.
210 The opportunity presented by the Japanese population 
is  to  study  AMD  genetics  without  the  “noise”  interference  of  the  CFH  Y402H 81 
 
polymorphism that seems to contribute to a great proportion of AMD risk in Caucasian 
populations. 
The complement family genes are of particular interest, and further detail on these and 
other significant genes follows. 
Complement Component 2 and Complement Factor B  
Following the discovery that CFH haplotypes were associated with AMD, Gold et al.
134 
hypothesised that the same may be true for activators of the same pathway, such as CFB.
134 
CFB  and  C2  are  paralogous  genes  located  only  500bp  apart  on  human  chromosome 
6p21.
134 These two genes, along with genes encoding complement components 4A (C4a) 
and 4B(C4B), reside in the major histocompatibility complex (MHC) class 3 region.
134 
CFB and C2 are expressed in the neural retina, RPA, and choroid.
134  
Haplotype analyses identified a statistically significant common risk haplotype and two 
protective haplotypes in the C2/CFB genes.
134 Gold et al.
134 also found individuals at high 
risk  of  AMD  owing  to  their  CFH  genotype  who  had  not  developed  AMD  had  a  high 
frequency  of  protective  allele(s)  at  the  C2/BF  locus,  suggesting  possible  interactions 
between CFH and C2/CFB loci.
134 The hypothesised interactions between the C2, CFB and 
CFH genes and their roles in the complement cascade were described previously in the 
section entitled “Proposed Pathogenesis” (Section 2.10, page 69). 
Complement factor H  
A key regulator of the complement cascade is CFH. Recent evidence suggests that CFH 
may play a significant role in the pathogenesis of AMD.
131-133 CFH is a single polypeptide 
chain with a molecular weight of 155 kD that is present in the plasma at a concentration of 82 
 
110-615 µg/mL. It is constitutively produced by the liver. Extrahepatic synthesis of CFH 
occurs in a wide variety of cells such as lymphocytes, glomerular mesangial cells, neurons 
and  glial  cells.  In  the  context  of  AMD,  CFH  is  synthesised  in  the  RPE  cells  and 
accumulates in drusen. CFH controls the complement system in the fluid phase and on 
cellular surfaces. It inhibits the activation of C3 to C3 and C3b and also directly binds to 
C3b (Figure 2). It is a major inhibitor of the alternate complement pathway. CFH can also 
interact with polyanionic molecules sialic acid and heparin on cell surfaces conferring them 
resistance to damage induced by complement activation. It also binds to CRP which may 
help  arrest  CRP  dependent  complement  activation  induced  by  damaged  tissues.
221  The 
protein  is  composed  of  20  short  consensus  repeats  (SCR)  directed  towards  different 
fragments  C3.  The  SCR7  and  SCR  19-20  are  the  most  likely  sites  involved  in  the 
interaction  with  C3b,  heparin  and  CRP.
222  This  complement  regulatory  protein  also 
displays  functions  outside  the  complement  system  such  as  binding  to  cellular  integrin 
receptor and interaction with cell surface glycosaminoglycans.
169  
The  positive  CFH  Y402H  findings  have  since  been  replicated  in  numerous  studies  of 
Caucasian populations, but not Japanese populations. However, more recent studies have 
discovered several variations in CFH that appear to be more significant to AMD risk than 
Y402H. High linkage disequilibrium between the SNPs suggests that the apparent risk from 
Y402H may be caused by another closely linked SNP rather than Y402H itself. The CFH 
Y402H  polymorphism  potentially  causes  a  functional  difference  in  the protein
223  while 
many other CFH polymorphisms are intronic and may act by affecting expression of the 
gene  product.  The  exact  mechanism  by  which  these  variants  might  act  is  theoretical 
currently, and further research is required to support their hypothesised involvement.  83 
 
The mutational screening of the CFH gene in independent series of patient with AMD 
resulted in the identification of a polymorphism in the CFH gene. The four studies used 
distinct but complementary methods to screen the genomes from nonoverlapping groups of 
AMD patients and all the studies identified the risk allele as a tyrosine-histidine substitution 
at amino acid 402 of the CFH gene.
131-133 While studies in additional ethnic groups will be 
required, as well as prospective studies on disease risk associated with this variant, current 
data  suggest  that  a  single  histidine  allele  (heterozygous)  confers  a  two-  to  four-fold 
increased risk of developing AMD, while two histidine alleles (homozygous) confer a five- 
to seven-fold increased risk.  
ARMS2 (aka LOC387715) and HTRA1 (HtrA serine peptidase 1) 
The age-related maculopathy  susceptibility 2 (ARMS2) gene was aptly named due to a 
significant  correlation  between  the  A69S  locus  and  AMD  risk  found  recently  in  both 
Japanese and Caucasian populations.
157, 208-210 Located on chromosome 10 (10q26.13), this 
gene is located remarkably close to the HTRA1 gene (10q26.3), also under investigation as 
a significant risk factor in AMD.
220, 224, 225 The SNPs of significance in both genes appear to 
be in a state of high linkage disequilibrium with each other, warranting further analysis to 
determine which locus is primarily responsible for the observed AMD risk.
210 
DeWan et al.
211 found that a SNP in the promoter region of HTRA1 is a major genetic risk 
for neovascular AMD, applying a whole genome association mapping strategy to a Chinese 
population.
211  Individuals  with  the risk-associated  genotype were estimated to  be at  10 
times the risk of developing neovascular AMD than individuals with non-risk genotypes.
211  
It is likely that these genes will be studied in depth mostly in Asian populations, because 84 
 
the  CFH  Y402H  variant  responsible  for  much  of  the  AMD  risk  in  Caucasians  is  not 
accountable for AMD risk in Asians.
219 85 
 
2.11 Research Aims and Hypotheses 
Polymorphic genetic loci have a potential role in determining the clinical severity of AMD 
and the manifestation of different AMD subphenotypes. My hypothesis was that C2/CFB 
genes are associated with AMD severity, independent of known AMD risk factors such as 
the  complement  factor  H  (CFH)  Y402H  polymorphism,  smoking,  and  other  plausible 
covariates. 
Specifically, the aims of this project were to: 
1.  Design, establish and coordinate a human research study to collect phenotypic data 
and blood from which DNA could be obtained. Participant numbers must be large 
enough to grant sufficient statistical power to detect modest effects. All subjects 
must have AMD to best facilitate research focused on AMD severity. 
a.  Design two questionnaires; the first designed to collect patient demographics 
and  phenotypic  data  such  as  medical  history,  smoking  history  and 
anthropometric measurements; the second to collect specific clinical details 
regarding the manifestation of AMD in each subject.  
b.  Design,  construct  and  implement  data  collection,  extraction  and  storage 
solutions, with emphasis on security, confidentiality and practicality. This 
task will form part of the establishment of the Western Australian Genetic 
Epidemiology Resource (WAGER). 
2.  Select  and  genotype  a  set  of  haplotype-tagging  SNPs  to  capture  majority  of 
variation and known variants of interest across the adjacent C2 and CFB genes. 86 
 
3.    Identify  AMD  subphenotypes  of  interest  and  biologically  plausible  covariates. 
Perform  multivariate  analyses  to  determine  which  covariates  are  significantly 
associated  with  each  AMD  subphenotype,  and  construct  phenotypic  predictive 
models accordingly 
4.  Perform  univariate  analyses  of  genotyped  SNPs  and  AMD  subphenotypes  to 
identify simple associations, then perform multivariate genotypic analyses utilising 
phenotypic predictive models. 87 
 
Chapter 3: Methods 
In order to achieve the aims of this thesis, the Western Australian Macular Degeneration 
Study (WAMDS) was created, resulting in the development of a comprehensive resource 
for AMD research. The author was significantly involved in the creation of this resource, 
from planning and commencing the pilot study to cleaning data in preparation for analysis. 
I also performed the role of study coordinator throughout the first two years of the study, 
and unless otherwise specified, I was involved in every element of the study, including 
recruitment, data collection, phlebotomy, protocol design, and design and construction of 
questionnaires. The WAMDS is an excellent resource, containing thorough phenotypic and 
genotypic data on a large number of AMD cases. Since its inception, this data has formed 
the basis of several B.Med.Sci Honours theses, and is now the basis of this PhD thesis. 
3.1: Study Design 
The current study was designed as a nested case-control genetic association study within a 
clinic-based case series. Association between C2/CFB genetic variants with AMD disease 
phenotypes was assessed using an indirect genetic association approach by using an optimal 
set of C2/CFB tagging SNPs.  
3.2: Study Subjects 
Some references to key study variables and clinical terms are made in this section; it may 
be helpful  to  refer to  Section 3.6.1:  Definition of Study Variables  (page  103), and the 
Glossary (page 21). 88 
 
The  study  population  consists  of  subjects  from  the  Western  Australian  Macular 
Degeneration Study (WAMDS), overseen by Professors Ian Constable and Lyle Palmer. 
WAMDS is a case series comprising all consenting AMD patients who attended the Lions 
Eye Institute (LEI) clinic in Nedlands, Western Australia between March 2005 and August 
2007.  I assisted in establishing the study and in collecting data from the subjects described 
in this thesis. 
Patients visiting the LEI eye clinic were screened and were eligible for WAMDS if they 
had written diagnosis of AMD in their LEI medical file, or direct referral by a LEI retinal 
ophthalmologist (Prof. Ian Constable, Prof. Ian McAllister or Dr Tim Isaacs). Patients were 
examined  by  trained  ophthalmologists.    Subjects  were  excluded  if  they  (1)  had  other 
unstable bilateral eye condition; (2) had CNV due to degenerative myopia, angioid streaks, 
chorioretinal  inflammatory  disease,  hereditary  retinal  disorders  or  central  serous 
chorioretinopathy;  (3)  were  under  the  age  of  40  at  time  of  recruitment;  or  (4)  had 
inadequate hearing or low cognitive function.  
A total of 1,013 subjects aged between 41 and 98 years, recruited between March 2005 and 
August 2007, were included in the case-control analysis. The 746 late AMD patients were 
selected as “cases”, of which 71 patients had the atrophic subtype (GA) and 674 patients 
had the neovascular subtype (CNV) of late AMD. The remaining 267 early AMD patients 
formed  the  “controls”.  Participation  rates  exceeded  95%,  and  there  was  no  selective 
recruitment  bias based  on AMD type within the clinic; AMD subtype  classification of 
subjects was determined after recruitment.  89 
 
Colour fundus photographs were graded according to standardised classification systems.
5, 
205, 226 746 late (AREDS grade 4 either eye) AMD patients were selected as “cases” (mean 
age  79.8  +/-  7.6  years),  of  which  71  patients  had  the  atrophic  subtype  (GA)  and  674 
patients had the neovascular subtype (CNV) of late AMD. 267 early (AREDS grade 0-3 
both  eyes)  AMD  patients  formed  the  “controls”  (mean  age  75.2  +/-  9.8  years).  The 
difference  in  mean  age  of  the  “cases”  and  “controls”  was  statistically  significant  (P  < 
0.001), a factor taken into consideration in the multivariate models. 
Genomic DNA was  generated from peripheral  blood leukocytes using  standard phenol-
chloroform extraction. Subjects completed a comprehensive questionnaire to provide data 
on environmental exposure, medical history, cigarette smoking and other relevant factors.  
Written  informed  consent  was  obtained  from  all  participants  (Appendix  A).  The  study 
protocol and all subsequent amendments (SCGH HREC 2004-098) were approved by the 
Human Research Ethics Committee at the Sir Charles Gairdner Hospital, Perth, Western 
Australia.  
Recruitment  was  performed  by  the  author,  Caroline  Adams,  Jing  Xiao,  Judith  Willis 
Alexander Tan, Xia Ni Wu, and Irwin Kashani. Screening was performed by Ian Constable, 
Ian McAllister and Xuefeng Feng. Unless otherwise mentioned, all study protocols were 
designed/adapted and coordinated by the author. 
3.3: Data Collection 
Genotypic and phenotypic data were collected from each subject on date of consent for 
later  analysis.  These  data  took  the  form  of  blood  samples,  Snellen  visual  acuity 90 
 
measurements, colour fundus photographs (CFPs) and basic demographic information such 
as date of birth and gender.  
Sampling and data collection was coordinated by the author, assisted by research nurse 
Caroline  Adams  and  Professor  Ian  Constable.  Sample  collection  was  performed  by 
Caroline Adams, Jing Xiao, Judith Willis, Alexander Tan, Xia Ni Wu, Irwin Kashani and 
the author. 
3.3.1: Visual Acuity 
Best corrected Snellen visual acuity was recorded for all patients on the day of consent by 
experienced LEI ophthalmic nurses according to standard protocol. Eyes with severe visual 
loss due to other unstable eye disease or traumatic eye injury were excluded from analysis. 
3.3.2: Venous Blood 
A non-fasting 20 mL venous blood sample was collected from each subject by trained 
phlebotomists on the day of consent.  Blood samples were processed and stored by the 
PathWest Molecular Genetics Service, Perth, (prior to June 2006) or the WA DNA Bank 
(from June 2006 onwards) for later analysis. Laboratory methods for the processing of 
venous blood for DNA preparation can be found in Section 3.5.1. 
3.3.3: AMD Grading and Phenotyping 
CFPs were taken by experienced ophthalmic photographers Frank Shilton and Chris Barrie 
on the day of consent. Eyes were dilated using 10% Phenylephrine hydrochlorate and/or 
1.0% Tropicamide prior to fundus photography. CFPs were taken with either 1) Canon 
60UVI (Tokyo, Japan) with Canon 30D Digital Camera lens, or 2) Zeiss FF4 (Oberkochen, 
Germany) with Canon EOS IDS Mark II Digital Camera lens.  91 
 
AMD was graded for each eye on the basis of CFP findings according to a modified Age-
Related  Eye  Disease  Study  (AREDS)  classification  system  into  four  categories  of 
increasing severity (Table 3. 1). Eyes with grade 4 AMD were further recorded as either 
atrophic or neovascular.  
Table 3. 1: Definitions of AREDS AMD grades in WAMDS 
Grade  Definition 
Grade 1  Few small or no drusen. 
Grade 2  Many small or few medium drusen. 
Grade 3  Many medium drusen, or at least 1 large drusen, or non-central GA 
Grade 4 
Advanced AMD or vision loss, characterised by central GA, CNV, RPE 
detachment, haemorrhage and/or presence of a fibrous scar. 
AREDS= Age-Related Eye Disease Study; AMD= Age-Related Macular Degeneration 
WAMDS= Western Australian Macular Degeneration Study; GA= Geographic Atrophy; 
CNV= Choroidal Neovascularisation; RPE= Retinal Pigment Epithelium 
 
For  the  exploratory  analysis  of  CNV  subphenotypes,  presence  of  haemorrhage,  RPE 
detachment  and  subretinal  scar  tissue  were  recorded  from  CFPs  for  neovascular  AMD 
subjects only. CNV lesion size and composition were recorded from a retrospective review 
of initial fluorescein angiograms (FA) of all neovascular AMD subjects. This is because FA 
is an invasive procedure and was not a part of the routine data collection process for the 
current study. Method of evaluation of FAs has been described previously.
2,3,4 Where there 
was uncertainty, the cases were discussed among two senior ophthalmologists at LEI to 
obtain a consensus.  
All grading and classification was performed by ophthalmologist Dr Xuefeng Feng with 
assistance from Prof. Ian Constable and Prof Ian McAllister and without knowledge of each 
subject‟s  genotype.  All  data  was  recorded  in  specialised  diagnostic  scannable 92 
 
questionnaires (Appendix B) designed by Dr Xuefeng Feng and Prof. Ian Constable. CFP 
and  FA  images  were  managed  using  Digital  Healthcare  software  (Cambridge,  UK), 
archived to a secure server and backed up weekly. Images were also printed and stored in 
the patient‟s medical files. CFPs and FAs were examined and classified in either electronic 
or printed form.  
3.3.4: Questionnaire Data 
A detailed self-completed questionnaire (Appendix C) was used to record demographic 
information, smoking and alcohol consumption, family history of AMD, comorbidities and 
use of medications that might influence development of AMD. Each participant was given 
a questionnaire to complete and return via reply paid mail. Where assistance was required, 
the questionnaire was completed face to face with an interviewer at the LEI clinic on the 
day of consent, or via telephone interview. Questionnaires were then scanned electronically 
by an independent research facilitation company (Savant Surveys and Strategies, Perth). 
The resulting data was stored securely on the Western Australian Genetic Epidemiology 
Resource (WAGER) server, and then extracted using Oracle SQL Developer.  
The questionnaire itself consisted largely of questions derived from pre-existing validated 
questionnaires, with some original additions and experimental modifications.   
This questionnaire (Appendix C) was designed and compiled by the author with assistance 
from Professor Lyle Palmer, Professor Ian Constable, Professor Piroska E. Rakoczy, Dr 
Sutapa Mukherjee and Dr Xuefeng Feng. 93 
 
3.4: SNP Selection 
Nineteen tag SNPs were chosen using a pairwise tagging approach to capture variation in 
the  adjacent  C2/CFB  genes.  The  C2/CFB  gene  coordinates  (Chr6:32003473–
Chr6:32027839) were determined by using the University of California Santa Cruz Human 
Genome Browser Gateway (NCBI build 35).
4 To capture potential regulatory regions of the 
C2/CFB genes, the final search coordinates (Chr6:31993473–Chr6:32037839) included  
10 kb upstream of the C2 gene and 10 kb downstream of the CFB gene. A list of HapMap 
SNPs within the target region was generated by searching the final search coordinates in the 
HapMap Centre d'Etude du Polymorphisme Humain (CEPH) data (HapMap-CEU).
5 The 
CEPH organisation created this resource by collecting genetic data from Utah residents 
with Northern and Western European ancestry in 1980.
5 There is evidence that patterns of 
LD  are  similar  between  the  HapMap-CEU  sample  and  the  Caucasian-Australian 
population,  and  that  tag  SNPs  chosen  using  HapMap-CEU  data  perform  very  well  on 
Australian study samples.
6 A graphical display of HapMap SNPs generated for the target 
region at the time of SNP selection is available as a preview (Appendix D) and in high 
resolution electronic and hard copy A3 versions from the author upon request. 
The Haploview software package
7 was used to measure pairwise LD between common 
C2/CFB genetic variants, defined as having a minor allele frequency (MAF) ≥ 5%, in the 
HapMap-CEU data. The Haploview software enables selection of a maximally informative 
set of tag SNPs that may be appropriate markers for variation across the C2/CFB genes on 
the  basis  of  strong  LD.  The  threshold  for  significant  LD  was  set  to  r
2  ≥  0.80.  One 
nonsynonymous  HapMap  SNP,  rs4151651,  was  force  included  in  the  SNP  selection 
procedure, but the probes designed for this SNP failed manufacture. 94 
 
Five functional SNPs (rs2072633, rs9332739, rs547154, rs4151667 and rs641153) were 
previously studied
134 and were captured by the chosen tagging SNPs. 
A set of 19 tag SNPs (Table 3. 2) were found to capture 40 out of 51 common HapMap 
SNPs in the target region, providing 78% coverage of the region with a mean pairwise r
2 of 
0.969.  
These 19 SNPs were selected and submitted for genotyping. The locations of the tag SNPs 
are illustrated in the schematic diagrams of the C2/CFB genes (Figure 3. 1 and Figure 3. 2). 
Details of all 41 captured SNPs are presented in Table 3. 3. All 41 SNPs are bi-allelic, and 
together span a total area of 52 kb. Eleven of the captured SNPs were coding; six of which 
were synonymous (do not result in an amino acid change), whilst the remaining five were 
nonsynonymous. The rs9332739, rs4151667, rs641153, rs438999 and rs437179 variants 
result in Asp
318Glu, His
9Leuc, Gln
32Arg, Arg
151Gln and Leu
214Met changes respectively. 
The  seven  most  upstream  SNPs  captured  were  not  assigned  to  a  particular  functional 
location in NCBI. One SNP (rs547154) was located in a promoter region, and two SNPs 
(rs522162  and  rs760070)  were  located  in  a  3‟  untranslated  region  (3‟  UTR)  while  the 
remaining 20 SNPs were intronic (Table 3. 3).   95 
 
 
Table 3. 2: List of tag SNPs genotyped, and alleles captured. 
Tag SNP  Alleles Captured 
rs9267673  rs9267673 
rs644045  rs644045 
rs3130683  rs3130683, rs3128761 
rs3020644  rs3020644 
rs7746553  rs7746553 
rs9332735  rs9332735 
rs1048709  rs1048709 
rs4151670  rs4151670 
rs512559  rs512559 
rs537160  rs437179, rs440454, rs419788, rs537160 
rs2072634  rs2072634 
rs4151657  rs2280774, rs2072632, rs4151657 
rs1270942  rs1270942, rs497309, rs1314000 
rs2072633  rs2072633 
rs4151672  rs4151667, rs9332739, rs4151669, rs4151672 
rs547154  rs609061, rs1042663, rs438999, rs541862, rs641153, rs550605, rs550513, rs760070, 
rs403569, rs497239, rs522162,rs547154 
rs4151664  rs4151664 
rs9501161  rs9501161 
rs429608  rs429608 96 
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Table 3. 3: Details of all captured C2/CFB SNPs. Tag SNPs are in bold. (Continued on next page) 
SNP RS number  Coordinates  Distance from first SNP  Alleles  HapMap CEU MAF  Location  Gene  A/A change 
rs519417  Chr6:31986412  0  G/A  0.1  N/A  C2 
 
rs3128761  Chr6:31987137  725 
   
N/A  C2 
 
rs9267673  Chr6:31991658  5246  C/T  0.075  N/A  C2 
 
rs644045  Chr6:31991936  5524  C/T  0.375  N/A  C2 
 
rs3130683  Chr6:31996346  9934  T/C  0.217  N/A  C2 
 
rs497309  Chr6:32000463  14051  T/G  0.092  N/A  C2 
 
rs3020644  Chr6:32002605  16193  A/G  0.325  N/A  C2 
 
rs7746553  Chr6:32003952  17540  C/G  0.192  Intron  C2 
 
rs9332735  Chr6:32009752  23340  G/A  0.025  Intron  C2 
 
rs9332739  Chr6:32011783  25371  G/C  0.067  Coding-Nonsynonymous  C2  Asp318Glu 
rs1042663  Chr6:32013109  26697  G/A  0.067  Coding - Synonymous  C2 
 
rs550605  Chr6:32015126  28714  T/C  0.067  Intron  C2 
 
rs497239  Chr6:32016740  30328  T/C  0.067  Intron  C2 
 
rs609061  Chr6:32018141  31729  C/T  0.109  Intron  C2 
 
rs547154  Chr6:32018917  32505  C/A  0.109  Promoter  C2 
 
rs4151667  Chr6:32022003  35591  T/A  0.067  Coding-Nonsynonymous  CFB  His9Leuc 
rs641153  Chr6:32022159  35747  C/T  0.058  Coding-Nonsynonymous  CFB  Gln32Arg 
rs1048709  Chr6:32022914  36502  G/A  0.25  Coding - Synonymous  CFB 
 
rs4151669  Chr6:32023123  36711  G/A  0.068  Coding - Synonymous  CFB 
 
rs4151670  Chr6:32023511  37099  C/T  0.008  Coding - Synonymous  CFB 
 
rs512559  Chr6:32024041  37629  T/C  0.017  Intron  CFB 
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Table 3.3: Details of all captured C2/CFB SNPs. Tag SNPs are in bold. (Continued from previous page) 
SNP RS number  Coordinates  Distance from first SNP  Alleles  HapMap CEU MAF  Location  Gene  A/A change 
rs537160  Chr6:32024379  37967  G/A  0.383  Intron  CFB 
 
rs541862  Chr6:32024930  38518  A/G  0.058  Intron  CFB 
 
rs2072634  Chr6:32025270  38858  G/A  0.021  Coding - Synonymous  CFB 
 
rs4151657  Chr6:32025519  39107  T/C  0.308  Intron  CFB 
 
rs1270942  Chr6:32026839  40427  T/C  0.092  Intron  CFB 
 
rs2072633  Chr6:32027557  41145  C/T  0.45  Intron  CFB 
 
rs4151672  Chr6:32027809  41397  C/T  0.062  Exon  CFB 
 
rs522162  Chr6:32027896  41484  A/G  0.059  3' UTR  CFB 
 
rs760070  Chr6:32027935  41523  A/G  0.058  3' UTR  CFB 
rs550513  Chr6:32028666  42254  G/A  0.057  Intron  CFB 
 
rs4151664  Chr6:32028852  42440  C/T  0.062  Intron  CFB 
 
rs2072632  Chr6:32029454  43042  C/T  0.282  Intron  CFB 
 
rs9501161  Chr6:32032306  45894  G/A  0.108  Intron  CFB 
 
rs403569  Chr6:32032859  46447  C/T  0.058  Intron  CFB 
rs440454  Chr6:32035321  48909  C/T  0.35  Intron  CFB 
rs438999  Chr6:32036285  49873  T/C  0.058  Coding-Nonsynonymous  CFB  Arg151Gln 
rs2280774  Chr6:32036670  50258  C/T  0.292  Intron  CFB 
 
rs419788  Chr6:32036778  50366  G/A  0.35  Intron  CFB 
 
rs437179  Chr6:32036993  50581  G/T  0.35  Coding-Nonsynonymous  CFB  Leu214Met 
rs429608  Chr6:32038441  52029  G/A  0.125  Intron  CFB    98 
 
 
Figure 3. 1: Tag SNPs located in the complement component 2 (C2) gene 99 
 
 
 
Figure 3. 2: Tag SNPs located in the complement factor B (CFB) gene 100 
 
3.5: Laboratory Methods 
3.5.1: Blood sample processing 
Blood samples were processed by the PathWest Molecular Genetics Service, Perth (prior 
to June 2006) or the WA DNA Bank (from June 2006 onwards). Unfasted blood samples 
in  10mL  Vacutainer  EDTA  tubes  were  centrifuged  at  3000  g  for  15  minutes  at  room 
temperature to separate the plasma from the leukocytes and erythrocytes. The layer of 
leukocytes (“buffy coat”) was removed using a plastic transfer pipette and transferred to a 
5mL centrifuge tube, which was then stored at -20 ºC until DNA extraction. 
3.5.2: DNA Preparation 
DNA  extraction  and  sample  preparation  was  performed  by  the  PathWest  Molecular 
Genetics  Service,  Perth  (prior  to  June  2006)  or  the  WA  DNA  Bank  (from  June  2006 
onwards). DNA was extracted  at  room temperature from  leukocytes using the phenol-
chloroform method, and then suspended in TE buffer. DNA was quantitated using a ND-
1000  Nanodrop  Spectrophotometer  (Nanodrop  Technologies)  to  ensure  that  sufficient 
quantities of good quality DNA were present. DNA samples of > 20 ng/µL concentration 
were diluted to approximately 2 ng/µL using the PerkinElmer Multiprobe II liquid handing 
robot. Two microlitres of each DNA sample was dispersed into each well of a 384-well 
plate using the Beckman Coulter Biomek FX robot, resulting in 4 ng of DNA sample per 
well. Plates were left to dry at room temperature overnight prior to use. 101 
 
3.5.3: Genotyping 
DNA samples were genotyped by the PathWest Molecular Genetics Service, Perth. All 
polymorphisms were genotyped using TaqMan SNP genotyping assays purchased from 
Applied Biosystems Incorporated (ABI), Australia. 
The  TaqMan  SNP  genotyping  assay  combines  polymerase  chain  reaction  (PCR) 
amplification and allele detection into a single step, by including fluorogenic allele-specific 
probes  in  a  typical  PCR  reaction.
227,  228  The  probes  are  oligonucleotides  labeled  with 
fluorescent reporter dyes, Vic or Fam, at one end and nonfluorescent quenchers at the other 
end. For a bi-allelic system, Vic-labeled fluorescent probe is specific for allele 1 and Fam-
labelled fluorescent probe is specific for the alternate allele 2. The allele-specific probes 
hybridise  to  the  amplified  target  sequence  containing  the  specific  allele  during  the 
annealing/  extension  step  of  the  PCR.  When  Taq  DNA  polymerase  encounters  the 
hybridised  probes,  the  probes  are  cleaved  by  the  5‟  nuclease  activity  of  the  Taq 
polymerase.  
Cleavage  of  the  probes  liberates  the  fluorescent  reporter  dyes,  causing  an  increase  in 
reporter  fluorescence,  indicating  that  the  probe-specific  target  has  been  detected  and 
amplified. The nonfluorescent quenchers act to reduce the reporter fluorescence as long as 
the probes remain intact. Substantial increase in Vic- or Fam- fluorescent signals indicates 
homozygosity  for  the  Vic-  or  Fam-  specific  alleles,  respectively.  An  increase  in  both 
signals indicates heterozygosity. This process is shown diagrammatically in Figure 3. 3. 
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Figure 3. 3: TaqMan SNP genotyping: cleavage of hybridised allele-specific probes by 
Taq DNA polymerase generates  increases in reporter fluorescence.   Vic and Fam 
fluorescent signals are generated for Alleles 1 and 2 respectively.
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All  TaqMan  SNP  genotyping  assay  mixes  were  designed  and  manufactured  by  ABI, 
Australia. Each assay mix contains two sequence specific primers (forward and reverse), 
two allele-specific TaqMan probes, deoxyribonucleotide triphosphate (dNTP), magnesium 
chloride (MgCl2), Taq polymerase and reaction buffer. The master mix recipe for a 3µL 
reaction mix per well is presented in Table 3. 4.  103 
 
 
Table 3. 4: Master mix recipe for a 3µL TaqMan assay 
Master mix components  Quantity in a single reaction (µL) 
Buffer  0.3 
MgCI2  0.42 
dNTP  0.024 
TaqMan probe  0.075 
Taq polymerase  0.036 
H2O  2.145 
Total  3 
 
PCR amplification proceeded using the following thermal cycling conditions: 
Incubation        50° for 2 minutes 
Taq polymerase activation     95° for 10 minutes     
Denaturation         95° for 15 seconds     
Annealing/extension       60° for 1 minute     
Steps 3 and 4 of the PCR cycle were repeated 40 times or until optimised.  
Upon completion of the PCR, fluorescence levels were measured using Tecan EasySNP 
E2.0 (Tecan Australia Ges.m.b.H 2001) and displayed graphically using Microsoft Excel 
to make genotype calls. Fluorescence plots at 10 cycle intervals were examined to allow 
for optimal clarity and assignment of genotypes. 104 
 
For  quality  control,  a  DNA  control  sample  was  sequenced  for  each  genotype  in  each 
TaqMan SNP genotyping assay. If the control samples failed to be genotyped correctly, the 
assay was repeated. Additionally, as a quality control measure, genotyping was repeated on 
10% of the samples and the assay was rejected if more than 2% of the results differed. 
All laboratory personnel were blinded from pertinent characteristics of the samples, study 
subjects, and hypotheses being investigated.  
105 
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Table 3. 5: TaqMan tag SNP assay sequences 
SNP  Assay ID  Context Sequence (5’        3’ [Vic/Fam]) 
rs1048709  C___3125453_1_  ATCGCACCTGCCAAGTGAATGGCCG[A/G]TGGAGTGGGCAGACAGCGATCTGTG 
rs1270942  C___7515125_10  GCTTAGGGGACATCTACTGAGTGAC[A/G]AAGGCAATGGGGAGATGACAGTGGT 
rs2072633  C___3125456_1_  CTGATTCCTTTAGGTCAGCTAAGAC[A/G]CAAGCAGGAACAGCCATGCTTCCAG 
rs2072634  C__15861919_10  ACAATGAGCAACATGTGTTCAAAGT[C/T]AAGGATATGGAAAACCTGGAAGATG 
rs3020644  C__15980822_10  TTGGTCTTATTTATTTTTACCCTAC[A/G]TTGTTCAAAAAGGTATTGAAAAGAC 
rs3130683  C__27463041_10  CTTACCTGGGTTACCCAGGGCAGCT[C/T]CCCTGATGGGTAGCAAGAAGTGGGT 
rs4151657  C___3125455_10  TCTGAGCACTTCAGAGATCTTTCTA[C/T]AGTCCTACATTTGACACGTGGAAAC 
rs4151664  C__29604053_10  ACTCCCTCTTTCTCAAAGTGTGTGT[C/T]CTTTTGCTTCAGTGGCCCAGGCCCC 
rs4151670  C__25630793_10  TGACTCTCCCAGACTCCTTCATGTA[C/T]GACACCCCTCAAGAGGTGGCCGAAG 
rs4151672  C__32401987_10  TAAGGGGTTTCCTGCTGGACAGGGG[C/T]GTGGGATTGAATTAAAACAGCTGCG 
rs429608  C____940304_10  GGAGGGGGTGGAGACGAGCCACTGG[A/G]GAGTCAATCCTTGGCCTCTTCTCCC 
rs512559  C____940290_10  CTCAGCCCTTGAGCCTCTTACTGAG[A/G]GCCTCCCTGTCCCAGCAAAGTCGCT 
rs537160  C____940291_1_  AGTGGGGAACAGGCACTGGCCATGT[C/T]GTTACACTGAGATCAAACCTGACAG 
rs547154  C____940286_10  GGTGAGGAGCCCGCCAGAGGCCCGT[G/T]TTGGGAACCTGGACACAGTGCCCCT 
rs644045  C__45268208_10  GCAGAGCTTGAGACAGGACTTGGCC[A/G]TAGGTAGTTAATTTAGGTGATCCCA 
rs7746553  C___2451819_10  CTCCCTGTGGGCTTTGCTCAGGGTG[C/G]TACACCAGGGGCCACCCCAGAACTT 
rs9267673  C__30033673_10  AAGAGCCTCAATGGCTGCCTCAACT[C/T]GGTGTAGCGCTGACTGGCTCACATA 
rs9332735  C__25630767_10  TGTTTGAGGTGGGGTTTCTGGTTGA[A/G]CAGGGTGCTGGATCTGGGCCGGAGC 
rs9501161  C___3125457_10  AAATGGAGAATTCAGGAGTCGTCTA[A/G]TTTTTTCATTTTATACATGAGAGGT 
rs1061170
a  ARMS-PCR
b  TTTGGAAAATGGATATAATCAAAAT[C/T]ATGGAAGAAAGTTTGTACAGGGTAA 
ars1061170 represents the CFH Y402H variation 
brs1061170 genotyped using ARMS-PCR method, not Taqman assay  
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Table 3. 6: PCR Sequencing Primers 
SNP  Forward Primer  Reverse Primer 
rs1048709  TTCGAGAACGGGGAATACTG  CCCGTGAGCAAGGTAGAGAG 
rs1270942  CTACCACTTGCCAGCAACAA  CTGGGGCATATTGAGCATCT 
rs2072633  CACCTTAGGACCGCATGTCT  AAAAACGGCTGTCAGGTTTG 
rs2072634  CAAAAACCCAAGGGAGGATT  GTGAACAGTGCCAGGAAACA 
rs3020644  GTTCTCTAAGGACTCACT  TAAATCATAACCTACACT 
rs3130683  AGGAAAACATTAGAGAGG  TCAGACAAAAACTCAACC 
rs4151657  ACATCAATGCTTTGGCTTCC  CGGGTATTTGTTTCCTCGTG 
rs4151664  TCACACTAAGAAATGCTA  CAGAGAAAAAAAAACGAC 
rs4151670  GGTCAGATCCTGGTCTTCCA  CTTCTCCATTTTCCCCCAGT 
rs4151672  CCATGCTTCCAGGATTAGGA  CTGGATTCCTTGTGCCTCAT 
rs429608  ACCATCTACACTTCGCCC  TCCAGGTCCCGAATAACA 
rs512559  GGAATCTCGCTGATCTTCCA  ACCTCCCACCATTCCCTAAC 
rs522162  CCATGCTTCCAGGATTAGGA  CTGGATTCCTTGTGCCTCAT 
rs537160  GTTAGGGAATGGTGGGAGGT  CCATCACCTCACCTGGTCTT 
rs547154  GCCACAGGAGTCTGGTGATT  TGGTGTCTGTGAGCTTGGAG 
rs644045  GCCTCAACTCGGTGTAGC  ACTGGCCTTTCCTCCTTC 
rs7746553  GTTCCCACGGCTCTAGGTCT  CCTGGCTTTAGTACCCCACA 
rs9267673  TGGGTCAGTAGGAGTGTT  CTGCTAAAGGGTAGGAAC 
rs9332735  CTATCGCTGCTCCTCGAATC  GAAATGTGGAAGGGGAGGAT 
rs9501161  TATGTATTCAGTTTATTT  GTCTCTCCAGCACTATCA  
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3.6: Statistical Methods 
Descriptive statistics for the phenotypic variables and the genotyped SNPs were calculated. 
Single-point  and  haplotypic  association  with  AMD  subphenotypes  and  loss  of  Visual 
Acuity  (VA)  attributable  to  AMD  were  investigated.  Microsoft  Excel  2003  and  2007, 
Minitab V13, JLIN v1.5.2,
229 R v2.5.0
230 and  
SimHap v2.1b
231 were used to manage and analyse data. 
Original data produced for this study consisted of SNP genotypes and phenotypic data 
collected for the Western Australian Macular Degeneration Study (WAMDS) at the Lions 
Eye Institute (LEI). Data in the WAMDS database were collated for analysis by the author 
with  support  from  the  Bioinformatics  Group,  Centre  for  Genetic  Epidemiology  and 
Biostatistics, University of Western Australia (UWA).  
Some  statistical  formulae  are  included  to  aid  future  students  utilising  this  thesis  as  a 
complete and practical reference. 
3.6.1: Definition of Study Variables 
The majority of key data such as genotype, clinical phenotypes and basic demographics 
were complete for the entire population (N=1013), but some data such as smoking history, 
alcohol consumption, ethnicity and age at diagnosis were not available for 100% of the 
population due to slightly reduced response rates to some sections of the self-completed 
questionnaire. Hence covariate analyses involving these variables dealt only with subjects 
with complete data for all covariates used in that particular model, potentially reducing the 
power of the model involved.  
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Clinical Variables 
Dichotomous Variables 
The primary dichotomous outcome variable for the case-control analysis was case status for 
late AMD. Late AMD was defined as having grade 4 disease (according to the AREDS 
classification  system)  in  either  eye,  and  was  further  classified  into  either  atrophic  or 
neovascular  subtypes.
232  Neovascular  AMD  was  defined  as  having  Choroidal 
Neovascularisation (CNV), Retinal Pigment Epithelium (RPE) detachment, haemorrhage or 
subretinal  scar  in  either  eye.  Secondary  dichotomous  outcome  variables  were  AMD-
attributable low vision and AMD-attributable legal blindness. Atrophic AMD was defined 
as having Geographic Atrophy (GA) in either eye and no presence of neovascular AMD in 
either eye. Early AMD was used to classify subjects with AREDs grades equal to or less 
than  3  in  both  eyes.  Other  dichotomous  outcome  variables  included  presence  of  RPE 
detachment, RPE tear, haemorrhage and subretinal scar tissue in either eye.  
Classifications of “better” and worse” eyes were based on Snellen Visual Acuity (VA) or 
AREDS AMD grade, depending on which was more appropriate in context. Low vision 
was defined as best corrected VA < 6/12 in the better eye. Legal blindness was defined as 
best corrected VA ≤ 6/60 in the better eye. Whilst legal blindness in Australia is defined as 
best corrected VA < 6/60 in the better eye (excluding individuals with an exact VA of 6/60) 
for  purposes  of  determining  eligibility  for  the  Australian  Government‟s  Centrelink‟s 
Disability Support Pension (blind) and Age Pension (blind), the United States‟ cut-off of 
VA ≤ 6/60 was employed in this study for consistency with the majority of the published 
literature.  
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Continuous Variables 
Snellen VA measurements for both the left and right eyes of all subjects were recorded in 
the  traditional  6/denominator  format.  Additionally  the  VA  measurements  were  further 
classified  as  “better  eye”  and  “worse  eye”  for  each  subject  according  to  the  VA 
measurements themselves. 
Categorical Variables 
In the neovascular AMD subgroup, categorical outcome variables included CNV lesion size 
and composition in worse eye. The three categories of CNV lesion size were ≤ 3 Disc 
Areas (DA), 3-6 DA and ≥ DA. The disc area unit is determined by the approximate area 
covered by the optic disc in the retina photograph. CNV lesion composition categories were 
„predominantly classic‟, „minimally classic‟ and „occult‟. Dichotomous outcome variables 
included presence of RPE detachment, RPE tear, haemorrhage and subretinal scar tissue in 
either eye.  
Genetic Variables 
The principal explanatory variables were the C2/CFB genetic polymorphisms. Each of the 
bi-allelic SNPs was coded into three genotype categories according to the number of copies 
of the minor allele present (number in brackets): major homozygote (0), heterozygote (1) 
and minor homozygote (2). 
Other Variables  
A list of biologically plausible covariates was generated from available data. Age at study, 
age at diagnosis, gender, ethnicity, smoking, alcohol consumption, maximum lifetime body 
mass  index  (BMI),  family  history  of  AMD,  past  medical  history  of  hypertension,  
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hypercholesterolaemia,  myocardial  infarction, stroke, diabetes,  use of blood  pressure or 
cholesterol  lowering  medications  (current  usage)  and  Non-Steroidal  Anti-Inflammatory 
Drugs (NSAIDs) (ever used) were analysed as potential covariates. Cigarette smoking was 
recorded  as  both  a  categorical  variable  (never/ex/current  smoker  and  as  a  continuous 
variable  (pack-years  of  smoking).  History  of  CNV  treatment  was  recorded  as  both  a 
categorical and dichotomous variable. 
Dichotomous Variables 
Gender was assessed as a binary variable, with males encoded as „1‟ and females as „0‟. 
Ethnicity (self-reported) was treated as a dichotomous variable (Caucasian-European=1 or 
Asian=2).  In  the  neovascular  AMD  subgroup  only,  additional  dichotomous  covariates 
analysed included previous CNV treatment in the worse eye (any treatment yes=1, no=0).  
Categorical Variables 
Smoking status was encoded as a categorical variable, with a „2‟ denoting a current smoker, 
„1‟ denoting a former smoker, and „0‟ denoting a non-smoker. “Smoker” was defined as 
subjects who smoked at least 1 cigarette per day for a year. Alcohol consumption was 
analysed as a categorical variable (never/ex/current drinker 0, 1, 2).  In the neovascular 
AMD  subgroup  only,  previous  CNV  treatment  was  recorded  as  a  categorical  variable 
(Photodynamic  Therapy  (PDT)  /  intravitreal  anti-Vascular  Endothelial  Growth  Factor 
(VEGF) / subtenon or vitreous steroids / focal laser / combination therapy) in addition to 
the dichotomous variable previously mentioned.  
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Continuous Variables 
Age at study was calculated by subtracting the date of study sample processing from the 
subject‟s date of birth,  and was recorded in  years. Age at diagnosis was calculated by 
subtracting  the  self-reported  year  of  AMD  diagnosis  from  the  subject‟s  year  of  birth. 
Maximum lifetime BMI was calculated using self-reported data in the formulae: maximum 
lifetime body weight (kg) / maximum lifetime height
2 (m
2), where maximum lifetime body 
weight is the highest body weight recorded in any particular decade of life, while height at 
age 25 is used as a proxy for maximum lifetime height. This method reduces the likelihood 
of overestimated BMI that would inevitably result if the current height of subjects were to 
be used, as age-related reduction in height is common. The primary use of this maximum 
lifetime BMI value is as an indicator of significant obesity, which was considered to be the 
most appropriate signifier in the absence of more rigorous and informative data such as 
waist:hip ratio. 
Pack years of smoking was analysed as a continuous variable. To calculate pack years of 
smoking, the average number of cigarettes smoked per day was divided by 20 to give packs 
per day, and multiplied by the total number of years smoking.
233 
3.6.2: Descriptive Analyses 
Descriptive statistics of study variables 
Standard descriptive analyses of study variables were carried out using Minitab v13.32.
11 
Means  and  standard  deviations  of  continuous  variables,  and  percentages  and  counts  of 
dichotomous and categorical variables, were calculated for cases and controls separately 
and tabulated. Distribution of study variables was compared between cases and controls by  
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using a t-test for continuous variables and the Chi-Squared (χ2) test for dichotomous and 
categorical variables. Prior to analysis, all data were exported from Microsoft Excel into 
Minitab.  Descriptive  statistics  of  study  variables  were  calculated  in  the  entire  study 
population. The distribution of continuous traits (age at study, age at diagnosis and pack 
years  of  smoking)  were  examined  for  normality  and  illustrated  as  histograms  using 
Minitab. Means and standard deviations for these traits were also calculated using the same 
software. 
Descriptive statistics of genotype data 
Allele  and  genotype  frequencies  were  calculated  using  the  JLIN  software  package.
229 
Consistency  of  genotype  frequencies  with  Hardy-Weinberg  equilibrium  (HWE)  was 
examined at each SNP locus using a χ
2 goodness-of-fit test. The Hardy-Weinberg principle 
states  that  a  „genetic  equilibrium‟  exists  between  the  frequencies  of  alleles  and  the 
corresponding  genotypes  in  a  population,  given  that  underlying  Hardy-Weinberg 
assumptions such as random mating and zero net migration are not violated.
234 If p and q 
are the frequencies of the two alternative alleles A and a for a bi-allelic locus respectively, 
then the HWE-expected genotypic frequencies will be p
2 for the AA genotype, 2pq for the 
Aa genotype, and q
2 for the aa genotype and p
2 + 2pq + q
2 = 1.  Based on this principle, 
known population allele frequencies are used to calculate the HWE-expected genotypic 
proportions,  with  which  observed  genotypic  frequencies  are  compared.  HWE  testing  is 
commonly used for quality control of large-scale genotyping.
234 
Pairwise  LD  was  analysed  using  the  Java-based  Linkage  analysis  (JLIN)  software 
package
229 to examine the inter-locus Linkage Disequilibrium (LD) pattern in the C2/CFB  
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genes within the WAMDS population. JLIN quantifies the degree of LD in both D‟ and r
2 
statistics, and displays these values in a graphical form. Calculation of D‟ and r
2 were as 
follows: 
D = ƒAB – ƒA x ƒB 
Where ƒAB is the frequency of the „AB‟ haplotype and ƒA and ƒB are the frequencies of the 
common alleles „A‟ and „B‟ at the two loci 
Then    D‟ = |D/Dmax| 
Where Dmax represents the maximum possible value of D for the pair of alleles in question. 
And  
 
 
3.6.3: Hypothesis Testing 
Statistical tests are used to assess the strength of evidence against a null hypothesis, H0, 
which  states  that  there  is  no  effect  or  association  between  the  exposure  and  outcome 
variables.
235 The alternate hypothesis, H1, is the research hypothesis which states that the 
observed effect or association between the variables is genuine. In a genetic association 
study, the exposure variable is the presence of an allele or genotype, and the outcome 
variable is the disease phenotype of interest. The alternative hypothesis of interest may be 
specified in terms of differing means for continuous measures, or in terms of Odds Ratios 
(ORs)  for  dichotomous  measures.  Additionally,  the  possibility  of  a  chance  finding  is 
addressed by  calculating a test  statistic and its  corresponding  P value.   A test  statistic 
measures by how many standard errors the estimated exposure effect differs from the null  
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value of zero. The P value is defined as the probability of observing a test statistic equal or 
more extreme than that observed if the null hypothesis of no association is true. The smaller 
the  P  value,  the  stronger  the  evidence  against  the  null  hypothesis.  By  convention,  the 
significance  level,  α,  is  defined  at  the  5%  level.
235  Based  on  the  same  arbitrary  5% 
threshold, a 95% confidence interval (CI) is commonly constructed around the estimated 
value and defines a range of values within which we can be reasonably confident that the 
true value lies. 
3.6.4 Association Analyses 
Phenotypic analysis 
Univariate Phenotypic Analysis 
Chi
2 testing was used to evaluate potential associations between history of cataract surgery 
(prior  to  AMD  diagnosis)  and  several  dichotomous  and  categorical  AMD  phenotypic 
outcomes. Eyes were regarded individually, and the involved variables were redefined for 
this purpose. 
Multivariate Phenotypic Analysis 
Multivariate  models  were  derived  using  generalised  linear  models  (linear  and  logistic 
regression)  as  implemented  in  the  SimHap  v2.1b  software  package.
231  Independent 
predictors of the outcome variables were identified from the available list of biologically 
plausible covariates (Section 3.6.1) using a reverse stepwise regression strategy according 
to the Akaike Information Criterium (AIC).
236 A final set of statistical models were created 
in this manner, seen in Table 3. 7. Subsequent multivariate analyses utilised these models, 
thus adjusting for the most biologically plausible and statistically significant covariates.   
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Quadratic and cubic terms were used to explore the non-linear effects of the continuous 
variable age at study. Age*gender interactions were also examined via the inclusion of 
interaction terms in the models. The model with the lowest AIC value was retained for SNP 
and haplotype association analysis. The equation for Akaike Information Criterium is given 
by AIC = 2k – 2ln L, where k= number of parameters, and L is the likelihood function. 
Genotypic analyses 
Univariate analyses 
All SNPs in the entire sample set were tested for association with neovascular AMD (often 
referred  to  simply  as  CNV),  low  vision  and  legal  blindness  using  SimHap.  SimHap 
generates  a  full  model  log  likelihood  to  determine  whether  the  model  using  genotypic 
information significantly improves how well the model fits the data. Initially the SNPs 
were tested under additive models,  then dominant  and recessive  models if the additive 
models appeared significant. 
Kruskal-Wallis Analyses 
All SNPs in the entire sample set were tested for association with the Snellen Visual Acuity 
(VA) of subjects‟ “worse eye” and “better eye” using Kruskal-Wallis one-way analysis of 
variance by ranks, performed in Minitab.
237 This non-parametric method is designed to test 
equality of population medians among groups. As a non-parametric test, Kruskal -Wallis 
does  not  require  the  outcome  variable  to  be  normally  distributed,  instead  assuming  an 
identical shaped distribution for each group (excepting any difference in medians). 
In this test, all data is ranked from 1 to N regardless of group membership. Any tied values 
are assigned the average of the ranks they would have received had they not been tied.  
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The formulae that are used to calculate the Kruskal Wallis test statistic are as follows
21: 
             or                   
 
   
K is the Kruskal-Wallis test statistic 
ng is the number of observations in group g 
rij is the rank (among all observations) of observation j from group i 
N is the total number of observations across all groups 
 
     is the average of all the rij 
A correction for ties can be made by dividing K by    
 
where G is the number of groupings of different tied ranks 
ti is the number of tied values within group i that are tied at a particular value  
This correction usually makes little difference in the value of K unless there are a large 
number of ties, as was the case with the VA datasets. 
Finally, the Kruskal-Wallis P value can be approximated using the formula: 
 
The null hypothesis of equal population medians would then be rejected if: 
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Minitab generates the Kruskal-Wallis test statistic and two P values, one adjusted for ties, 
and  the  other  unadjusted.    In  these  analyses,  I  used  the  “adjusted  for  ties”  P  value  in 
preference to the unadjusted P value, due to the high frequency of tied data in the VA 
measurements.  
Multivariate Analyses  
Multivariate  analyses  of  gene-disease  associations  were  performed  using  the  SimHap 
v1.0.0 software package. SimHap performs a Likelihood Ratio Test to determine whether 
inclusion of genetic factors in the statistical model would significantly improve how well 
the model fits the data. Genotypes were firstly analysed under codominant models, that is, 
using the major homozygous genotype as a baseline by which to compare the effects of the 
heterozygous  and  minor  homozygous  genotypes.  Significant  codominant  models  were 
explored further, under dominant, recessive or additive models to determine the best fitting 
model. ORs and 95% CIs and P values were reported where required. 
Gene-gene interaction between C2/CFB and CFH genetic variants were analysed using the 
SimHap v1.0.0 software package by including two-way interaction terms into the models. 
CFH tagging SNPs were genotyped from blood samples of WAMDS subjects previously. P 
values for the interaction terms were reported.  
Utilising  the  optimised  phenotypic  models  arising  from  the  previously  discussed 
phenotypic multivariate analysis, single-point SNP association analyses were performed for 
dichotomous and continuous outcomes in SimHap. All analyses were performed initially in 
an additive model. Further analyses were performed using dominant or recessive models if 
the additive model was significant.   
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Due to a minor functionality limitation in SimHap, categorical outcomes were tested in 
Minitab. The sequential categories of CNV lesion size were analyzed by ordinal logistic 
regression, using the smallest lesion size category (lesions smaller than or equal to 3 Disc 
Areas (DA) in size) as the baseline. The non-sequential types of CNV lesion composition 
were analyzed by nominal logistic regression, using “occult” lesion  composition as the 
reference category.  
In order to obtain a single likelihood ratio (LR) P value for each test, the Microsoft Excel 
Chi
2 distribution function was used to process the formula:  
(loglikelihoodmodel only   -    loglikelihoodmodel with SNP)*
2 
with 2 degrees of freedom.  
Table 3. 7 shows the type of regression, the model covariates, and the population used for 
single-point SNP association analysis of each outcome.  
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Table 3. 7: Summary of statistical models used in multivariate analyses 
 
 
 
Model #  Pop.  Outcome  Covariates  Regression Type 
1  All  Late AMD   Age at Study, Gender, Smoke pack years, 
alcohol consumption  Binary Logistic 
2  All  CNV  Age at Study, Gender, Smoke pack years, 
alcohol consumption  Binary Logistic 
3  GA=0  CNV  Age at Study, Gender, Smoke pack years, 
alcohol consumption  Binary Logistic 
4  Late  CNV  Smoke pack years  Binary Logistic  
5  CNV  CNV Lesion 
Composition  CNV treatment  Nominal Logistic 
6  CNV  CNV Lesion 
Size  CNV treatment  Ordinal Logistic 
7  All  GA   Age at Study  Binary Logistic  
8  CNV= 0  GA   Age at Study, Smoke Status  Binary Logistic 
9  All  Legal Blindness   Age at Study  Binary Logistic 
10  Late  Legal Blindness   CNV treatment, Age at Study  Linear 
11  All  Low Vision   Smoke pack years, Age at Study  Binary Logistic  
12  Late  Low Vision   CNV treatment, Age at Study  Linear 
13  Early  Low Vision   Age at study, alcohol consumption, 
NSAID use, smoking status  Linear 
14  CNV  RPE detachment  alcohol consumption, CNV treatment  Binary Logistic 
15  CNV  RPE scarring  gender, smoking pack years, cholesterol 
medication  Binary Logistic 
16  All  Age at 
Diagnosis 
ethnicity, maximum lifetime BMI, high 
cholesterol, hypertension, NSAID use  Linear  
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3.6.5: Statistical Power Calculation 
Statistical power calculation allows determination of the power of a test to detect a modest 
genetic  effect  given  the  study  sample  size.  The  statistical  power  of  a  test  (β)  is  the 
probability of reporting true positives. This equates to the probability of rejecting false 
negatives, or Type II errors, in statistical analysis. The statistical power to detect a range of 
ORs  for  various  case-control  analyses  was  calculated  as  a  function  of  minor  allele 
frequency and number of cases. This was performed using R software,
230 generating a set of 
power curves for each case-control scenario. 
Population risk of each AMD subphenotype within the AMD population was estimated 
using basic prevalence data. One in eight early AMD cases go on to develop late AMD, and 
in this study the late AMD cases were split into one third atrophic AMD and two thirds 
neovascular AMD.
19,  238 Expanding these fractions for simplicity, the probability that an 
AMD case within the WAMDS study population is: 
 Early = 21/24 
Late (Atrophic+Neovascular) = 3/24 (or 1/8) 
Atrophic = 1/24 
Neovascular = 2/24  (or 1/12) 
And the probability of the case being Neovascular versus Early = 2/23 
Atrophic versus Early = 1/22 
Neovascular versus Atrophic= 2/3  
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3.6.6: Multiple Testing 
Based on a statistical significance level of α = 0.05, there is a one-in-twenty chance of 
reporting an association when it does not truly exist, known as a false positive. When the 
number of tests performed simultaneously increases, the overall chance of reporting false 
positives also increases. These errors in statistical analysis are known as Type I errors, 
where  null  hypotheses  are  incorrectly  rejected.  Multiple  testing  is  common  in  genetic 
association studies due to the many genetic markers tested simultaneously, making them 
inevitably susceptible to Type I errors. The traditional method of correcting for multiple 
testing is the Bonferroni correction, which compensates for multiple testing by employing a 
more stringent significance level, of α‟ = 0.05 / n, where n is the number of independent 
tests performed. The Bonferroni correction can become overly stringent when the number 
of genetic markers tested is high.  
For  these  analyses  the  False  Discovery  Rate  (FDR)  approach  was  used  instead  of  the 
Bonferroni correction as the correction method for multiple testing. The FDR approach 
controls the expected proportion of false positives, as opposed to the Bonferroni correction 
which controls the chance of any false positives assuming a null hypothesis at any genetic 
loci. The FDR approach is therefore more realistic and less stringent than the Bonferroni 
method. An FDR threshold, known as a Q value, is calculated in light of the number of 
significant  results  and  measures  the  minimum  FDR  (rate  of  false  positives  among  the 
significant tests) that is incurred when calling that test significant. The Q values for each 
test were calculated using R software. A test was deemed to be significant when q-value ≤ 
α, where α was defined at the 5% level.   
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3.6.7: Sensitivity Testing 
The presence of genetic sub-populations, or population stratification, in a ethnically diverse 
population is a well recognised cause for artificial genotype-disease association in genetic 
association studies.
239 The WAMDS population is predominantly Caucasian. In this study 
sensitivity testing was performed by re-analysing all positive findings in the Caucasian 
subset.   
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Chapter 4: Results 
4.1: Descriptive Statistics 
4.1.1: Phenotypic Data 
 
The study population consisted of 1013 unrelated individuals with clinically documented 
AMD (mean age 78.1 +/- 8.5 years) from the Western Australian Macular Degeneration 
Study (WAMDS). WAMDS is a cohort study comprising all consenting AMD patients who 
attended  the  Lions  Eye  Institute  (LEI)  clinic  in  Nedlands,  Western  Australia  between 
March 2005 and August 2007. Clinical and demographic characteristics of the WA Macular 
Degeneration Study (WAMDS) population as a whole, and in subsets of late and early 
AMD, are presented in Table 4.1. 
The study population predominantly consisted of individuals of Caucasian descent (97.7%), 
with the remaining 2.3% comprised of individuals of Asian descent. The gender breakdown 
of  the  population  was  skewed,  comprised  of  57.9%  females  and  42.1%  males;  these 
proportions  differed  between  the  early  AMD/”control”  subset  (62.9%  females,  37.1% 
males)  and  the  late  AMD/”case”  subset  (56.2%  females,  43.8%  males),  but  these 
differences were not statistically significant (P = 0.06). 
In  line  with  the  nature  of  AMD  progression,  the  mean  study  age  of  late  AMD  was 
significantly higher than the mean study age of early AMD cases. A similar trend was 
observed with the age at diagnosis between late and early AMD. It is important to control 
for age because early AMD cases often progress to late AMD with increasing age. Due to a  
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lower number of responses for age at diagnosis it was deemed appropriate to use age at 
study as a suitable proxy for this important covariate. Age at study is thus used as a proxy 
for age at diagnosis in many multivariate models throughout the analyses found in this 
chapter.  
Of the 1013 individuals, 746 late (AREDS Grade 4 either eye) AMD patients were selected 
as “cases” (mean age 79.8 +/- 7.6 years), of which 71 patients had the atrophic subtype 
(Geographic Atrophy or GA) and 674 patients  had the neovascular subtype (Choroidal 
Neovascularisation or CNV) of late AMD. A total of 267 early (AREDS Grade 0-3 both 
eyes) AMD patients formed the “controls” (mean age 75.2 +/- 9.8 years).  
There was a higher incidence of smoking (both current and past), and higher mean pack-
years of smoking in members of the late AMD subset compared to the early AMD subset; 
this difference was statisticially significant (P = 0.01).  Alcohol consumption also varied 
between the two subsets (P = 0.04), with current drinkers over-represented (relative to the 
entire study population) in the early AMD subset while people with no history of alcohol 
consumption were under-represented in the early AMD subset. 
Frequency  of  self-reported  history  of  hypertension,  history  of  high  cholesterol  levels, 
treatment for high cholesterol, and use of non-steroidal anti-inflammatory drugs (NSAIDS) 
did not vary significantly between the early AMD and late AMD subsets.   
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Table 4. 1: Demographic and clinical characteristics of subjects in the WA Macular 
Degeneration Study (WAMDS) population 
Variable 
Study Population 
(N=1013) 
Early AMD  Late AMD 
(n=267)  (n= 746) 
Continuous variables, mean (SD) [n] 
Age at study  78.1 (8.5) [1013]  75.2 (9.8) [267]  79.8 (7.6) [746] 
Age at AMD diagnosis
a  74.4 (9.6) [768]  71.3 (10.1) [202]  75.3 (9.3) [566] 
Pack-years of smoking
b  17.3 (25.6) [767]  11.2 (18.8) [211]  19.7 (27.5) [556] 
Maximum lifetime BMI
c  26.3 (4.4) [659]  26.1 (4.2) [184]  26.3 (4.4) [475] 
Dichotomous and categorical variables, % [n] 
Gender 
         Males  42.1 [426]  37.1 [99]  43.8 [327] 
   Females  57.9 [587]  62.9 [168]  56.2 [419] 
Ethnicity
d 
         Caucasian  97.7 [811]  98.2 [221]  97.5 [590] 
   Asian  2.3 [19]  1.8 [4]  2.5 [15] 
Smoking
e 
         Never smoked  42.9 [348]  50.5 [112]  40.0 [236] 
   Ex-smokers  48.9 [397]  44.6 [99]  50.5 [298] 
   Current smokers  8.2[67]  5.0 [11]  9.5 [56] 
Alcohol consumption
f 
         Never drank  24.4 [201]  20.7 [46]  25.8 [155] 
   Ex-drinker  9.2 [76]  6.3 [14]  10.3 [62] 
   Current drinker  66.3 [546]  72.8 [162]  63.9 [384] 
Hypertension  53.4 [430]  54.2 [116]  53.2 [314] 
Cholesterol medication  27.5 [220]  25.8 [56]  28.2 [164] 
Hypercholesterolaemia  44.2 [355]  45.1 [97]  44.0 [258] 
NSAIDs (ever)  49.0 [402]  50.5 [112]  48.4 [290] 
AMD grade 
         Grade 1  6.2 [63]  23.6 [63]  - 
   Grade 2  4.2 [42]  15.7 [42]  - 
   Grade 3  16.0 [162]  60.7 [162]  - 
   Grade 4 {  GA  7.0 [71]  -  9.5 [71] 
CNV  66.6 [675]  -  90.5 [675] 
Best corrected VA 
         VA ≥ 6/12  55.7 [564]  83.5 [223]  45.7 [341] 
   6/12 > VA > 6/60 
28.2 [286]  13.9 [37]  33.4 [249]     (Low vision) 
   VA ≤ 6/60 
16.1 [163]  2.6 [7]  20.9 [156]       (Legal blindness) 
Missing data details:
 a245 individuals with unspecified age of diagnosis; 
b246 individuals with unknown pack-years of 
smoking; 
c354 individuals with unspecified maximum lifetime BMI; 
d183 individuals with unspecified ethnicity; 
e201 
individuals with unspecified smoking status;
 f190 individuals with unspecified history of alcohol consumption 
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Table 4. 2: Clinical characteristics of neovascular AMD subjects in the WAMDS 
population 
Variable 
Neovascular AMD 
(n=675) 
Dichotomous and categorical variables, % [n] 
Lesion size  n=534 
   ≤3 DA  67.0 [358] 
   3–6 DA  13.9 [74] 
   ≥6 DA  19.1 [102] 
Lesion composition  n=510 
   Predominantly classic  36.7 [187] 
   Minimally classic  12.0 [61] 
   Occult  51.4 [262] 
RPE detachment  n=602 
   Yes  36.7 [221] 
   No  63.3 [381] 
Haemorrhage  n=619 
   Yes  58.6 [363] 
   No  41.4 [256] 
Scar tissue  n=656 
   Yes  52.0 [341] 
   No  48.0 [315] 
Previous treatment  n=665 
   Treatment  38.8 [262] 
   No treatment  61.2 [413] 
 
The clinical characteristics of the neovascular AMD subset of the WAMDS population are 
documented in Table 4. 2. Most CNV lesions were smaller than or equal to 3 Disc Areas 
(DA), and most commonly of occult composition. Just over a third of neovascular AMD 
patients had experienced retinal detachment in at least one eye, and over half of them had 
suffered a retinal haemorrhage, scar tissue, or both. Over a third of the neovascular AMD  
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patients had undergone some form of treatment in their worse eye prior to participating in 
this study.  
Table 4. 3: Clinical characteristics of individual eyes with a known history of cataract 
surgery 
Variable  All (N= 500)  Prior
a  Post
b 
Dichotomous and categorical variables, % [n] 
CNV  [254]  56.2 [143]  43.7 [111] 
GA  [46]  34.8 [16]  65.2 [30] 
AREDS Grade       
1  [47]  63.8 [30]  36.2 [17] 
2  [44]  63.6 [28]  36.4 [16] 
3  [103]  64.08 [66]  35.9 [37] 
4  [300]  53 [159]  47 [141] 
aPrior: Cataract Surgery Prior to AMD Diagnosis  
bPost: Cataract Surgery After AMD Diagnosis 
Table 4. 3 displays the characteristics of the 500 individual eyes, representing 307 subjects 
with known history of cataract surgery in one or both eyes in the WAMDS population.   
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4.1.2: Genotypic Data 
Genotyping  was  successful  in  over  99%  of  samples  for  all  nineteen  genetic  variants 
spanning the adjacent C2 and CFB genes. The resulting allele and genotype frequencies in 
the total study population and phenotypic subsets are shown in Table 4. 4 and Table 4. 5 
respectively. All variants were in Hardy-Weinberg Equilibrium (HWE). Nine of the 19 
SNPs had minor allele homozygote frequencies of less than 1%.  
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 Table 4. 4: Genotype frequencies of C2/CFB SNPs within WAMDS subjects, including minor allele frequencies and Hardy-
Weinberg Equilibrium (HWE) P values 
SNP (N) 
Major Homo.  Hetero.  Minor Hom.  Minor Allele  HWE 
  sf
a (n)    sf
a (n)    sf
a (n)    sMAF
b (n)  hMAF
c  P value
e 
rs1048709 (1008)  GG  65.1% (656)  GA  30.8% (310)  AA  4.2% (42)  A  19.5% (394)  25.0%  1.00 
rs1270942 (1011)  TT  75.2% (760)  TC  23.1% (234)  CC  1.7% (17)  C  13.3% (268)  9.2%  1.00 
rs2072633 (1010)  CC  30.4% (307)  TC  51.4% (519)  TT  18.2% (184)  T  43.9% (887)  45.0%  0.97 
rs2072634 (1012)  GG  98.1% (993)  GA  1.9% (19)  AA  0.0% (0)  A  0.9% (19)  2.1%  1.00 
rs3020644 (1011)  AA  35.3% (357)  AG  48.2% (487)  GG  16.5% (167)  G  40.6% (821)  32.5%  1.00 
rs3130683 (1010)  TT  74.7% (754)  TC  23.7% (239)  CC  1.7% (17)  C  13.5% (273)  21.7%  1.00 
rs4151657 (1007)  TT  41.4% (417)  TC  47.3% (476)  CC  11.3% (114)  C  35.0% (704)  30.8%  0.97 
rs4151664 (1013)  CC  86.5% (876)  CT  13.0% (132)  TT  0.5% (5)  T  7.0% (142)  6.2%  1.00 
rs4151670 (1013)  CC  97.1% (984)  CT  2.9% (29)  TT  0.0% (0)  T  1.4% (29)  0.8%  1.00 
rs4151672 (1012)  CC  95.3% (964)  CT  4.4% (45)  TT  0.3% (3)  T  2.5% (51)  6.2%  0.38 
rs429608 (1003)  GG  81.7% (819)  GA  17.1% (172)  AA  1.2% (12)  A  9.8% (196)  12.5%  0.97 
rs512559 (1011)  TT  93.6% (946)  TC  6.2% (63)  CC  0.2% (2)  C  3.3% (67)  1.7%  0.97 
rs537160 (1010)  GG  38.7% (391)  GA  48.6% (491)  AA  12.7% (128)  A  37.0% (747)  38.3%  0.97 
rs547154 (1012)  CC  88.5% (896)  CA  11.1% (112)  AA  0.4% (4)  A  5.9% (120)  10.9%  1.00 
rs644045 (1013)  GG  41.1% (416)  GA  47.0% (476)  AA  11.9% (121)  A  35.4% (718)  37.5%  0.97 
rs7746553 (1007)  CC  70.6% (711)  CG  27.1% (273)  GG  2.3% (23)  G  15.8% (319)  19.2%  1.00 
rs9267673 (1012)  CC  79.9% (809)  CT  19.3% (195)  TT  0.8% (8)  T  10.4% (211)  7.5%  0.97 
rs9332735 (1010)  GG  97.2% (982)  GA  2.8% (28)  AA  0.0% (0)  A  1.4% (28)  2.5%  1.00 
rs9501161 (1012)  GG  84.4% (854)  GA  15.1% (153)  AA  0.5% (5)  A  8.1% (163)  10.8%  1.00 
rs1061170
d (988)  TT  21.0% (207)  CT  46.4% (458)  CC  32.6% (322)  C  55.8% (1102)  28.2%  0.135 
asf= genotype frequency in this study 
bsMAF= minor allele frequency in this study 
chMAF= minor allele frequency in the HapMap CEU reference population 
drs1061170 represents the CFH Y402H variation  
eP values adjusted for multiple testing  
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Table 4. 5: Genotype frequencies of tag SNPs in major AMD subphenotype groups within the WAMDS population 
SNP 
Early AMD (N=267)  Neovascular AMD (N=675)  Atrophic AMD (N=71) 
Maj Homo  Hetero  Min Homo  Maj Homo  Hetero  Min Homo  Maj Homo  Hetero  Min Homo 
rs1048709  66.2%  30.5%  3.4%  63.9%  31.3%  4.8%  71.8%  26.8%  1.4% 
rs1270942  73.8%  24.3%  1.9%  76.1%  22.3%  1.6%  71.8%  26.8%  1.4% 
rs2072633  27.7%  55.4%  16.9%  30.8%  50.0%  19.2%  36.6%  49.3%  14.1% 
rs2072634  99.3%  0.7%  0.0%  97.6%  2.4%  0.0%  98.6%  1.4%  0.0% 
rs3020644  33.1%  50.4%  16.5%  37.7%  46.1%  16.2%  21.1%  59.2%  19.7% 
rs3130683  74.4%  25.6%  0.0%  73.8%  23.7%  2.5%  84.3%  15.7%  0.0% 
rs4151657  38.9%  50.2%  10.9%  43.8%  45.1%  11.1%  28.2%  56.3%  15.5% 
rs4151664  87.6%  12.4%  0.0%  85.3%  13.9%  0.8%  93.0%  7.0%  0.0% 
rs4151670  96.3%  3.7%  0.0%  97.3%  2.7%  0.0%  98.6%  1.4%  0.0% 
rs4151672  94.7%  4.9%  0.4%  95.4%  4.3%  0.3%  95.8%  4.2%  0.0% 
rs429608  79.1%  20.1%  0.8%  82.8%  15.7%  1.5%  80.0%  20.0%  0.0% 
rs512559  92.1%  7.9%  0.0%  94.1%  5.6%  0.3%  94.4%  5.6%  0.0% 
rs537160  37.1%  52.8%  10.1%  39.1%  46.9%  14.0%  40.8%  49.3%  9.9% 
rs547154  87.3%  12.7%  0.0%  88.7%  10.7%  0.6%  91.6%  8.4%  0.0% 
rs644045  38.6%  49.8%  11.6%  41.5%  45.9%  12.6%  46.5%  46.5%  7.0% 
rs7746553  76.0%  23.2%  0.8%  67.8%  29.1%  3.1%  77.5%  22.5%  0.0% 
rs9267673  82.0%  18.0%  0.0%  78.6%  20.2%  1.2%  84.5%  15.5%  0.0% 
rs9332735  95.9%  4.1%  0.0%  97.6%  2.4%  0.0%  98.6%  1.4%  0.0% 
rs9501161  86.5%  13.1%  0.4%  83.2%  16.2%  0.6%  87.3%  12.7%  0.0% 
rs1061170  24.1%  42.9%  33.0%  19.3%  48.0%  32.7%  25.0%  44.1%  30.9%  
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Inter-locus  Linkage  Disequilibrium  (LD)  amongst  typed  C2/CFB  variants  is  shown  in 
Figure 4. 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 1 Legend: Pairwise D‟ values are displayed in the upper left and r
2 values displayed in 
the lower right, with the degree of LD reflected by the colour intensity. D‟ exceeded 0.8 between 
most pairs of alleles, and pairwise r
2 values were generally low, with the exception of the rs9332735 
and rs4151670 SNPs, which gave a high r
2 value of greater than 0.8. 
 
Figure 4. 1: Inter-locus linkage disequilibrium plot of C2/CFB SNPs  
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4.2: Phenotypic Analysis 
4.2.1: Univariate Analysis  
Chi
2 tests were conducted on data from individual eyes that had a known history of cataract 
surgery (Table 4. 6). If the cataract surgery had been conducted at least one year prior to 
AMD diagnosis, these eyes were treated as cases, while all other cataract surgery conducted 
in the same year as or after AMD diagnosis led to those eyes being classified as controls. 
Of the outcomes tested, only atrophic AMD had a significant association (P = 0.001) with 
cataract surgery.  
Table 4. 6: Chi2 tests of the relationship between pre AMD diagnosis cataract surgery 
and various clinical outcomes 
Outcome 
All available eyes  Neovascular eyes only 
Chi
2 Test Statistic  Chi
2 P value  Chi
2 Test Statistic  Chi
2 P value 
Neovascular AMD (CNV)  0.21  0.65  *
a  *
a 
Atrophic AMD  10.50  0.001  *
a  *
a 
AREDS AMD Grade  5.74  0.13  *
a  *
a 
CNV Lesion Size  3.60  0.17  3.47  0.18 
CNV Lesion Composition  1.96  0.38  1.72  0.42 
Retinal Detachment  1.52  0.22  0.84  0.36 
Retinal Haemorrhage  1.70  0.19  2.10  0.15 
Retinal Scar  0.26  0.61  0.29  0.59 
aThese tests were not conducted due to redundancy  
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4.2.2: Multivariate Analysis 
Models that included a minimum set of biologically plausible and statistically significant 
covariates were used in subsequent analyses. Details of these models are provided in  
Table 3. 7 (page 119) in the methods chapter. 
Late AMD 
Significant associations were observed between late AMD and age at study, gender, current 
alcohol consumption status and pack-years of cigarette smoking in the WAMDS population 
(Table 4. 7). The presences of all of these covariates were associated with an increased risk 
of  late  AMD  (versus  early  AMD),  with  the  exception  of  current  alcohol  consumption 
status, which was associated with a lower risk of late AMD. 
In this model (Model 1) late AMD was adjusted for age at study, gender, pack years of 
smoking and history of alcohol consumption. 
Table 4. 7: Final multivariate model of late AMD in the WAMDS population 
Model 1: Late AMD
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Gender- Female (baseline)  -  -  - 
Gender- Male  1.49  1.03  0.04 
Age at Study  1.08  1.05  2.77e-12 
Smoke pack-years  1.02  1.01  4.47e-05 
Alcohol –Never (baseline)  -  -  - 
Alcohol - Past  0.89  0.43  0.76 
Alcohol - Current  0.59  0.38  1.00e-02 
aThe log-likelihood value for this model was -404.01 (with 6 degrees of freedom) and the Akaike Information Criterium (AIC) value was 
820.01.  
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CNV (Choroidal Neovascularisation / Neovascular AMD) 
CNV Presence  
Neovascular AMD in the WAMDS Population 
 
Significant  associations  were  observed  between  neovascular  AMD  (also  known  as 
Choroidal  Neovascularisation,  or  CNV)  and  age  at  study,  gender,  current  alcohol 
consumption status and pack-years of cigarette smoking in the WAMDS population  
(Table 4. 8).  The presence of each of these covariates was associated with an increased risk 
of neovascular AMD (versus early AMD and atrophic AMD), with the exception of current 
alcohol consumption status, which was associated with a lower risk of neovascular AMD. 
In this model (Model 2) neovascular AMD was adjusted for age at study, gender, pack 
years of smoking and history of alcohol consumption. 
Table 4. 8: Final multivariate model of neovascular AMD in the WAMDS population 
Model 2: CNV
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.05  1.03  9.28e-08 
Gender- Female (baseline)  -  -  - 
Gender- Male  1.62  1.15  0.01 
Smoke pack-years  1.02  1.01  1.28e-05 
Alcohol –Never (baseline)  -  -  - 
Alcohol - Past  0.84  0.43  0.60 
Alcohol - Current  0.63  0.43  0.02 
aThe log-likelihood value for this association was -456.37 (with 6 degrees of freedom) and the AIC value was 924.73. 
 
 
 
  
135 
   
173
 
Neovascular AMD in the non-atrophic AMD subset of the WAMDS Population 
Significant  associations  were  observed  between  neovascular  AMD  and  age  at  study, 
gender, current alcohol consumption status and pack-years of cigarette smoking in the non- 
atrophic WAMDS population (Table 4. 9). The presence of each of these covariates was 
associated  with  an  increased  risk  of  neovascular  AMD  (versus  early  AMD),  with  the 
exception of current alcohol consumption status, which was associated with a lower risk of 
neovascular AMD. 
In this model (Model 3) neovascular AMD was adjusted for age at study, gender, pack 
years of smoking and history of alcohol consumption. 
Table 4. 9: Final multivariate model of neovascular AMD in the WAMDS population 
(excluding GA only individuals) 
Model 3: CNV
a (GA= 0) 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.07  1.05  6.02e-11 
Gender- Female (baseline)  -  -  - 
Gender  1.56  1.07  0.02 
Smoke pack-years  1.02  1.01  2.98e-05 
Alcohol –Never (baseline)  -  -  - 
Alcohol – Past  0.88  0.41  0.73 
Alcohol – Current  0.58  0.38  0.01 
aThe log-likelihood value for this association was -387.38 (with 6 degrees of freedom) and the AIC value was 786.75. 
 
Neovascular AMD in the Late AMD subset of the WAMDS Population 
A  significant  association  was  observed  between  neovascular  AMD  and  pack  years  of 
smoking in the late AMD subset of the WAMDS population (Table 4. 10). The presence of 
this covariate was associated with an increased risk of neovascular AMD (versus atrophic 
AMD).  
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In this model (Model 4) neovascular AMD was adjusted for pack years of smoking. 
Table 4. 10: Final multivariate model of neovascular AMD in the late AMD subset of 
the WAMDS population 
Model 4: CNV
a (Late) 
Coefficient [β]  Standard Error  P value 
Covariates 
Smoke pack-years  1.02  1.00  0.03 
aThe log-likelihood value for this association was -176.60 (with 2 degrees of freedom) and the AIC value was 357.19. 
 
CNV Lesion Composition 
A significant association was observed between CNV lesion composition and prior CNV 
treatment in the neovascular AMD subset of the WAMDS population (Table 4. 11) The 
presence of this covariate was associated with an increased chance of predominantly classic 
or minimally classic lesion type (versus occult lesion type). 
In  this  model  (Model  5)  CNV  lesion  composition  was  adjusted  for  history  of  CNV 
treatment. 
Table 4. 11: Final multivariate model of CNV lesion composition in the WAMDS 
population 
Model 5: CNV 
Lesion 
Composition
a 
 
Min classic versus occult  Predom classic versus occult 
Coefficient 
[β] 
Standard 
Error  P value  Coefficient 
[β] 
Standard 
Error  P value 
Covariates 
CNV Treatment- 
Never (baseline)  -  -  -  -  -  - 
CNV Treatment- 
Ever  1.52  0.30  <0.001  1.75  0.21  <0.001 
aThe log-likelihood value for this association was -449.52. 
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CNV Lesion Size 
A significant association was observed between CNV lesion size and prior CNV treatment 
in the neovascular AMD subset of the WAMDS population (Table 4. 12). The presence of 
this covariate was associated with smaller lesion size (versus larger lesion size). In this 
model (Model 6) CNV lesion size was adjusted for history of CNV treatment. 
Table 4. 12: Final multivariate model of CNV lesion size in the WAMDS population 
Model 6: CNV Lesion Size
a 
Coefficient [β]  Standard Error  P value 
Covariates 
CNV Treatment- Never (baseline)  -  -  - 
CNV Treatment- Ever  0.63  0.18  0.001 
aThe log-likelihood value for this association was -452.42. 
 
GA (Geographic Atrophy / Atrophic AMD) 
Atrophic AMD in the WAMDS Population 
A significant association was observed between atrophic AMD (also known as Geographic 
Atrophy, or GA) and age at study in the WAMDS population (Table 4. 13). The presence 
of this covariate was associated with an increased risk of atrophic AMD (versus early AMD 
and neovascular AMD). In this model (Model 7) atrophic AMD was adjusted for age at 
study. 
Table 4. 13: Final multivariate model of atrophic AMD in the WAMDS population 
Model 7: GA
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.04  1.01  0.01 
aThe log-likelihood value for this association was -253.66 (with 2 degrees of freedom) and the AIC value was 511.31. 
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Atrophic AMD in the non-neovascular AMD subset of the WAMDS Population 
Significant  associations  were  observed  between  atrophic  AMD  and  age  at  study,  and 
smoking status in the non-neovascular WAMDS population (Table 4. 14). The presence of 
each of these covariates was associated with an increased risk of atrophic AMD (versus 
early AMD). In this model (Model 8) atrophic AMD was adjusted for history of smoking 
and age at study. 
Table 4. 14: Final multivariate model of atrophic AMD in the WAMDS population 
(excluding CNV cases) 
Model 8: GA
a (CNV=0) 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.12  1.07  1.34e-06 
Smoking- Never (baseline)  -  -  - 
Smoking- Past  1.32  0.69  0.40 
Smoking- Current  5.03  1.50  0.01 
aThe log-likelihood value for this association was -127.75 (with 4 degrees of freedom) and the AIC value was 263.50. 
Legal Blindness 
Legal Blindness in the WAMDS Population 
A significant association was observed between legal blindness and age at study in the 
WAMDS population (Table 4. 15). The presence of this covariate was associated with an 
increased risk of legal blindness (versus better than 6/60 vision). 
In this model (Model 9) legal blindness was adjusted for age at study. 
Table 4. 15: Final multivariate model of legal blindness in the WAMDS population 
Model 9: Legal Blindness
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.08  1.05  1.59e-09 
aThe log-likelihood value for this association was -425.66 (with 2 degrees of freedom) and the AIC value was 855.33.  
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Legal Blindness in the Late AMD subset of the WAMDS Population 
Significant associations were observed between legal blindness and age at study and prior 
CNV treatment in the late AMD subset of the WAMDS population (Table 4. 16). The 
presence  of  the  age  at  study  covariate  was  associated  with  an  increased  risk  of  legal 
blindness (versus better than 6/60 vision), while a prior history of CNV treatment was 
associated with a lower risk of legal blindness. In this model (Model 10) legal blindness 
was adjusted for age at study and history of CNV treatment. 
Table 4. 16: Final multivariate model of legal blindness in the late AMD subset of the 
WAMDS population 
Model 10: Legal Blindness
a (Late) 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.06  1.03  7.46e-05 
CNV Treatment- Never (baseline)  -  -  - 
CNV Treatment- Ever  0.62  0.41  0.02 
aThe log-likelihood value for this association was -320.17 (with 3 degrees of freedom) and the AIC value was 646.33. 
 
Low Vision 
Low Vision in the WAMDS Population 
Significant associations were observed between low vision and age at study and pack-years 
of cigarette smoking in the WAMDS population (Table 4. 17). The presence of each of 
these covariates was associated with an increased risk of low vision (versus better than 6/12 
vision). In this model (Model 11) low vision was adjusted for age at study and pack-years 
of smoking. 
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Table 4. 17: Final multivariate model of low vision in the WAMDS population 
Model 11: Low Vision
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.08  1.06  2.69e-13 
Smoke pack-years  1.01  1.00  0.03 
aThe log-likelihood value for this association was -492.05 (with 3 degrees of freedom) and the AIC value was 990.09. 
 
Low Vision in the Late AMD subset of the WAMDS Population 
Significant associations were observed between low vision and age at study and prior CNV 
treatment in the late AMD subset of the WAMDS population (Table 4. 18). The presence of 
the age at study covariate was associated with an increased risk of low vision (versus better 
than 6/12 vision), while a history of prior CNV treatment was associated with a lower risk 
of low vision. In this model (Model 12) low vision was adjusted for age at study and 
history of CNV treatment. 
Table 4. 18: Phenotypic covariates for predictive multivariate model of low vision in 
the late AMD subset of the WAMDS population 
Model 12: Low Vision
a (Late) 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.06  1.04  1.02e-07 
CNV Treatment- Never (baseline)  -  -  - 
CNV Treatment- Ever  0.57  0.41  0.001 
aThe log-likelihood value for this association was -444.57(with 3 degrees of freedom) and the AIC value was 895.13. 
 
Low Vision in the Early AMD subset of the WAMDS Population 
Significant associations were observed between low vision and age at study, NSAID (non-
steroidal  anti-inflammatory  drug)  use,  current  alcohol  consumption  status  and  smoking 
status in the early AMD subset of the WAMDS population (Table 4. 19). The presence of 
each of these covariates was associated with an increased risk of low vision (versus better  
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than 6/12 vision), with the exception of current alcohol consumption status,  which was 
associated  with  a  lower  risk  of  low  vision.  In  this  model  (Model  13)  low  vision  was 
adjusted for age at study, history of alcohol consumption, history of NSAID use and history 
of smoking. 
Table 4. 19: Final multivariate model of low vision in the early AMD subset of the 
WAMDS population 
Model 13: Low Vision
a (Early) 
Coefficient [β]  Standard Error  P value 
Covariates 
Age at Study  1.12  1.06  1.36e-05 
NSAID Use- Never (baseline)  -  -  - 
NSAID Use- Ever  3.45  1.39  0.01 
Smoking- Never (baseline)  -  -  - 
Smoking - Past  3.52  1.29  0.01 
Smoking - Current  3.36  5.14  0.0002 
Alcohol- Never (baseline)  -  -  - 
Alcohol – Past  0.56  0.11  0.47 
Alcohol – Current  0.24  0.08  0.01 
aThe log-likelihood value for this association was -75.88 (with 7 degrees of freedom) and the AIC value was 165.76. 
Serious Complications and Manifestations 
Retinal detachment 
Significant  associations  were  observed  between  retinal  detachment  and  current  alcohol 
consumption status and prior CNV treatment in the neovascular subset of the WAMDS 
population (Table 4. 20). The presence of the current alcohol consumption covariate was 
associated with an increased risk of retinal detachment in at least one eye (versus no retinal 
detachment) while a history of prior CNV treatment was associated with a lower risk of 
retinal detachment.  In this model (Model 14) retinal detachment was adjusted for history of 
alcohol consumption and history of CNV treatment.  
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Table 4. 20: Final multivariate model of retinal detachment in the neovascular AMD 
subset of the WAMDS population 
Model 14: Retinal Detachment
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Alcohol- Never (baseline)  -  -  - 
Alcohol - Past  1.18  0.58  0.65 
Alcohol - Current  1.64  1.05  0.03 
CNV Treatment- Never (baseline)  -  -  - 
CNV Treatment- Ever  0.54  0.37  0.002 
aThe log-likelihood value for this association was -317.02 (with 4 degrees of freedom) and the AIC value was 642.05. 
Retinal Scar 
Significant  associations  were  observed  between  retinal  scarring  and  gender,  use  of 
cholesterol-lowering medication and pack-years of cigarette smoking in the neovascular 
AMD subset of the  WAMDS population  (Table 4.  21). The presence  of each  of these 
covariates was  associated with  an increased risk of retinal  scarring in  at  least  one eye 
(versus no retinal scarring), with the exception of gender (male), which was associated with 
a lower risk of retinal scarring. 
In this model (Model 15) retinal scarring was adjusted for gender, pack years of smoking 
and use of medications for treatment of high cholesterol. 
Table 4. 21: Final multivariate model of retinal scarring in the neovascular AMD 
subset of the WAMDS population 
Model 15: Retinal Scar
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Gender- Female (baseline)  -  -  - 
Gender- Male  0.64  0.43  0.03 
Smoke pack-years  1.01  1.00  0.04 
Cholesterol Medication  1.96  1.29  0.002 
aThe log-likelihood value for this association was -310.71(with 6 degrees of freedom) and the AIC value was 629.43.  
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Age at Diagnosis 
Significant  associations  were  observed  between  age  of  AMD  diagnosis  and  ethnicity, 
NSAID (Non-steroidal anti-inflammatory drug) use, maximum lifetime BMI (Body mass 
index), high cholesterol and hypertension in the WAMDS population (Table 4. 22). The 
presence of each of these covariates was associated with a reduced age of AMD diagnosis, 
with  the  exception  of  hypertension  and  NSAID  use  which  were  associated  with  an 
increased age of AMD diagnosis. In this model (Model 16) age at diagnosis was adjusted 
for ethnicity, maximum lifetime BMI, history of hypertension, use of NSAIDS and use of 
medications for treatment of high cholesterol. 
Table 4. 22: Final multivariate model of age at diagnosis in the WAMDS population 
Model 16: Age at Diagnosis
a 
Coefficient [β]  Standard Error  P value 
Covariates 
Ethnicity- Caucasian (baseline)  -  -  - 
Ethnicity- Asian  -8.06  2.61  0.002 
NSAID Use- Never (baseline)  -  -  - 
NSAID Use- Ever   2.84  0.75  0.0002 
Max Lifetime BMI  -0.32  0.08  0.0001 
High Cholesterol  -1.71  0.76  0.03 
Hypertension  3.90  0.76  3.5e-07 
aThe log-likelihood value for this association was -2085.69 (with 7 degrees of freedom) and the AIC value was 4185.4, while the adjusted 
R-squared value was 0.10. 
 
4.3: Genotypic Analysis 
4.3.1: Univariate Analysis 
Late AMD 
Two C2/CFB SNPs  were significantly associated with  late AMD when analyzed using 
Fisher‟s Exact test (Table 4.23); rs3130683 (P = 0.02) and rs7746553 (P = 0.03).    
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Table 4. 23: Fisher's Exact test of association of C2/CFB variants with Late AMD in 
WAMDS subjects 
SNP  Fisher's P value 
rs1048709  0.78 
rs1270942  0.80 
rs2072633  0.32 
rs2072634  0.19 
rs3020644  0.65 
rs3130683  0.02 
rs4151657  0.55 
rs4151664  0.49 
rs4151670  0.39 
rs4151672  0.78 
rs429608  0.26 
rs512559  0.34 
rs537160  0.19 
rs547154  0.35 
rs644045  0.55 
rs7746553  0.03 
rs9267673  0.19 
rs9332735  0.13 
rs9501161  0.59 
 
 
 
Neovascular AMD 
Neovascular AMD versus Early AMD or Atrophic AMD 
Two C2/CFB SNPs were significantly associated with neovascular AMD when analyzed 
using Fisher‟s Exact test (Table 4. 24); rs3130683 (P = 0.004) and rs7746553 (P = 0.002).    
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Table 4. 24: Fisher's Exact test of association of C2/CFB variants with Neovascular 
AMD in WAMDS subjects 
SNP  Fisher's P value 
rs1048709  0.31 
rs1270942  0.61 
rs2072633  0.38 
rs2072634  0.14 
rs3020644  0.08 
rs3130683  0.004 
rs4151657  0.09 
rs4151664  0.14 
rs4151670  0.69 
rs4151672  0.89 
rs429608  0.12 
rs512559  0.38 
rs537160  0.13 
rs547154  0.39 
rs644045  0.53 
rs7746553  0.002 
rs9267673  0.06 
rs9332735  0.31 
rs9501161  0.38 
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Neovascular AMD versus Early AMD 
Three C2/CFB SNPs  were significantly associated with neovascular AMD versus early 
AMD  when  analyzed  using  Fisher‟s  Exact  test  (Table  4.25);  rs1048709  (P  <0.0001), 
rs3130683 (P = 0.01) and rs7746553 (P = 0.01).   
Table 4. 25: Fisher's Exact test of association of C2/CFB variants with Neovascular 
AMD versus Early AMD 
SNP  Fisher's P value 
rs1048709  <0.0001 
rs1270942  0.74 
rs2072633  0.33 
rs2072634  0.12 
rs3020644  0.65 
rs3130683  0.01 
rs4151657  0.35 
rs4151664  0.38 
rs4151670  0.40 
rs4151672  0.88 
rs429608  0.19 
rs512559  0.29 
rs537160  0.15 
rs547154  0.37 
rs644045  0.58 
rs7746553  0.01 
rs9267673  0.15 
rs9332735  0.19 
rs9501161  0.52 
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Neovascular AMD versus Atrophic AMD 
Two C2/CFB SNPs were significantly associated with neovascular AMD versus atrophic 
AMD when analyzed using Fisher‟s Exact test (Table 4.26); rs3020644 (P = 0.02), and 
rs4151657 (P = 0.03).   
 
Table 4. 26: Fisher's Exact test of association of C2/CFB variants with Neovascular 
AMD versus Atrophic AMD 
SNP  Fisher's P value 
rs1048709  0.29 
rs1270942  0.66 
rs2072633  0.46 
rs2072634  1.00 
rs3020644  0.02 
rs3130683  0.13 
rs4151657  0.03 
rs4151664  0.22 
rs4151670  1.00 
rs4151672  1.00 
rs429608  0.51 
rs512559  1.00 
rs537160  0.69 
rs547154  0.79 
rs644045  0.37 
rs7746553  0.14 
rs9267673  0.53 
rs9332735  1.00 
rs9501161  0.66 
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Atrophic AMD 
Atrophic AMD versus Early AMD and Neovascular AMD 
Two C2/CFB SNPs were significantly associated with atrophic AMD versus early AMD 
and neovascular AMD when analyzed using Fisher‟s Exact test (Table 4.27); rs3020644  
(P =0.03), and rs4151657 (P = 0.05).   
Table 4. 27: Fisher's Exact test of association of C2/CFB variants with Atrophic AMD 
among WAMDS subjects 
SNP  Fisher's P value 
rs1048709  0.38 
rs1270942  0.73 
rs2072633  0.43 
rs2072634  1.00 
rs3020644  0.03 
rs3130683  0.16 
rs4151657  0.05 
rs4151664  0.29 
rs4151670  0.72 
rs4151672  1.00 
rs429608  0.65 
rs512559  1.00 
rs537160  0.81 
rs547154  0.67 
rs644045  0.38 
rs7746553  0.32 
rs9267673  0.69 
rs9332735  0.72 
rs9501161  0.73 
 
Atrophic AMD versus Early AMD 
There were no significant associations between C2/CFB SNPs and atrophic AMD versus 
early when analyzed using Fisher‟s Exact test (Table E. 1, Appendix).  
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Retinal Scarring in Neovascular AMD 
There  were  no  significant  associations  between  C2/CFB  SNPs  and  retinal  scarring  in 
neovascular AMD when analyzed using Fisher‟s Exact test (Table E. 2, Appendix). 
Retinal Detachment in Neovascular AMD 
Two C2/CFB SNPs were significantly associated with retinal detachment in neovascular 
AMD when analyzed using Fisher‟s Exact test (Table 4.28); rs4151670 (P = 0.04), and 
rs429608 (P = 0.04).   
Table 4. 28: Fisher's Exact test of association of C2/CFB variants with retinal 
detachment in neovascular AMD 
SNP  Fisher's P value 
rs1048709  0.80 
rs1270942  0.47 
rs2072633  0.45 
rs2072634  0.27 
rs3020644  0.60 
rs3130683  0.92 
rs4151657  0.71 
rs4151664  0.81 
rs4151670  0.04 
rs4151672  0.34 
rs429608  0.04 
rs512559  0.43 
rs537160  0.83 
rs547154  0.13 
rs644045  0.50 
rs7746553  0.78 
rs9267673  0.60 
rs9332735  0.10 
rs9501161  0.30 
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Retinal Haemorrhage in Neovascular AMD 
One  C2/CFB  SNP  was  significantly  associated  with  retinal  detachment  in  neovascular 
AMD when analyzed using Fisher‟s Exact test (Table 4.29); rs3130683 (P = 0.03).   
Table 4. 29: Fisher's Exact test of association of C2/CFB variants with Retinal 
Haemorrhage in Neovascular AMD 
SNP  Fisher's P value 
rs1048709  0.08 
rs1270942  0.34 
rs2072633  0.77 
rs2072634  0.57 
rs3020644  0.25 
rs3130683  0.03 
rs4151657  0.35 
rs4151664  0.88 
rs4151670  0.81 
rs4151672  0.60 
rs429608  0.44 
rs512559  0.64 
rs537160  0.34 
rs547154  0.19 
rs644045  0.58 
rs7746553  0.45 
rs9267673  0.76 
rs9332735  1.00 
rs9501161  0.50 
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Legal Blindness 
Legal Blindness in all types of AMD 
Three  C2/CFB  SNPs  were  significantly  associated  with  legal  blindness  when  analyzed 
using Fisher‟s Exact Test (Table 4. 30); rs512559, rs547154 and rs7746553 (P = 0.02 for 
each SNP). None of the remaining C2/CFB SNPs were significantly associated with legal 
blindness in univariate tests. 
Table 4. 30: Fisher's Exact test of association of C2/CFB variants with legal blindness 
in WAMDS subjects 
SNP  Fisher's P value 
rs1048709  0.17 
rs1270942  0.88 
rs2072633  0.45 
rs2072634  0.21 
rs3020644  0.17 
rs3130683  0.21 
rs4151657  0.22 
rs4151664  0.29 
rs4151670  0.61 
rs4151672  0.81 
rs429608  0.26 
rs512559  0.02 
rs537160  0.23 
rs547154  0.02 
rs644045  0.65 
rs7746553  0.02 
rs9267673  0.28 
rs9332735  0.60 
rs9501161  0.22 
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Legal Blindness in Late AMD 
Table 4. 31: Fisher's Exact test of association of C2/CFB variants with Legal 
Blindness in Late AMD 
SNP  Fisher's P value 
rs1048709  0.10 
rs1270942  0.89 
rs2072633  0.42 
rs2072634  0.37 
rs3020644  0.25 
rs3130683  0.21 
rs4151657  0.26 
rs4151664  0.51 
rs4151670  0.78 
rs4151672  0.89 
rs429608  0.27 
rs512559  0.05 
rs537160  0.14 
rs547154  0.05 
rs644045  0.80 
rs7746553  0.08 
rs9267673  0.58 
rs9332735  1.00 
rs9501161  0.37 
 
Legal Blindness in Early AMD 
 
There were no significant associations between C2/CFB SNPs and legal blindness in early 
AMD when analyzed using Fisher‟s Exact test (Table E. 3, Appendix).   
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Low Vision 
Low Vision in all types of AMD 
There were no significant associations between C2/CFB SNPs and low vision in all AMD 
types combined when analyzed using Fisher‟s Exact test (Table E. 4, Appendix).  
Low Vision in Late AMD 
There were no significant associations between C2/CFB SNPs and low vision in late AMD 
when analyzed using Fisher‟s Exact test (Table E. 5, Appendix). There were two borderline 
associations; rs3020644 (P = 0.06) and rs644045 (P = 0.09).  
Low Vision in Early AMD 
There were no significant  associations  between C2/CFB  SNPs  and low vision in  early 
AMD when analyzed using Fisher‟s Exact test  (Table E. 6, Appendix). There was one 
borderline association; rs547154 (P = 0.09). 
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Visual Acuity 
Two C2/CFB SNPs rs2073634 (P = 0.004) and rs7746553 (P = 0.04) were significantly 
associated with Snellen visual acuity measurement in the worse eye of subjects (Table 4. 
32). None of the remaining SNPs were significantly associated with worse eye Snellen 
visual acuity.  
Table 4. 32: Kruskal Wallis univariate test of association of worse eye Snellen visual 
acuity with C2/CFB genotypes 
SNP  Test Statistic H  P value  Q value 
rs1048709  0.83  0.66  0.74 
rs1270942  3.31  0.19  0.74 
rs2072633  1.31  0.52  0.74 
rs2072634  8.19  0.004  0.08 
rs3020644  0.31  0.86  0.91 
rs3130683  1.44  0.49  0.74 
rs4151657  1.73  0.42  0.74 
rs4151664  0.92  0.63  0.74 
rs4151670  0.2  0.66  0.74 
rs4151672  0.15  0.93  0.93 
rs429608  1.05  0.59  0.74 
rs512559  2.69  0.26  0.74 
rs537160  1.80  0.41  0.74 
rs547154  3.91  0.14  0.74 
rs644045  1.02  0.60  0.74 
rs7746553  6.52  0.04  0.38 
rs9267673  1.17  0.56  0.74 
rs9332735  1.06  0.30  0.74 
rs9501161  1.90  0.39  0.74 
 
None of the C2/CFB SNPs showed a significant association with Snellen visual acuity 
score in the best eye of subjects (Table E. 7, Appendix).  
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It should be noted that there were low numbers of minor homozygotes in the rs4151672, 
rs512559 and rs547154 SNPs, which should be taken into account when interpreting the 
results for these SNPs. 
Multivariate Analysis 
Sixteen multivariate predictive models were developed using biologically plausible factors 
as covariates. These models formed the basis of multivariate analyses of C2/CFB genetic 
variants.  
Late AMD 
Association of C2/CFB variants with late AMD (atrophic and neovascular) 
In this model (Model 1) late AMD was adjusted for age at study, gender, pack years of 
smoking  and  history  of  alcohol  consumption.  There  were  no  statistically  significant 
associations between C2/CFB variants and late AMD after adjusting for multiple testing 
(Table F. 1, Appendix). 
CNV (Choroidal Neovascularisation/Neovascular AMD) 
CNV Presence  
Association of C2/CFB variants with neovascular AMD 
Neovascular AMD versus Atrophic AMD or Early AMD 
In this model (Model 2) neovascular AMD was adjusted for age at study, gender, pack 
years of smoking and history of alcohol  consumption. Under a  codominant  model,  the 
rs3020644 (P = 0.02) and rs4151657 (P = 0.03) variants were significantly associated with 
decreased  risk  of  neovascular  AMD  (versus  early  AMD  and  atrophic  AMD)  and  the 
rs7746553  (P  =  0.01)  variant  was  significantly  associated  with  increased  risk  of  
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neovascular  AMD.    These  associations  were  strengthened  when  the  rs3020644  and 
rs4151657  variants  were  fitted  to  dominant  genetic  models  (P  =  0.004  and  P  =  0.01 
respectively) and the rs7746553 variant was fitted to a recessive genetic model (P = 0.004) 
(Table 4. 34).  
Table 4. 33: Estimated odds ratios of neovascular AMD for C2/CFB genetic variants 
among WAMDS subjects (continued on next page) 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.09 
0.33 
GA  1.43 (1.01, 2.03) 
AA  1.53 (0.64, 3.69) 
rs1270942 
TT  1 
0.74 
0.78 
TC  0.95 (0.66, 1.37) 
CC  1.61 (0.42, 6.22) 
rs2072633 
CC  1 
0.21 
0.35 
CT  1.07 (0.75, 1.52) 
TT  1.50 (0.93, 2.42) 
rs2072634
b 
GG  1 
0.15 
0.35  GA + AA  2.43 (0.67, 8.87) 
rs3020644 
AA  1 
0.02 
0.19 
AG  0.63 (0.44, 0.90) 
GG  0.58 (0.37, 0.93) 
rs3130683
b 
TT  1 
0.06 
0.29  TC + CC  1.43 (0.98, 2.08) 
rs4151657 
TT  1 
0.03 
0.19 
TC  0.65 (0.46, 0.91) 
CC  0.62 (0.37, 1.03) 
rs4151664
b 
CC  1 
0.12 
0.33  CT + TT  1.45 (0.91, 2.32) 
rs4151670
b 
CC  1 
0.29 
0.39  CT + TT  1.64 (0.65, 4.14) 
rs4151672 
CC  1 
0.71 
0.78 
CT  0.71 (0.33, 1.56) 
TT  0.92 (0.08, 10.39) 
aNeovascular AMD adjusted for age at study, gender, pack-years of smoking, and 
alcohol consumption 
 
bDominant model used due to low minor allele frequency 
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Table 4. 33: Estimated odds ratios of neovascular AMD for C2/CFB genetic variants 
among WAMDS subjects (continued from previous page) 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value 
rs429608 
GG  1 
0.28  0.39  GA  0.76 (0.50, 1.15) 
AA  0.93 (0.39, 9.60)   
rs512559
b 
TT  1 
0.12 
0.33  TC + CC  0.50 (0.32, 1.13) 
rs537160 
GG  1 
0.21 
0.35 
GA  1.15 (0.82, 1.61) 
AA  1.61 (0.94, 2.76) 
rs547154
b 
CC  1 
0.99 
0.99  CA + AA  1.00 (0.61, 1.62) 
rs644045 
GG  1 
0.22 
0.35 
GA  1.19 (0.86, 1.67) 
AA  1.58 (0.92, 2.71) 
rs7746553 
CC  1 
0.01 
0.19 
CG  1.24 (0.86, 1.77) 
GG  6.30 (1.41, 28.16) 
rs9267673
b 
CC  1 
0.2 
0.35  CT + TT  1.30 (0.87, 1.93) 
rs9332735
b 
GG  1 
0.72 
0.78  GA+ AA  1.18 (0.47, 2.94) 
rs9501161 
GG  1 
0.57 
0.72 
GA  1.28 (0.81, 2.03) 
AA  1.18 (0.10, 13.64) 
aNeovascular AMD adjusted for age at study, gender, pack-years of smoking, and alcohol 
consumption 
 
bDominant model used due to low minor allele frequency 
 
 
Note that heterozygotes and minor homozygotes were combined and analyzed as a single 
category  (simulating  a  dominant  model)  for  several  genetic  variants,  as  the  number  of 
mutant  homozygotes  for  these  variants  were  too  low  in  the  WAMDS  population.  This 
technique was also applied for analyses of other outcomes.  
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In the codominant  genetic model,  the  rs1048709 was  associated with  increased risk of 
neovascular AMD with borderline significance (P = 0.09) (Table 4. 33). This association 
with rs1048709 reached significance (P = 0.03) when tested under a dominant genetic 
model (Table 4. 34). Under these new genetic models and after adjustment for multiple 
testing, the rs3020644 and rs7746553 associations were significant (Q = 0.04 for each), and 
the rs4151657 association was borderline significant (Q = 0.06). 
Table 4. 34: Estimated odds ratios of neovascular AMD for C2/CFB genetic variants 
among WAMDS subjects: under dominant and recessive models 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value
  
rs3020644
 b 
AA  1.00 
0.004  0.04  AG + GG  0.61 (0.44, 0.86) 
rs4151657
 b 
TT  1.00 
0.01  0.06  TC + CC  0.64 (0.46, 0.89) 
rs7746553
 c 
CC + CG  1.00 
0.004  0.04  GG  5.95 (1.34, 26.54) 
aNeovascular AMD adjusted for age at study, gender, pack-years of smoking, and alcohol consumption 
bDominant genetic model 
cRecessive genetic model 
 
In  summary,  there  were  two  significant  associations  and  one  borderline  significant 
association  between  C2/CFB  variants  and  increased  risk  of  neovascular  AMD  in  the 
WAMDS  population  when  adjusted  for  age  at  study,  gender,  pack-years  of  smoking, 
alcohol consumption and multiple testing. Minor allele homozygosity and heterozygosity of 
the rs3020644 (P = 0.004, Q = 0.04) and rs4151657 (P = 0.01, Q = 0.06) SNPs were 
independently  associated  with  a  decreased  risk  of  neovascular  AMD.  Minor  allele  
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homozygosity  at  the  rs7746553  locus  (P  =  0.004,  Q  =  0.04)  was  associated  with  an 
increased risk of neovascular AMD. 
Neovascular AMD versus Early AMD  
In this model (Model 3) neovascular AMD was adjusted for age at study, gender, pack 
years  of  smoking  and  history  of  alcohol  consumption.  There  were  no  statistically 
significant associations between C2/CFB variants and neovascular AMD versus early AMD 
after adjusting for multiple testing (Table F. 2, Appendix).  
Neovascular AMD versus Atrophic AMD  
In this model (Model 4) neovascular AMD was adjusted for pack years of smoking.  
When tested under codominant genetic models the rs3020644 and rs4151657 variants were 
associated (P = 0.002 and P = 0.01 respectively) with reduced risk of neovascular AMD 
versus  atrophic  AMD,  associations  that  were  significant  or  borderline  significant  after 
adjustment  for  multiple  testing  (Q  =  0.04  and  Q  =  0.06  respectively).  The  rs3130683 
variant  was  associated  with  an  increased  risk  of  neovascular  AMD  under  a  default 
dominant model (P = 0.01, Q = 0.06) with borderline significance after adjustment for 
multiple testing. 
When  fitted  in  a  dominant  genetic  model,  the  associations  strengthened  between  the 
rs3020644  and  rs4151657  variants  (P  =  0.0004,  Q  =  0.01  and  P  =  0.002,  Q  =  0.02 
respectively) and neovascular AMD (Table 4. 36).  
The rs1048709 variant was associated (P = 0.07) with an increased risk of neovascular 
AMD  with  borderline  significance  under  an  initial  codominant  model,  which  was  not  
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significant  after  multiple  testing.  However,  under  a  dominant  model,  the  association 
strengthened (P = 0.02, Q < 0.10) and is perhaps worth further investigation.  
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Table 4. 35: Estimated odds ratios of neovascular AMD versus Atrophic AMD for 
C2/CFB genetic variants under codominant models (continued on next page) 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.07  0.33 
GA  2.00 (1.02, 3.91) 
AA  2.89 (0.38, 22.16) 
rs1270942
b 
TT  1 
0.9  0.91  TC + CC  0.96 (0.50, 1.82) 
rs2072633 
CC  1 
0.17  0.40 
CT  1.53 (0.84, 2.81) 
TT  2.15 (0.88, 5.25) 
rs2072634
b 
GG  1 
0.69  0.82  GA + AA  1.49 (0.19, 11.68) 
rs3020644 
AA  1 
0.002  0.04 
AG  0.30 (0.14, 0.65) 
GG  0.30 (0.12, 0.74) 
rs3130683
b 
TT  1 
0.01  0.06  TC + CC  2.60 (1.14, 5.90) 
rs4151657 
TT  1 
0.01  0.06 
TC  0.40 (0.20, 0.78) 
CC  0.33 (0.14, 0.79) 
rs4151664
b 
CC  1 
0.09  0.33  CT + TT  2.29 (0.80, 6.55) 
rs4151670
b 
CC  1 
0.47  0.68  CT + TT  1.99 (0.26, 15.28) 
rs4151672
b 
CC  1 
0.81  0.91  CT + TT  1.20 (0.27, 5.29) 
aNeovascular AMD adjusted for pack-years of smoking 
 
bDominant model used due to low minor allele frequency 
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Table 4. 35: Estimated odds ratios of neovascular AMD versus Atrophic AMD for 
C2/CFB genetic variants: under codominant models (continued from previous page) 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value 
rs429608
b 
GG  1 
0.5  0.68  GA + AA  0.78 (0.38, 1.58) 
rs512559
b 
TT  1 
0.47  0.68  TC + CC  0.66 (0.22, 1.98) 
rs537160 
GG  1 
0.24  0.46 
GA  1.36 (0.76, 2.45) 
AA  2.29 (0.77, 6.84) 
rs547154
b 
CC  1 
0.91  0.91  CA + AA  1.05 (0.43, 2.58) 
rs644045 
GG  1 
0.12  0.33 
GA  1.42 (0.80, 2.54) 
AA  2.99 (0.88, 10.20) 
rs7746553
b 
CC  1 
0.12  0.33  CG + GG  1.67 (0.85, 3.25) 
rs9267673
b 
CC  1 
0.21  0.44  CT + TT  1.61 (0.73, 3.52) 
rs9332735
b 
GG  1 
0.58  0.73  GA+ AA  1.72 (0.22, 13.35) 
rs9501161
b 
GG  1 
0.32  0.55  GA + AA  1.54 (0.64, 3.72) 
aNeovascular AMD adjusted for pack-years of smoking 
 
bDominant model used due to low minor allele frequency 
 
 
Table 4. 36: Estimated odds ratios of neovascular AMD versus atrophic AMD for 
C2/CFB genetic variants: under dominant models 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value 
rs1048709 
GG  1.00 
0.02  < 0.10  GA + AA  2.07 (1.08, 3.96) 
rs3020644 
AA  1.00 
0.0004  0.01  AG + GG  0.30 (0.14, 0.63) 
rs3130683 
TT  1.00 
0.01  0.06  TC + CC  2.60 (1.14, 5.90) 
rs4151657 
TT  1.00 
0.002  0.02  TC + CC  0.38 (0.20, 0.73) 
aNeovascular AMD adjusted for pack-years of smoking  
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In summary, two C2/CFB SNPs were significantly associated with neovascular AMD 
versus atrophic AMD after adjusting for pack-years of smoking and multiple testing, with 
an additional SNP reaching borderline significance and another SNP worth further 
investigation. Minor allele homozygosity and heterozygosity at the rs3020644 (P = 0.0004, 
Q = 0.01) and rs4151657 (P = 0.002, Q = 0.02) loci were independently associated with a 
reduced risk of neovascular AMD, while the same genoptypic patterns at the rs1048709  
(P = 0.03 Q < 0.1) and rs3130683 (P = 0.01, Q = 0.06) loci were independently associated 
with an increased risk of neovascular AMD with borderline significance.  
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CNV Lesion Composition 
In  this  model  (Model  5)  CNV  lesion  composition  was  adjusted  for  history  of  CNV 
treatment. Six C2/CFB SNPs were significantly associated with CNV lesion composition in 
the neovascular AMD subset of the WAMDS population after adjusting for history of prior 
CNV treatment and multiple testing under codominant models.  
Table 4. 37: Estimated odds ratios of CNV lesion composition for C2/CFB genetic 
variants among neovascular AMD WAMDS subjects under codominant models 
(continued on next page) 
SNP  Genotypes 
CNV Lesion Composition
a 
LR P 
value
d 
Q 
value  Predom Classic versus 
Occult 
Min Classic versus 
Occult  OR (95% CI)  OR (95% CI) 
rs1048709 
GG  1  1 
0.001  0.01 
GA  0.73 (0.46, 1.14)  1.10 (0.60, 2.01) 
AA  0.38 (0.15, 1.00)  0.19 (0.02, 1.49) 
rs1270942 
TT  1  1 
0.22  0.32 
TC  1.18 (0.72, 1.93)  1.06 (0.53, 2.14) 
CC  2.66 (0.34, 20.71)  3.65 (0.31, 43.30) 
rs2072633 
CC  1  1 
0.0003  0.005 
CT  1.17 (0.74, 1.87)  1.75 (0.88, 3.48) 
TT  0.45 (0.24, 0.84)  0.87 (0.37, 2.07) 
rs2072634
b 
GG  1  1 
*
c  *
c  GA + AA  *
c  *
c 
rs3020644 
AA  1  1 
0.15  0.24 
AG  1.02 (0.65, 1.59)  1.37 (0.73, 2.57) 
GG  1.20 (0.67, 2.14)  0.87 (0.35, 2.17) 
rs3130683 
TT  1  1 
0.02  0.05 
TC  0.89 (0.55, 1.46)  1.62 (0.86, 3.04) 
CC  0.39 (0.11, 1.36)  0.35 (0.04, 2.96) 
rs4151657 
TT  1  1 
0.02  0.05 
TC  1.17 (0.75, 1.80)  1.30 (0.71, 2.38) 
CC  1.64 (0.84, 3.20)  1.12 (0.40, 3.08) 
rs4151664
b 
CC  1  1 
0.4  0.46  CT + TT  1.16 (0.66, 2.02)  0.63 (0.25, 1.60) 
rs4151670
b 
CC  1  1 
*c  *c  CT + TT  *
c  *
c 
rs4151672
b 
CC  1  1 
0.52  0.52  CT + TT  0.95 (0.35, 2.55)  1.09 (0.29, 4.15) 
aCNV lesion composition adjusted for prior CNV treatment       
bDominant model used due to low minor allele frequency       
cModel failed to converge after 20 iterations 
   
dLR(Likelihood ratio) P value calculated using Excel CHIDIST( (loglikelihoodmodelonly-loglikelihoodmodelwithSNP)*2, 2 degrees of 
freedom)   
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Table 4. 37: Estimated odds ratios of CNV lesion composition for C2/CFB genetic 
variants among neovascular AMD WAMDS subjects under codominant models 
(continued from previous page) 
SNP  Genotypes 
CNV Lesion Composition
a 
LR P 
value
d  Q value  Predom Classic versus 
Occult 
Min Classic versus 
Occult  OR (95% CI)  OR (95% CI) 
rs429608 
GG  1  1 
0.01  0.04  GA  1.26 (0.72, 2.19)  1.29 (0.60, 2.77) 
AA  0.18 (0.02, 1.70)  0.59 (0.06, 5.63)   
rs512559
b 
TT  1  1 
0.24 
0.32  TC + CC  1.36 (0.54, 3.44)  2.11 (0.68, 6.48) 
rs537160 
GG  1  1 
0.001 
0.005 
GA  0.98 (0.63, 1.52)  1.29 (0.69, 2.44) 
AA  0.35 (0.18, 0.70)  0.81 (0.34, 1.95) 
rs547154
b 
CC  1  1 
0.37 
0.46  CA + AA  1.27 (0.67, 2.40)  0.94 (0.36, 2.45) 
rs644045 
GG  1  1 
0.11 
0.2 
GA  1.00 (0.65, 1.55)  1.56 (0.84, 2.88) 
AA  0.73 (0.38, 1.42)  0.69 (0.24, 2.00) 
rs7746553 
CC  1  1 
0.1 
0.2 
CG  1.12 (0.71, 1.75)  0.64 (0.31, 1.29) 
GG  0.97 (0.33, 2.90)  1.13 (0.28, 4.56) 
rs9267673 
CC  1  1 
0.06 
0.14 
CT  1.23 (0.75, 2.01)  0.60 (0.27, 1.37) 
TT  0.37 (0.04, 3.56)  0.98 (0.10, 9.20) 
rs9332735
b 
GG  1  1 
*c 
*c  GA+ AA  *
c  *
c 
rs9501161
b 
GG  1  1 
0.49 
0.52  GA + AA  1.02 (0.58, 1.78)  1.17 (0.55, 2.49) 
aCNV lesion composition adjusted for prior CNV treatment 
     
bDominant model used due to low minor allele frequency 
     
cModel failed to converge after 20 iterations         
dLR(Likelihood Ratio) P value calculated using Excel CHIDIST( (loglikelihoodmodelonly-
loglikelihoodmodelwithSNP)*2, 2 degrees of freedom)   
 
 
Under codominant genetic models, the rs1048709, rs2072633 and rs537160 variants were 
associated  (P  =  0.001,  Q = 0.01;  P = 0.0003,  Q = 0.005;  and  P  = 0.001, Q =  0.005 
respectively) with a reduced risk of predominantly classic type lesions as opposed to occult 
type  lesions.  When  fitted  to  alternative  genetic  models,  only  the  association  with  the  
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rs537160 variant (P = 0.001, Q = 0.01) strengthened (under a recessive genetic model), 
albeit  very  minutely.  While  there  were  borderline  significant  associations  between  the 
rs3130683, rs4151657 and rs429608 variants (P = 0.02, Q = 0.05; P = 0.02, Q = 0.05;  
P = 0.01, Q = 0.04 respectively), it was unclear which lesion types were associated with 
these variants. 
Table 4. 38: Estimated odds ratios of CNV lesion composition for C2/CFB genetic 
variants among neovascular AMD WAMDS subjects: under recessive models 
SNP  Genotypes 
CNV Lesion Composition
a 
LR P value
c  Q value  Predom Classic versus 
Occult 
Min Classic versus 
Occult  OR (95% CI)  OR (95% CI) 
rs537160 
GG + GA  1  1 
0.001  0.01  AA  0.35 (0.19, 0.68)  0.70 (0.32, 1.55) 
aCNV lesion composition adjusted for prior CNV treatment 
   
bDominant model used due to low minor allele frequency 
 
 
cLR(Likelihood Ratio)  P value calculated using Excel CHIDIST( (loglikelihoodmodelonly-
loglikelihoodmodelwithSNP)*2, 2 degrees of freedom) 
 
 
In  summary,  three  C2/CFB  variants  were  significantly  associated  with  reduced  risk  of 
predominantly classic type lesions versus occult type lesions after adjusting for prior CNV 
treatment. Minor allele homozygosity at the rs537160 locus was associated (P = 0.001,  
Q = 0.01) with reduced risk of predominantly classic lesions versus occult lesions; similar 
associations were observed with the rs1048709 and rs2072633 variants (P = 0.001,  
Q = 0.005; and P = 0.003, Q = 0.005 respectively) but the exact genetic model for these 
variants  was  not  resolved.  Although  several  other  C2/CFB  variants  appeared  to  be 
significantly associated with lesion composition, direction of association and appropriate 
genetic models could not be determined, and the significance of these associations  was  
167 
   
173
 
modest in comparison to the three most significant variants. No other C2/CFB variants 
appeared to be associated with lesion composition. 
CNV Lesion Size 
In this model (Model 6) CNV lesion size was adjusted for history of CNV treatment and 
multiple  testing.  Three  C2/CFB  variants  were  borderline  significantly  associated  with 
lesion size. 
Under  an  initial  codominant  model,  the  rs1270942  variant  was  borderline  significantly 
associated (P = 0.01, Q = 0.06) with reduced lesion size in the neovascular AMD subset of 
the  WAMDS  population  after  adjusting  for  history  of  prior  CNV  treatment.  This 
association was modestly refined (P = 0.01, Q = 0.06) when fitted to a recessive genetic 
model.  Under  codominant  models,  borderline  significant  associations  were  observed 
between rs1048709 and rs4151657 variants (P = 0.01, Q = 0.06 for each) with lesion size, 
but it was not discernable whether the associations were with increased or decreased lesion 
size.   
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Table 4. 39: Estimated odds ratios of CNV lesion size for C2/CFB genetic variants 
among neovascular AMD WAMDS subjects under codominant models (continued on 
next page) 
SNP  Genotypes 
CNV Lesion Size
a 
LR P value
c  Q value 
OR (95% CI) 
rs1048709 
GG  1 
0.01  0.06 
GA  0.95 (0.64, 1.39) 
AA  2.54 (0.92, 7.02) 
rs1270942 
TT  1 
0.01  0.06 
TC  1.14 (0.73, 1.79) 
CC  0.25 (0.07, 0.90) 
rs2072633 
CC  1 
0.07  0.19 
CT  1.24 (0.83, 1.87) 
TT  1.05 (0.63, 1.75) 
rs2072634
b 
GG  1 
0.35  0.60  GA + AA  0.51 (0.17, 1.48) 
rs3020644 
AA  1 
0.18  0.34 
AG  0.75 (0.50, 1.11) 
GG  1.04 (0.61, 1.79) 
rs3130683 
TT  1 
0.14  0.30 
TC  1.12 (0.73, 1.71) 
CC  3.30 (0.74, 14.63) 
rs4151657 
TT  1 
0.01  0.06 
TC  0.74 (0.51, 1.09) 
CC  0.97 (0.53, 1.79) 
rs4151664 
CC  1 
0.82  0.83 
CT  1.12 (0.66, 1.90) 
TT  0.73 (0.13, 4.06) 
rs4151670
b 
CC  1 
0.83  0.83  CT + TT  0.74 (0.27, 2.02) 
rs4151672
b 
CC  1 
0.69  0.83  CT + TT  0.85 (0.37, 1.97) 
aCNV lesion composition adjusted for prior CNV treatment 
 
bDominant model used due to low minor allele frequency 
 
cLR (Likelihood Ratio) P value calculated using Excel CHIDIST( (loglikelihoodmodelonly-
loglikelihoodmodelwithSNP)*2, 2 degrees of freedom) 
 
  
169 
   
173
 
Table 4. 39: Estimated odds ratios of CNV lesion size for C2/CFB genetic variants 
among neovascular AMD WAMDS subjects under codominant models (continued 
from previous page) 
SNP  Genotypes 
CNV Lesion Size
a 
LR P value
c  Q value 
OR (95% CI) 
rs429608 
GG  1 
0.03  0.11 
GA  0.78 (0.48, 1.26) 
AA  1.03 (0.20, 5.36) 
rs512559
b 
TT  1 
0.67  0.83  TC + CC  1.21 (0.54, 2.67) 
rs537160 
GG  1 
0.03  0.11 
GA  1.18 (0.80, 1.74) 
AA  1.03 (0.59, 1.78) 
rs547154 
CC  1 
0.12  0.29 
CA  1.12 (0.62, 2.02) 
AA  0.10 (0.01, 1.64) 
rs644045 
GG  1 
0.77  0.83 
GA  1.15 (0.78, 1.69) 
AA  1.05 (0.60, 1.85) 
rs7746553 
CC  1 
0.07  0.19 
CG  1.32 (0.87, 1.99) 
GG  0.92 (0.36, 2.33) 
rs9267673 
CC  1 
0.51  0.80 
CT  1.22 (0.77, 1.92) 
TT  0.93 (0.23, 3.80) 
rs9332735
b 
GG  1 
0.55  0.80  GA+ AA  0.79 (0.27, 2.36) 
rs9501161
b 
GG  1 
0.74  0.83  GA + AA  0.97 (0.60, 1.58) 
aCNV lesion composition adjusted for prior CNV treatment 
 
bDominant model used due to low minor allele frequency 
 
cLR (Likelihood Ratio) P value calculated using Excel CHIDIST( (loglikelihoodmodelonly-
loglikelihoodmodelwithSNP)*2, 2 degrees of freedom) 
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Table 4. 40: Estimated odds ratios of CNV lesion size for C2/CFB genetic variants 
among neovascular AMD WAMDS subjects: under recessive model 
SNP  Genotypes 
CNV Lesion Size
a 
LR P value
b  Q value 
OR (95% CI) 
rs1270942 
TT + TC  1 
0.01  0.06  CC  0.25 (0.07, 0.88) 
aCNV lesion composition adjusted for prior CNV treatment 
 
bLR (Likelihood Ratio)  P value calculated using Excel CHIDIST( (loglikelihoodmodelonly-
loglikelihoodmodelwithSNP)*2, 2 degrees of freedom) 
 
 
In summary, three C2/CFB variants were borderline significantly associated with lesion 
size in the neovascular AMD subset of the WAMDS population after adjusting for prior 
CNV treatment. Minor allele homozygosity of the rs1270942 variant was associated  
(P  =  0.01,  Q  =  0.06)  with  reduced  lesion  size.  Associations  with  the  rs1048709  and 
rs4151657 variants were also borderline significant under codominant genetic models  
(P = 0.01, Q = 0.06).   
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GA (Geographic Atrophy / Atrophic AMD) 
Atrophic AMD versus Neovascular AMD and Early AMD 
In this model (Model 7) atrophic AMD was adjusted for age at study and multiple testing.  
Table 4. 41: Estimated odds ratios of atrophic AMD for C2/CFB genetic variants 
among WAMDS subjects under codominant models (continued on next page) 
SNP  Genotypes 
Atrophic AMD
a 
LR P value  Q value 
OR (95% CI) 
rs1048709 
GG  1 
0.23  0.73 
GA  0.76 (0.44, 1.31) 
AA  0.29 (0.04, 2.13) 
rs1270942 
TT  1 
0.76  0.77 
TC  1.22 (0.70, 2.11) 
CC  0.81 (0.10, 6.26) 
rs2072633 
CC  1 
0.37  0.74 
CT  0.75 (0.44, 1.28) 
TT  0.61 (0.29, 1.30) 
rs2072634
b 
GG  1 
0.77  0.77  GA + AA  0.75 (0.10, 5.73) 
rs3020644 
AA  1 
0.02  0.32 
AG  2.20 (1.20, 4.04) 
GG  2.06 (0.97, 4.38) 
rs3130683
b 
TT  1 
0.05  0.32  TC + CC  0.55 (0.29, 1.08) 
rs4151657 
TT  1 
0.05  0.32 
TC  1.85 (1.06, 3.23) 
CC  2.11 (0.98, 4.56) 
rs4151664
b 
CC  1 
0.11  0.52  CT + TT  0.50 (0.20, 1.27) 
rs4151670
b 
CC  1 
0.49  0.75  CT + TT  0.52 (0.07, 3.93) 
rs4151672
b 
CC  1 
0.76  0.77  CT + TT  0.83 (0.25, 2.76) 
aAtrophic AMD adjusted for age at study 
 
bDominant model used due to low minor allele frequency 
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Table 4. 41: Estimated odds ratios of atrophic AMD for C2/CFB genetic variants 
among WAMDS subjects under codominant models (continued from previous page) 
SNP  Genotypes 
Atrophic AMD
a 
LR P value  Q value 
OR (95% CI) 
rs429608
b 
GG  1 
0.67  0.77  GA + AA  1.14 (0.62, 2.10) 
rs512559
b 
TT  1 
0.74  0.77  TC + CC  0.84 (0.30, 2.40) 
rs537160 
GG  1 
0.73  0.77 
GA  0.93 (0.56, 1.55) 
AA  0.71 (0.30, 1.67) 
rs547154
b 
CC  1 
0.43  0.74  CA + AA  0.72 (0.30, 1.70) 
rs644045 
GG  1 
0.31  0.74 
GA  0.84 (0.51, 1.38) 
AA  0.50 (0.19, 1.32) 
rs7746553
b 
CC  1 
0.19  0.72  CG + GG  0.69 (0.39, 1.23) 
rs9267673
b 
CC  1 
0.39  0.74  CT + TT  0.75 (0.39, 1.46) 
rs9332735
b 
GG  1 
0.51  0.75  GA+ AA  0.54 (0.07, 4.03) 
rs9501161
b 
GG  1 
0.41  0.74  GA + AA  0.74 (0.36, 1.53) 
aAtrophic AMD adjusted for age at study 
 
bDominant model used due to low minor allele frequency 
 
 
 Under an initial codominant model, the rs3020644 and rs4151657 variants were associated 
(P = 0.02 and P = 0.05 respectively) with an increased risk of atrophic AMD (versus 
neovascular  AMD  and  early  AMD)  but  the  strengths  of  these  associations  were 
insignificant when adjusted for multiple testing. These associations were refined (P = 0.01, 
Q  =  0.095  for  each)  under  a  dominant  genetic  model,  making  them  worth  future 
investigations.   
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Table 4. 42: Estimated odds ratios of Atrophic AMD for C2/CFB genetic variants 
among WAMDS subjects: under dominant models 
SNP  Genotypes 
Atrophic AMD
a 
LR P value  Q value 
OR (95% CI) 
rs3020644 
AA  1 
0.01  0.095  AG + GG  2.16 (1.20, 3.89) 
rs4151657 
TT  1 
0.01  0.095  TC + CC  1.90 (1.11, 3.25) 
aAtrophic AMD adjusted for age at study 
 
 
In summary, none of the C2/CFB variants were significantly associated with atrophic AMD 
(versus  all  other  AMD)  after  adjusting  for  age  at  study  and  multiple  testing,  but  the 
rs3020644 and rs4151657 variants could  potentially reach significance if  included  in  a 
smaller pool of simultaneous analyses. 
 
Atrophic AMD versus Early AMD 
In this model (Model 8) atrophic AMD was adjusted for history of smoking and age at 
study.  There  were  no  significant  associations  between  C2/CFB  genetic  variants  and 
atrophic AMD in the non-neovascular subset of the WAMDS population after adjusting for 
age at study and smoking status (Table F. 3, Appendix).  
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Legal Blindness 
 
Legal Blindness in the WAMDS Population 
In  this  model  (Model  9)  legal  blindness  was  adjusted  for  age  at  study.  Two  C2/CFB 
variants were significantly associated with legal blindness in the WAMDS population.  
Table 4. 43: Estimated odds ratios of legal blindness for C2/CFB genetic variants 
among WAMDS subjects under codominant models (continued on next page) 
SNP  Genotypes 
Legal Blindness
a 
LR P value  Q value 
OR (95% CI) 
rs1048709 
GG  1 
0.09  0.40 
GA  0.71 (0.48, 1.05) 
AA  0.48 (0.16, 1.37) 
rs1270942 
TT  1 
0.91  0.91 
TC  0.91 (0.60, 1.38) 
CC  0.97 (0.27, 3.54) 
rs2072633 
CC  1 
0.43  0.63 
CT  0.96 (0.65, 1.42) 
TT  0.72 (0.42, 1.23) 
rs2072634
b 
GG  1 
0.21  0.40  GA + AA  2.04 (0.70, 5.91) 
rs3020644 
AA  1 
0.1  0.40 
AG  1.11 (0.76, 1.61) 
GG  0.63 (0.36, 1.10) 
rs3130683 
TT  1 
0.14  0.40 
TC  0.65 (0.42, 1.01) 
CC  1.00 (0.28, 3.62) 
rs4151657 
TT  1 
0.16  0.40 
TC  1.06 (0.74, 1.52) 
CC  0.58 (0.30, 1.13) 
rs4151664 
CC  1 
0.21  0.40 
CT  1.24 (0.75, 2.06) 
TT  5.05 (8.00, 31.92) 
rs4151670
b 
CC  1 
0.56  0.63  CT + TT  0.70 (0.20, 2.41) 
rs4151672
b 
CC  1 
0.89  0.91  CT + TT  0.95 (0.43, 2.10) 
aLegal blindness adjusted for age at study 
 
bDominant model used due to low minor allele frequency 
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Table 4. 43: Estimated odds ratios of legal blindness for C2/CFB genetic variants 
among WAMDS subjects under codominant models (continued from previous page) 
SNP  Genotypes 
Legal Blindness
a  LR P 
value 
Q value 
OR (95% CI) 
rs429608 
GG  1 
0.45  0.63 
GA  1.06 (0.67, 1.67) 
AA  2.30 (0.66, 7.99) 
rs512559
b 
TT  1 
0.54  0.63  TC + CC  0.80 (0.38, 1.66) 
rs537160 
GG  1 
0.2  0.40 
GA  0.98 (0.68, 1.40) 
AA  0.59 (0.32, 1.10) 
rs547154 
CC  1 
0.06  0.40 
CA  0.92 (0.52, 1.63) 
AA  12.01 (1.24, 116.51) 
rs644045 
GG  1 
0.5  0.63 
GA  0.82 (0.57, 1.19) 
AA  0.78 (0.43, 1.39) 
rs7746553 
CC  1 
0.01  0.19 
CG  1.61 (1.11,  2.33) 
GG  3.04 (1.12, 8.27) 
rs9267673 
CC  1 
0.13  0.40 
CT  1.43 (0.94, 2.17) 
TT  3.27 (0.61, 17.44) 
rs9332735
b 
GG  1 
0.56  0.63  GA+ AA  0.71 (0.21, 2.43) 
rs9501161 
GG  1 
0.42  0.63 
GA  1.36 (0.87, 2.12) 
AA  0.93 (0.10, 8.50) 
aLegal blindness adjusted for age at study 
 
bDominant model used due to low minor allele frequency 
 
 
Under an initial codominant model, none of the observed associations between C2/CFB 
variants were significant after adjustment for multiple testing. However, under an additive 
genetic model the rs7746553 variant was significantly associated with  legal blindness  
(P = 0.002, Q = 0.04).  
  
176 
   
173
 
Table 4. 44: Estimated odds ratios of legal blindness for C2/CFB genetic variants 
among WAMDS subjects: under recessive and additive models 
SNP  Genotypes 
Legal Blindness
a 
LR P value  Q value 
OR (95% CI) 
rs547154
b 
CC + CA  1 
0.02  0.19  AA  12.11 (1.25, 117.41) 
rs7746553
c 
CC  1 
0.002  0.04  CG + GG  1.65 (1.20, 2.27) 
aLegal blindness adjusted for age at study 
 
bRecessive genetic model 
   
 
cAdditive genetic model 
   
 
 
In summary, one C2/CFB variant was significantly associated with risk of legal blindness 
amongst WAMDS subjects after adjusting for age of study and multiple testing. The risk of 
legal blindness increased proportionately (P = 0.002, Q = 0.04) to the number of copies of 
the  minor  allele  at  the  rs7746553  locus.  No  other  C2/CFB  variants  were  significantly 
associated with risk of legal blindness in the WAMDS population.  
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Legal Blindness in the Late AMD subset of the WAMDS Population 
In this model (Model 10) legal blindness was adjusted for age at study, history of CNV 
treatment  and  multiple  testing.  None  of  the  C2/CFB  variants  tested  were  significantly 
associated with legal blindness in late AMD under this model (Table F. 4, Appendix).  
Low Vision 
 
Low Vision in the WAMDS Population 
In  this  model  (Model  11)  low  vision  was  adjusted  for  age  at  study  and  pack-years  of 
smoking. There were no significant associations between C2/CFB genetic variants and low 
vision in the WAMDS population after adjusting for smoke pack years and age at study 
(Table F. 5, Appendix). 
Low Vision in the Late AMD subset of the WAMDS Population 
In  this  model  (Model  12)  low  vision  was  adjusted  for  age  at  study,  history  of  CNV 
treatment and multiple testing. There were no significant associations between  C2/CFB 
genetic variants and low vision in late AMD under this model (Table F. 6, Appendix).  
Low Vision in the Early AMD subset of the WAMDS Population 
In this  model  (Model  13) low vision was  adjusted for age at  study, history of alcohol 
consumption, history of NSAID use and history of smoking. There were no significant 
associations between C2/CFB genetic variants and low vision in the early AMD subset of 
the WAMDS population, after adjusting for age at study, alcohol consumption, history of 
NSAID use and smoking status (Table F. 7, Appendix).  
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Serious Complications and Manifestations 
Retinal detachment 
In  this  model  (Model  14)  retinal  detachment  was  adjusted  for  history  of  alcohol 
consumption and history of CNV treatment. There were no significant associations between 
C2/CFB  genetic  variants  and  retinal  detachment  in  the  CNV  subset  of  the  WAMDS 
population, after adjusting for alcohol consumption and history of CNV treatment (Table F. 
8, Appendix). 
Retinal Scar 
In this model (Model 15) retinal scarring was adjusted for gender, pack years of smoking 
and  use  of  medications  for  treatment  of  high  cholesterol.  There  were  no  significant 
associations between C2/CFB genetic variants and retinal scarring in the CNV subset of the 
WAMDS  population,  after  adjusting  for  gender,  smoking  pack  years  and  use  of  high 
cholesterol treatment medication (Table F. 9, Appendix).  
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Age at Diagnosis 
In this model (Model 16) age at diagnosis was adjusted for ethnicity, maximum lifetime 
BMI, use of NSAIDS, history of hypertension, history of high cholesterol, and multiple 
testing (Table 4. 45). 
Table 4. 45: Estimated influence of C2/CFB variants on age of AMD diagnosis among 
WAMDS subjects under a codominant model (continued on next page) 
SNP  Genotypes 
Age at Diagnosis
a 
LR P value  Q value 
Coefficient (Std Error) 
rs1048709 
GG  1 
0.81  0.94 
GA  0.16 (0.82) 
AA  -1.18 (2.02) 
rs1270942 
TT  1 
0.91  0.94 
TC  -0.04 (0.86) 
CC  1.49 (3.44) 
rs2072633 
CC  1 
0.05  0.16 
CT  1.00 (0.84) 
TT  -1.53 (1.13) 
rs2072634
b 
GG  1 
0.73  0.94  GA + AA  0.95 (2.72) 
rs3020644 
AA  1 
0.13  0.31 
AG  -0.76 (0.84) 
GG  1.26 (1.084) 
rs3130683 
TT  1 
0.85  0.94 
TC  -0.34 (0.90) 
CC  -1.51 (3.42) 
rs4151657 
TT  1 
0.37  0.74 
TC  -0.32 (0.81) 
CC  1.34 (1.21) 
rs4151664 
CC  1 
0.39  0.74 
CT  -1.48 (1.10) 
TT  -1.29 (4.52) 
rs4151670
b 
CC  1 
0.004  0.08  CT + TT  -5.65 (1.94) 
rs4151672 
CC  1 
0.66  0.94 
CT  1.78 (1.99) 
TT  -0.34 (5.193) 
aAge at diagnosis adjusted for ethnicity, maximum lifetime BMI, high cholesterol, hypertension and NSAID use
 
bDominant model used due to low minor allele frequency 
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Table 4. 45: Estimated influence of C2/CFB variants on age of AMD diagnosis among 
WAMDS subjects under codominant models (continued from previous page) 
SNP  Genotypes 
Age at Diagnosis
a 
LR P value  Q value 
Coefficient (Std Error) 
rs429608 
GG  1 
0.72  0.94 
GA  -0.70 (1.05) 
AA  -1.84 (3.69) 
rs512559 
TT  1 
0.88  0.94 
TC  0.90 (1.88) 
CC  1.36 (8.98) 
rs537160 
GG  1 
0.05  0.16 
GA  0.91 (0.80) 
AA  -2.03 (1.26) 
rs547154 
CC  1 
0.54  0.93 
CA  -1.39 (1.26) 
AA  0.69 (5.18) 
rs644045 
GG  1 
0.05  0.16 
GA  0.68 (0.78) 
AA  -2.45 (1.30) 
rs7746553 
CC  1 
0.94  0.94 
CG  -0.11 (0.83) 
GG  -0.78 (2.45) 
rs9267673 
CC  1 
0.07  0.19 
CT  -1.32 (0.94) 
TT  -7.47 (4.04) 
rs9332735
b 
GG  1 
0.01  0.10  GA+ AA  -5.04 (1.97) 
rs9501161 
GG  1 
0.05  0.16 
GA  1.99 (1.05) 
AA  10.34 (6.33) 
aAge at diagnosis adjusted for ethnicity, maximum lifetime BMI, high cholesterol, hypertension and NSAID use
 
bDominant model used due to low minor allele frequency 
 
 
Two  of  the  C2/CFB  SNPs  were  borderline  significantly  associated  with  age  of  AMD 
diagnosis in the WAMDS population, after adjusting for ethnicity, maximum lifetime BMI, 
high cholesterol, hypertension, use of NSAIDS and multiple testing (Table 4. 45). Under  
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default  dominant  models,  the  rs4151670  and  rs9332735  variants  were  independently 
associated (P = 0.004, Q = 0.08 and P = 0.01, Q = 0.10 respectively) with a reduction in 
age of diagnosis.  
4.3.3 Evidence of Interaction with CFH Y402H Variant 
All  significant  multivariate  tests  were  modified  by  the  inclusion  of  the  CFH  Y402H 
dominant  genotype  as  a  covariate  (Table  4.46)  and  stratified  thusly,  followed  by  the 
inclusion of an interaction term (Table 4.47) between the CFH Y402H variable and the 
C2/CFB SNP being tested. The covariate adjustments and respective outcomes for each 
model can be found in Table 3.6 in the Methods chapter. 
All  tests  remained significant  or borderline significant  under these  conditions,  and two 
significant interactions were found, such that the interaction with CFH Y402H strengthened 
the original association.   
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Table 4. 46: Modification of positive tests by inclusion of CFH Y402H covariate (under a dominant genetic model) 
aP value after adjustment for multiple testing using FDR method 
bβ (SE, P[SE]) 
Outcome 
C2/CFB Variant  CFH Y402H Variant  Raw LR P 
Value 
Original model 
LR P value 
Modified LR 
SNP  Genotype  OR (95% CI)  OR (95% CI)  Q value
a 
Neovascular 
AMD versus 
Early AMD and 
Atrophic AMD 
rs3020644  AA  1  1 
   
 
dominant  AG + GG  0.62 (0.43, 0.87)  1.51 (1.02, 2.25)  0.006  0.004  0.0093 
rs4151657  TT  1  1 
   
 
dominant  TC + CC  0.63 (0.45, 0.88)  1.53 (1.03, 2.27)  0.006  0.01  0.012 
rs7746553  CC + CG  1  1 
   
 
recessive  GG  6.33 (1.40, 28.66)  1.54 (1.04, 2.29)  0.004  0.004  0.0093 
Neovascular 
AMD versus 
Atrophic AMD 
rs1048709  GG  1  1 
   
 
dominant  GA + AA  1.89 (0.98, 3.64)  1.26 (0.62, 2.570  0.05  0.02  0.02 
rs3020644  AA  1  1 
   
 
dominant  AG + GG  0.32 (0.15, 0.67)  1.22 (0.60, 2.50)  0.0009  0.0004  0.0056 
rs3130683  TT  1  1 
   
 
dominant  TC + CC  2.38 (1.04, 5.43)  1.28 (0.62, 2.61)  0.02  0.01  0.012 
rs4151657  TT  1  1 
   
 
dominant  TC + CC  0.41 (0.21, 0.79)  1.23 (0.60, 2.52)  0.005  0.002  0.0093 
Atrophic AMD 
vs Neovascular 
AMD and Early 
AMD 
rs3020644  AA  1  1 
   
 
dominant  AG + GG  2.04 (1.13, 3.68)  0.82 (0.46, 1.47)  0.01  0.01  0.012 
rs4151657  TT  1  1 
   
 
dominant  TC + CC  1.78 (1.04, 3.05)  0.82 (0.46, 1.47)  0.03  0.01  0.012 
Legal Blindness 
in All AMD 
rs7746553  CC  1  1 
   
 
additive  CG + GG  1.69 (1.23, 2.33)  1.65 (1.03, 2.65)  0.002  0.002  0.0093 
Legal Blindness 
in Late AMD 
rs547154  CC + CA  1  1 
   
 
recessive  AA  10.12 (1.02, 100.93)  2.27 (1.26, 4.11)  0.03  0.02  0.02 
rs7746553  CC  1  1 
   
 
additive  CG + GG  1.65 (1.15, 2.35)  2.27 (1.26, 4.10)  0.007  0.01  0.012 
Age of 
Diagnosis 
rs4151670  CC  1  1 
   
 
dominant  CT + TT  - 6.47 (1.98, 0.001)
b  - 0.57 (0.93, 0.55)
b  0.0010  0.004  0.0093 
rs9332735  GG  1  1 
   
 
dominant  GA + AA  - 5.81 (2.01, 0.004)
b  - 0.73 (0.94, 0.44)
b  0.0040  0.01  0.012  
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Table 4. 47: Modification of positive tests by the inclusion of CFH Y402H:C2/CFB interaction term 
               
   
Outcome  C2/CFB Variant  CFH Y402H 
Variant 
LR P 
Value 
Interaction 
Term P value 
Original model 
LR P value 
LR Q 
value
a 
Interaction 
term Q value
a  SNP  Genotype  OR (95% CI)  OR (95% CI) 
Neovascular 
AMD vs 
Early AMD 
and 
Atrophic 
AMD 
rs3020644  AA  1  1           
dominant  AG + GG  0.88 (0.42, 1.83)  2.04 (1.04, 3.99)  0.01  0.29  0.004  0.02  0.68 
rs4151657  TT  1  1           
dominant  TC + CC  1.28 (0.63, 2.59)  2.60 (1.41, 4.78)  0.002  0.03  0.01  0.009  0.14 
rs7746553  CC + CG  1  1           
recessive  GG  4.98 (0.5, 49.42)  1.53 (1.03, 2.28)  0.01  0.79  0.004  0.02  0.85 
Neovascular 
AMD 
versus 
Atrophic 
AMD 
rs1048709  GG  1  1           
dominant  GA + AA  1.6 (0.39, 6.49)  1.19 (0.52, 2.75)  0.14  0.79  0.02  0.14  0.85 
rs3020644  AA  1  1           
dominant  AG + GG  0.39 (0.08, 1.91)  1.48 (0.29, 7.52)  0.004  0.79  0.0004  0.01  0.85 
rs3130683  TT  1  1           
dominant  TC + CC  1.59 (0.32, 7.97)  1.17 (0.54, 2.58)  0.07  0.58  0.01  0.08  0.85 
rs4151657  TT  1  1           
dominant  TC + CC  1.27 (0.36, 4.52)  3.43 (1.05, 11.18)  0.003  0.05  0.002  0.01  0.18 
Atrophic 
AMD vs 
Neovascular 
AMD and 
Early AMD 
rs3020644  AA  1  1           
dominant  AG + GG  1.76 (0.55, 5.64)  0.71 (0.22, 2.31)  0.04  0.78  0.01  0.05  0.85 
rs4151657  TT  1  1           
dominant  TC + CC  0.96 (0.35, 2.64)  0.47 (0.18, 1.22)  0.04  0.17  0.01  0.05  0.48 
Legal 
Blindness in 
All AMD 
rs7746553  CC  1  1           
additive  CG + GG  1.21 (0.54, 2.75)  1.45 (0.84, 2.50)  0.005  0.38  0.002  0.01  0.76 
Legal 
Blindness in 
Late AMD 
rs547154  CC + CA  1  1           
recessive  AA  10.12 (1.02, 100.93)  2.27 (1.26, 4.11)  0.03  1  0.02  0.04  1 
rs7746553  CC  1  1           
additive  CG + GG  2.1 (0.87, 5.05)  2.55 (1.24, 5.27)  0.02  0.56  0.01  0.03  0.85 
Age of 
Diagnosis 
rs4151670  CC  1  1           
dominant  CT + TT  - 21.58
 (5.16, 0.0003)
b  - 1.08 (0.94, 0.25)
b  0.0000
3 
0.002  0.004  0.000
4 
0.02 
rs9332735  GG  1  1           
dominant  GA + AA  - 23.56
 (6.25, 0.0002)
b  -1.13 (0.94, 0.23)
b  0.0002  0.003  0.01  0.001  0.02 
aP value after adjustment for multiple testing using FDR method 
bβ (SE, P[SE])   
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4.3.4 Power Analysis 
For  scenarios  comparing  late  and  early  AMD  cases,  power  analyses  demonstrated 
sufficient (≥80%) power to detect ORs ≥ 1.7 for most SNPs, and ORs ≥ 1.5 for SNPs with 
a MAF ≥ 0.15; whilst assuming an additive genetic model (Figure 4. 2). Under a dominant 
genetic model (Figure 4. 3), there was sufficient power to detect ORs ≥ 1.7 for most SNPs, 
whilst under a recessive model (Figure 4. 4) there was only sufficient power to detect ORs 
≥ 1.7 for SNPs with a MAF ≥ 0.3. 
 
Figure 4. 2: Power to detect associations between genetic variants and late AMD 
versus early AMD under an additive genetic model 
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Figure 4. 3: Power to detect associations between genetic variants and late AMD 
versus early AMD under a dominant genetic model 
 
 
Figure 4. 4: Power to detect associations between genetic variants and late AMD 
versus early AMD under a recessive genetic model   
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For scenarios comparing neovascular AMD cases with early AMD and atrophic AMD 
cases (combined), power analyses demonstrated sufficient (≥80%) powers to detect ORs ≥ 
1.5 for most SNPs, and ORs ≥ 1.3 for SNPs with a MAF ≥ 0.4; whilst assuming an additive 
genetic model (Figure 4. 5). Under a dominant genetic model (Figure 4. 6), there was 
sufficient power to detect ORs ≥ 1.7 for most SNPs, and ORs ≥ 1.5 for SNPs with MAFS 
between  0.15  and  0.4;  whilst  under  a  recessive  model  (Figure  4.  7)  there  was  only 
sufficient power to detect ORs ≥ 1.9 for SNPs with a MAF  ≥ 0.25, and ORs ≥ 1.7 for 
SNPs with a MAF ≥ 0.35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 5: Power to detect associations between genetic variants and neovascular 
AMD versus early and atrophic AMD under an additive genetic model   
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Figure 4. 6: Power to detect associations between genetic variants and neovascular 
AMD versus early and atrophic AMD under a dominant genetic model 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 7: Power to detect associations between genetic variants and neovascular 
AMD versus early and atrophic AMD under a recessive genetic model   
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For scenarios comparing neovascular AMD cases with early AMD cases, power analyses 
demonstrated sufficient (≥ 80%) power to detect ORs ≥ 1.7 for most SNPs, and ORs ≥ 1.5 
for SNPs with a MAF ≥ 0.13; whilst assuming an additive genetic model (Figure 4. 8). 
Under a dominant genetic model (Figure 4. 9), there was sufficient power to detect ORs ≥ 
1.7 for most SNPs; whilst under a recessive model (Figure 4. 10) there was only sufficient 
power to detect ORs ≥ 1.9 for SNPs with a MAF  ≥ 0.3, and ORs ≥ 1.7 for SNPs with a 
MAF ≥ 0.4. 
 
Figure 4. 8: Power to detect associations between genetic variants and neovascular 
AMD versus early AMD under an additive genetic model 
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Figure 4. 9: Power to detect associations between genetic variants and neovascular 
AMD versus early AMD under a dominant genetic model 
 
 
Figure 4. 10: Power to detect associations between genetic variants and neovascular 
AMD versus early AMD under a recessive genetic model   
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For  scenarios  comparing  neovascular  AMD  cases  with  atrophic  AMD  cases,  power 
analyses demonstrated sufficient (≥ 80%) power to detect ORs ≥ 1.9 for SNPs with a MAF 
≥ 0.2 , and ORs ≥ 1.7 for SNPs with a MAF ≥ 0.4; whilst assuming an additive genetic 
model (Figure 4. 11). Under dominant (Figure 4. 12) and recessive (Figure 4. 13) genetic 
models, there was insufficient power to detect ORs ≤1.9 for any SNPs. 
 
 
 
 
 
 
 
 
 
 
Figure 4. 11: Power to detect associations between genetic variants and neovascular 
AMD versus atrophic AMD under an additive genetic model 
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Figure 4. 12: Power to detect associations between genetic variants and neovascular 
AMD versus atrophic AMD under a dominant genetic model 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 13: Power to detect associations between genetic variants and neovascular 
AMD versus atrophic AMD under a recessive genetic model 
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For scenarios comparing  atrophic AMD cases  with early AMD and  neovascular AMD 
cases (combined), power analyses demonstrated sufficient (≥ 80%) power to detect ORs ≥ 
1.9 for most SNPs ( with MAF ≥ 0.1), and ORs ≥ 1.7 for SNPs with a MAF ≥ 0.25; whilst 
assuming an additive genetic model (Figure 4. 14). Under dominant (Figure 4. 15) and 
recessive (Figure 4. 16) genetic models, there was insufficient power to detect ORs ≤1.9 
for any SNPs. 
 
 Figure 4. 14: Power to detect associations between genetic variants and atrophic 
AMD versus neovascular and early AMD under an additive genetic model   
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Figure 4. 15: Power to detect associations between genetic variants and atrophic 
AMD versus neovascular and early AMD under a dominant genetic model 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 16: Power to detect associations between genetic variants and atrophic 
AMD versus neovascular and early AMD under a recessive genetic model   
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For  scenarios  comparing  atrophic  AMD  cases  with  early  AMD  cases,  power  analyses 
demonstrated sufficient (≥ 80%) power to detect ORs ≥ 1.9 for SNPs with a MAF ≥ 0.15; 
whilst assuming an additive genetic model (Figure 4. 17). Under dominant (Figure 4. 18) 
and recessive (Figure 4. 19) genetic models, there was insufficient power to detect ORs 
≤1.9 for any SNPs. 
 
 
 
 
 
 
 
 
 
Figure 4. 17: Power to detect associations between genetic variants and atrophic 
AMD versus early AMD under an additive genetic model 
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Figure 4. 18: Power to detect associations between genetic variants and atrophic 
AMD versus early AMD under a dominant genetic model 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 19: Power to detect associations between genetic variants and atrophic 
AMD versus early AMD under a recessive genetic model   
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4.3.5 Sensitivity Testing 
All positive findings were re-analysed for sensitivity testing by excluding non-Caucasian 
subjects.  Some  tests  remained  significant,  while  some  were  rendered  insignificant,  as 
shown in Table 4. 48. The effect sizes were generally modestly attenuated, possibly due to 
a reduction in sample size and statistical power.  
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Table 4. 48: Re-analysis of positive associations within Caucasian subset (n=811)
a 
Outcome  SNP  Genotype  OR (95% CI) / β (SE)  P value
b 
Neovascular AMD versus Early AMD and 
Atrophic AMD 
rs3020644  AA  1 
0.01  dominant  AG + GG  0.65 (0.46, 0.92) 
rs4151657  TT  1 
0.01  dominant  TC + CC  0.66 (0.47, 0.92) 
rs7746553  CC + CG  1 
0.03  recessive  GG  4.33 (0.96, 19.47) 
Neovascular AMD versus Atrophic AMD 
rs1048709  GG  1 
0.03  dominant  GA + AA  1.99 (1.04, 3.83) 
rs3020644  AA  1 
0.005  dominant  AG + GG  0.32 (0.15, 0.68) 
rs3130683  TT  1 
0.01  dominant  TC + CC  2.58 (1.13, 5.86) 
rs4151657  TT  1 
0.01  dominant  TC + CC  0.41 (0.21, 0.78) 
Atrophic AMD versus Neovascular AMD 
and Early AMD 
rs3020644  AA  1 
0.01  dominant  AG + GG  2.51 (1.28,  4.91) 
rs4151657  TT  1 
0.01  dominant  TC + CC  2.13 (1.17, 3.90) 
Legal Blindness in All AMD  rs7746553  CC  1 
0.03  additive  CG + GG  1.50 (1.04, 2.16) 
Lesion Size  rs1270942  TT+TC  1 
0.03  recessive  CC  0.19 (0.05, 0.75) 
Age of Diagnosis  rs4151670  CC  1 
0.01  dominant  CT + TT  -5.61 (1.94) 
rs9332735  GG  1 
0.01  dominant  GA + AA  -5.01 (1.97) 
Lesion Composition (Predominantly Classic 
versus Occult)
c 
rs1048709  GG  1 
0.01  additive  GA + AA  0.58 (0.39, 0.87) 
rs2072633  CC + CT  1 
0.005  recessive  TT  0.38 (0.21,0.70) 
rs537160  GG + GA  1 
0.005  recessive  AA  0.29 (0.14,0.62) 
aSensitivity test using original model, except only Caucasian subjects included 
bLR P value after adjustment for multiple testing using FDR method 
cNominal logistic regression analyses included minimally classic versus occult lesion type, odds ratios were not significant and are not shown here   
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4.4 Summary of Results 
Several C2/CFB SNPs were found to be significantly associated with various subtypes and 
manifestations of AMD in the WA Macular Degeneration Study (WAMDS) population 
after  adjusting  for  appropriate  phenotypic  factors  and  multiple  testing.  All  of  these 
associations were found to be independent of interactions with the CFH Y402H variant, 
and  were  sufficiently  powered.  Additional  borderline  significant  associations  were 
observed, which would potentially reach significance under adjusted conditions, such as 
inclusion in a smaller pool of simultaneous analyses.  
 
 Table 4. 49: Summary of significant associations between C2/CFB genetic variants 
and dichotomous AMD subphenotypes, adjusted for multiple testing 
Outcome  SNP  Genotypes  n
e (n
f)  OR (95% CI)  P value
d 
Neovascular AMD 
(n=675) versus all other 
AMD
a (n=338) 
rs3020644  AA  254 (357)  1   
dominant  AG + GG  420 (654)  0.65 (0.46, 0.92)  0.04 
rs7746553  CC + CG  652 (984)  1   
recessive  GG  21 (23)  5.95 (1.34, 26.54)  0.04 
Neovascular AMD (n-
675) versus Atrophic 
AMD
b (n=71) 
rs3020644  AA  254 (269)  1   
dominant  AG + GG  420 (476)  0.32 (0.15, 0.68)  0.008 
rs4151657  TT  293 (313)  1   
dominant  TC + CC  376 (427)  0.41 (0.21, 0.78)  0.02 
Legal Blindness in All 
AMD
c (n=1013) 
rs7746553  CC  96 (511)  1   
additive  CG + GG  60 (233)  1.50 (1.04, 2.16)  0.04 
aNeovascular AMD versus all other AMD adjusted for age at study, gender, pack years of smoking and alcohol consumption 
bNeovascular AMD versus atrophic AMD adjusted for pack years of smoking 
cLegal blindness in all AMD adjusted for age at study 
d LR P values adjusted for multiple testing using FDR method. 
eNumber of affected individuals with specified genotype in this test 
fTotal number of individuals with specified genotype in this test (both affected and unaffected)   
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Table 4. 50: Summary of significant associations between C2/CFB genetic variants 
and CNV lesion composition in neovascular AMD cases 
SNP  Genotypes 
  CNV Lesion Composition
a 
P value
b 
N= 508  Predom Clas. versus 
Occult 
Min Clas. versus 
Occult  n
c, n
d, n
e  OR (95% CI)  OR (95% CI) 
rs1048709  GG 
126, 37, 
155  1  1 
0.005  additive  GA + AA 
59, 24, 
106  0.67 (0.47, 0.95)  0.79 (0.49,1.28) 
rs2072633  CC + CT 
161, 50, 
195  1  1 
0.002  recessive  TT  24, 11, 67  0.41 (0.24, 0.71)  0.61 (0.29, 1.27) 
rs537160  GG + GA 
171, 52, 
209  1  1 
0.002  recessive  AA  13, 9, 51  0.35 (0.19, 0.68)  0.70 (0.32, 1.55) 
aCNV lesion composition adjusted for prior CNV treatment 
bLR P values adjusted for multiple testing using FDR method. 
cNumber of predominantly classic lesion type cases with the specified genotype   
dNumber of minimally classic lesion type cases with the specified genotype
   
eNumber of occult lesion type cases with the specified genotype
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Chapter 5: Discussion 
This study was designed to investigate whether variation in the C2 and CFB genes was 
associated with AMD severity and progression subphenotypes in a large, well-characterised 
Western Australian case series. The current study is the largest to provide comprehensive 
coverage of the C2/CFB genes, and is the first to investigate the association of variants in 
these genes with severity subphenotypes within a clinic-based AMD population.  
This study found associations between C2/CFB variants and several measures of AMD 
severity, including neovascular AMD, neovascular lesion composition and size, atrophic 
AMD,  age  of  diagnosis,  legal  blindness.    C2/CFB  variants  previously  associated  with 
overall  AMD  risk  were  found  to  be  associated  with  specific  AMD  subphenotypes,  in 
particular neovascular AMD. There was no evidence of ethnic population stratification in 
this predominantly European population, and all associations remained significant when the 
CFH Y402H variant was added as a covariate. Furthermore, significant interactions were 
observed  between  the  CFH  Y402H  variant  and  two  C2/CFB  variants,  such  that  the 
association was amplified and strengthened between these SNPs and age of diagnosis.  
Three prior studies have examined the relationship between the C2/CFB genes and overall 
AMD risk,
134, 213, 240 but none have focussed on the genetic differentiation of subphenotypes 
by direct  comparison within  the AMD population.  Instead, AMD subphenotype  groups 
were compared with non-AMD controls,
134, 240 or the delineation of “cases” and “controls” 
differed from that used in this study, such that individuals that we would classify as early 
AMD cases were divided between case and control groups.
213 This meant that some early 
AMD cases were grouped with the late AMD cases (geographic atrophy and choroidal   
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neovascularisation)  while  others  were  grouped  with  non-AMD  individuals  to  serve  as 
controls.
213 
Gold et al.
134 screened the C2/CFB genes for sequence variations associated with AMD risk 
in two independent cohorts comprising approximately 900 AMD cases and approximately 
400 matched controls, all unrelated individuals of European-American descent and over the 
age of 60. The study analysed all seven C2/CFB missense alleles with frequencies > 2% in 
European  populations  as  judged  by  resequencing  data,  finding  a  common  seven-SNP 
haplotype (comprised of E318D, Int10, L9H, R32Q, R150R, K565E and Int7 C2/CFB loci) 
that was associated with an increased (OR = 1.32, P = 0.0012) risk of AMD and 2 two-SNP 
haplotypes containing the Int10 and R32Q variants, and E218D and L9H variants that were 
associated with significantly reduced (OR = 0.36 and 0.45, respectively, P <0.0001 for 
each) risk of AMD
134. Combined analysis of the C2/CFB haplotypes and CFH variants 
showed that variation in the two loci could predict the clinical outcome in 74% of the 
affected individuals, and 56% of the controls.
134  
Maller et al.
240 tested a select subset of the C2/CFB variants Gold
134 investigated; using a 
study population consisting of 1,238 late AMD cases (with either geographic atrophy or 
choroidal  neovascularisation)  and  934  non-AMD  controls,  all  unrelated  individuals  of 
European descent and over the age of 60. Maller et al.
240 also included in these analyses the 
CFH  Y402H,  LOC387715  A69S  variants  and  numerous  SNPs  in  linkage  regions  of 
chromosomes 1 and 10. Their findings were consistent with those of Gold et al.,
134 and 
suggested that the rs4151667 and rs9332739 C2/CFB SNPs were associated with AMD risk 
independently of CFH Y402H in a large sample.
240    
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Spencer et al.
213 genotyped six C2/CFB SNPs (rs9332739, rs547154, rs12614, rs641153, 
rs1048709  and  rs2072633)  in  independent  family-based  and  case-control  non-Hispanic 
Caucasian datasets. The family-based dataset of 559 individuals (average age 72.8 years) 
consisted  of  144  multiplex  and  79  singleton  families,  while  the  case-control  dataset 
contained  698  “cases”  (including  all  incidences  of  geographic  atrophy,  choroidal 
neovascularisation,  drusenoid/non-drusenoid  RPE  detachment,  subretinal  haemorrhage, 
disciform scarring, extensive intermediate drusen and large soft drusen) and 282 “controls” 
(including individuals with no evidence of drusen, sparse or extensive small drusen, non-
extensive intermediate drusen, and pigmentary abnormalities) .
213 Case control analyses 
compared these two major groups, and also compared the neovascular subset of AMD cases 
with the most unaffected controls (those with no drusen, or small non-extensive drusen 
without pigmentary abnormalities, referred to as “grade 1”) .
213 Spencer et al.
213 reaffirmed 
the independent, protective associations of the rs9332739, rs547154 and rs641153 C2/CFB 
SNPs with both AMD risk in the case control dataset, and risk of neovascular AMD (versus 
“grade  1”  controls).  The  association  with  the  rs641153  SNP  remained  strong  after 
controlling  for  age,  CFH  Y402H,  LOC387715  A69S  and  smoking,  and  was  also 
significantly associated with protection from AMD in the family-based dataset.
213  
5.1: Summary and Interpretation of Results 
An optimal tagging set of 19 C2/CFB variants were genotyped in 1013 individuals with 
various types of AMD. These data were subjected to univariate genetic association analyses 
of key AMD outcomes including subphenotypes and visual acuity, followed by extensive 
multivariate  association  analyses  of  the  same  outcomes.  These  analyses  were 
complemented by univariate and multivariate analyses of biologically plausible covariates,   
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allowing  the  formation  of  appropriate  multivariate  models.  Additional  analyses  were 
undertaken to establish the independence and significance of the results in the context of 
other prominent research. The discussion and exploration of these results follow. 
5.1.1: Population Characteristics 
 
The WAMDS population consisted of a higher number of late AMD cases (n = 746) than 
early AMD cases (n = 267). This is not representative of the general AMD population, as 
other population based studies were reportedly be made up of nine early AMD cases for 
every late AMD case. This enrichment of the WAMDS population for more severe AMD is 
probably due to the lowered need for early AMD cases to present at a tertiary eye clinic. 
Furthermore, similar reasoning can probably explain the underrepresentation of atrophic 
AMD cases (n = 71, versus 675 neovascular AMD cases), for which there is usually no 
treatment and cases are tracked via annual or biannual visits.  Individuals with late AMD 
were more likely to suffer from low vision or legal blindness (P < 0.001), confirming the 
overall trend of observed late stage macular changes causing concomitant disability in the 
subject.  
The enrichment of severe AMD in this study population makes it ideal for studying AMD 
severity, but makes it difficult to translate these findings into generalisations applicable to 
the general population. Such findings could be usefully compared with similarly populated 
studies, or replication attempted in more population-representative studies.  
Females  were  overrepresented  in  all  categories  of  AMD  in  the  WAMDS  population, 
consistent with literature which suggests women have a slightly increased risk of suffering 
from AMD.
241 However, increased prevalence of a disease which has increasing age as its   
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chief risk factor is probably to be expected in a gender that enjoys greater life expectancy 
than its male counterparts. This is supported by the greater mean age of females (79.1 +/- 
8.4 years) compared to males (77.8 +/- 8.5 years) in the WAMDS population. 
Consistent  with  expectations,  age  and  lifetime  exposure  to  smoking  were  significantly 
increased in late versus early AMD cases. However, rates of self-reported hypertension, 
hypercholesterolaemia, obesity, cholesterol-lowering medication and NSAID use did not 
appear to be statistically different between late and early AMD cases.  
Covariate summaries 
Age at Study 
Consistent with the natural history of AMD, age at study was significantly associated with 
increased risk of late AMD, both neovascular AMD and atrophic AMD versus early AMD, 
legal blindness and low vision. Accordingly, age of study was the most important covariate 
for adjusting the subsequent multivariate analyses. 
Gender 
The imbalanced gender ratio found in the WAMDS population was consistent with the 
findings of meta-analyses of prevalence studies in Australia, America and Europe, all of 
which suggested that women were at a slightly higher risk of developing AMD than men.
30, 
114, 115 This effect is possibly due to the higher average longevity of women compared to 
men.
115 
In this study, males were more likely to suffer from late AMD or neovascular AMD in 
particular,  while  females  with  neovascular  AMD  were  more  likely  to  develop  retinal 
scarring than males with neovascular AMD.    
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Smoking 
Cigarette smoking was  associated with an increased risk of late AMD, atrophic AMD, 
neovascular  AMD  and  low  vision,  consistent  with  prior  research  that  indicates  current 
smokers  have  the  highest  risk  of  developing  AMD  compared  to  ex-smokers  and  non-
smokers.
61,  123,  124,  242-255  Cigarette  smoking  is  a  known  cause  of  oxidative  stress  and 
increased  angiogenesis.  Smoking  is  thought  to  contribute  to  AMD  pathogenesis  by 
reducing  antioxidant  levels,  such  as  vitamin  C  and  carotenoids,  as  well  as  inducing 
oxidative damage and altering choroidal blood flow.
61 Furthermore, cigarette smoking is 
associated with decreased plasma CFH levels.
167 
Alcohol 
Earlier research has debated whether alcohol consumption may increase risk of AMD.
256, 257 
Cho et al. found a mild increase of early AMD and atrophic AMD in female drinkers 
consuming 30 grams of alcohol or more per day, and overall did not support an inverse 
relationship  between  moderate  alcohol  consumption  and  risk  of  AMD.
258  In  this  study 
however, alcohol consumption was associated with a lower risk of late AMD, neovascular 
AMD and low vision in current drinkers (but not ex-drinkers or non drinkers), and an 
increased risk of retinal detachment in current drinkers with neovascular AMD. 
Cataract Surgery 
Previous studies suggested that cataract surgery may be a risk factor for AMD.
256, 259 This is 
a plausible association given that surgery and the subsequent recovery would stimulate 
involvement  from  the  immune  system.  In  this  study,  cataract  surgery  was  strongly 
associated with atrophic AMD, but no other subphenotypes. Due to the absence of AMD-
free controls in this study, it was not possible to determine if the incidence of cataract   
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surgery differed appreciably between AMD cases and AMD-free controls. Of the outcomes 
tested, only atrophic AMD had a significant association (P = 0.001) with cataract surgery.  
Cholesterol-lowering Medication 
Cholesterol-lowering medication was associated with an increased risk of retinal scarring in 
neovascular AMD cases, which may support its reported association with risk of AMD.
260-
262 
Prior Treatment for Choroidal Neovascularisation (CNV) 
Prior CNV treatment was associated with decreased lesion size, classic lesion types and 
reduced risk of retinal detachment in neovascular AMD cases, and decreased risk of legal 
blindness and low vision in the late AMD cohort. The latter findings are reassuring, given 
that some earlier forms of CNV treatment had very modest success rates and moderate 
chances of collateral damage, making it difficult to determine whether a decline in visual 
acuity was a result of the treatment or the disease.  
Interpretation of the Age of Diagnosis Outcome and Covariates 
Age of diagnosis is a potentially problematic outcome to use and interpret because there are 
two major issues that must be considered, relating to the plausibility of the assumption that 
age of diagnosis is a good measure of when the subject actually developed AMD symptoms 
warranting their presentation at an eye clinic. The first approach would be the assumption 
that age  at  diagnosis  is  a  good  measure of when the subject  actually  developed AMD 
symptoms  warranting  their  presentation  at  an  eye  clinic.  Assuming  this  assumption  is 
plausible, a reduced age of diagnosis would be considered to be unfavourable because it 
represents a subject developing AMD at a younger age.  However, the converse of this 
assumption is the possibility that age at diagnosis and age of AMD development are not   
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closely  associated  due  to  misdiagnosis,  delays  in  reporting  visual  disturbances,  or 
mistakenly attributing visual disturbances to other eye conditions common in the elderly. 
Under this scenario, a lowered age of diagnosis would be favourable, as early diagnosis of 
AMD may be very helpful for the treatment and management of the disease, particularly in 
neovascular AMD. If this assumption holds, the age of diagnosis outcome would be an 
interesting measure of AMD awareness and changes in AMD diagnosis rates, of great use 
to public health research. For example, it is suspected that the public awareness of AMD 
may have been slightly raised during the recruitment phase of the study due to coinciding 
media attention paid to the disease.  
It is likely that both approaches apply in determining age of diagnosis, but possibly to 
varying  degrees.  By  considering  the  associations  of  the  covariates  individually  it  was 
hypothesised that it would be possible to determine which assumption was more likely to 
be true. 
A review of the previous associations between BMI, hypercholesterolaemia, hypertension, 
NSAID use, ethnicity and AMD outcomes were considered in the hope that they would be 
informative in interpreting the age of diagnosis multivariate results. Unfortunately, most of 
the prior studies investigating the relationships between these outcomes and AMD have 
delivered inconclusive or contradictory results.   
Obesity
128, 251, 263, 264 and hypercholesterolaemia
252, 253, 265 have previously been found to be 
risk factors for AMD, and in this study, higher maximum BMI and hypercholesterolaemia 
were associated with a slightly reduced age of diagnosis. Hypertension has also been found 
to be a risk factor for AMD
25, 238, 252 but unlike the previous two risk factors, hypertension 
was associated with an increased age of diagnosis. Also associated with an increased age of   
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diagnosis  was  NSAID  use,  which  has  been  debated  as  a  possible  risk  factor,  but  with 
contradictory  results.
260,  262,  266  In  this  study  NSAID  use  was  also  associated  with  an 
increased risk of low vision in early AMD cases.  
Finally, ethnicity has been found to play an important role in determining risk of AMD, 
possibly due to iris and hair colour
267,  268 or other factors not yet determined. The CFH 
Y402H variant that is associated with significantly increased risk of AMD in Caucasians 
does  not  seem  to  have  this  association  in  Asians;  thus  there  must  be  some  major 
difference/s between these ethnic groups for such a strong association in Caucasians to be 
all but nullified in Asians. In this study, Asian ethnicity was associated with a significantly 
reduced age of diagnosis compared to that of Caucasians. This could be interpreted as an 
earlier age of onset in Asians, or a more prompt presentation at an eye clinic due to cultural 
differences.  This  variable  could  be  the  most  informative  in  judging  whether  age  of 
diagnosis  better represents  age of diagnosis  or promptness of presentation, but  without 
supporting data, theories such as this remain speculatory. 
5.1.2: Allele and Genotype Frequencies 
The MAFs of all nineteen C2/CFB SNPs were not significantly different than the MAFs of 
the HapMap-CEU   data or compared to other previous reports in European populations 
(Table 5. 1). Genotypic distributions of SNP markers were all consistent with HWE(Hardy-
Weinberg Equilibrium), with the sole exception of the rs4151672 variant. The genotype 
distribution of the rs4151672 SNP showed a marginally significant departure from HWE in 
the WAMDS population. Departure from HWE may be caused by systematic genotyping 
error, violation of any one of the underlying assumptions, or may be due to chance.
269 A 
biological explanation can sometimes be assumed for departure from HWE.
234 In the case   
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of rs4151672, adjustment for multiple testing suggested that this departure from HWE was 
non-significant in the context of the number of HWE tests performed.   
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Table 5. 1: Reported Minor Allele Frequencies 
SNP 
Pseudonyms in 
Previous Reports 
WAMDS 
MAF % 
HapMap-CEU 
MAF % 
Previous Reports MAF % 
(Control MAF % -      Case 
MAF %) 
rs1048709  A  19.5%  25.0%  21% (20%-21%) 
rs1270942  C  13.3%  9.2%   
rs2072633  T  43.9%  45.0%  45% (46%-45%) 
213 
rs2072634  A  0.9%  2.1%   
rs3020644  G  40.6%  32.5%   
rs3130683  C  13.5%  21.7%   
rs4151657  C  35.0%  30.8%   
rs4151664  T  7.0%  6.2%   
rs4151670  T  1.4%  0.8%   
rs4151672  T  2.5%  6.2% 
In LD with rs9332739 (5.4%-
2.6%)
240, 3% (5%-3%) 
213and 
rs4151667 (5.0%-2.9%) 
240 
rs429608  A  9.8%  12.5%   
rs512559  C  3.3%  1.7%   
rs537160  A  37.0%  38.3%   
rs547154  A  5.9%  10.9%  9.7%-5.4%
240, 7%(11%-5%) 
213 
rs644045  A  35.4%  37.5%   
rs7746553  G  15.8%  19.2%   
rs9267673  T  10.4%  7.5%   
rs9332735  A  1.4%  2.5%   
rs9501161  A  8.1%  10.8%   
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5.1.3 Linkage Disequilibrium analyses 
Apart from a pairwise r
2 value of  ≥ 0.8 between rs9332735 and rs4151670, pairwise r
2 
values  were  generally  low  (Figure  4.1).  This  suggests  that  the  tagging  procedure  was 
efficient and that little redundancy could be observed in this set of carefully chosen tagging 
markers. 
The lack of significant linkage disequilibrium (LD) among the tag SNPs typed meant that 
haplotype-based  analyses  were  not  appropriate  and  were  therefore  not  performed.  As 
discussed in Chapter Two, within a block of high LD, a small set of representative tag 
SNPs can distinguish a large fraction of the common haplotypes. At a relatively stringent r
2 
threshold of ≥ 0.8, LD-selected tag SNPs can be used to resolve > 80% of all haplotypes.
270 
Additionally, the power of association studies based on tag SNPs is generally similar to that 
using haplotype data.
271, 272 Thus the potential utility of haplotype-based analysis is greatly 
diminished  in  an  association  study  in  which  tagging  strategies  were  adopted  in  SNP 
selection. For this reason, statistical analysis of inferred haplotypes was believed to be no 
more informative than tag SNP based analyses, and was not performed.  
5.1.4 Genetic association analyses 
Review of C2/CFB genetic variants studied 
To provide appropriate context for interpreting the current study results, it is important to 
review the C2/CFB genetic variants studied, their purported biological functions and roles 
in AMD risk as suggested by prior research. 
The rs1048709 variant causes a synonymous coding mutation in the Arginine at position 
150 of CFB, which results in the same amino acid being produced by a different codon,   
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which should theoretically be a relatively benign situation. Two of the three prior C2/CFB 
studies investigated this variant and found no significant association with AMD.  
The  rs2072633  variant  is  located  in  intervening  sequence  17  of  CFB.  The  rs2072633 
variant has been previously found to be inversely associated with AMD generally, and the 
neovascular  and  early  forms  of  the  disease.
134  However,  a  different  study  found  no 
significant association between this variant and AMD.
213 
The rs4151672 variant is located in the 3‟ untranslated region (UTR) of the CFB gene, and 
in itself does not appear particularly interesting. It is the SNPs this variant relates closely to 
that make it noteworthy. The rs4151672 SNP is in high LD with the following SNPs: 
Rs4151667:  This variant causes a Leucine to Histidine amino acid change at position 9 of 
the  CFB  product,  found  to  be  inversely  associated  with  AMD  generally
134,  240  and 
neovascular and early AMD in particular.
134 
Rs9332739:  This variant causes a Glutamate to Aspartate residue change at position 318 
of the C2 product, found previously to be independently inversely associated with AMD 
generally,
134, 213, 240 and neovascular
134, 213 and early forms of AMD in particular.
134 
Despite these prior  associations,  the rs4151672  variant  was  not  significantly  associated 
with any of the AMD outcomes analyzed in this study.  
The  rs547154  variant,  located  in  intervening  sequence  10  (IVS)  of  the  C2  gene,  has 
previously  been  found  to  be  inversely  associated  with  AMD  generally,
134,  213,  240  and 
neovascular
134, 213 and early forms of AMD in particular.
134  
The rs547154 variant is in strong LD with a nonsynonymous CFB variant, rs641153. The 
rs641153 variant causes an Arginine to Glutamine amino acid change at position 32 in the   
  213 
CFB  product.  Like  rs547154,  the    rs641153  variant  has  previously  been  found  to  be 
inversely associated with AMD generally,
134, 213, 240 and neovascular
134, 213 and early forms 
of  AMD  in  particular.
134  Notably,    the  rs641153  variant  was  found  to  be  inversely 
associated with more severe grades of AMD and neovascular AMD in a family-based data 
set, while rs547154 did not have a significant association in these same analyses.
213 This 
finding lent support to a previously theoretical hypothesis, a summary of which follows. 
Initially, a haplotype consisting of both the rs547154 and rs641153 variants was found to 
be highly inversely associated with AMD.
134 As these two loci were in very high LD, it 
became difficult to determine which locus was responsible for the inverse association. The 
more popular theory favoured rs641153 as the crucial variant because, as a nonsynonymous 
SNP, it introduces an amino acid change in the CFB protein which could potentially alter 
the  protein  function.  Additionally,  CFB  is  an  important  species  in  the  alternative 
complement pathway, favouring its involvement in AMD pathogenesis over the classical 
pathway species C2. However, the potential role of intronic SNPs  such as rs547154 (in C2) 
could not be ruled out due to limited knowledge. 
Maller  et  al.  found  that  both  the  rs547154  and  rs641153  variants  were  both  strongly 
associated with AMD (P < 10
-11) and due to their high correlation (r
2 = 0.78) determined 
that both variants must represent the same association.
240 Finally, the work of Spencer et al. 
managed to isolate the significant inverse association with  rs641153 using family-based 
data, while rs547154 failed to reach any level of significance in the analyses.
213 Spencer‟s 
result strongly supports the theory that rs641153 is the most likely functionally protective 
variant amongst this cluster of LD linked SNPs, and that any observed association with the 
rs547154 SNP may be attributable to the rs641153 variant.    
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The rs537160 variant is in high LD with rs419788, an intronic variant of the SKIV2L gene 
highly proximal to the CFB gene. The rs419788 variant is notable largely because it has 
previously been associated with lupus.
273 
The remaining genetic variants and those linked to them with high LD are unlikely to result 
in a functional C2/CFB protein change due to their location or the type of allele change. 
Any observed association between these variants and AMD subphenotypes is likely to be a 
result of high LD with previously undocumented/unattributed functional loci. There may 
also be the possibility of altered gene expression if the variant happens to lie in the vicinity 
of transcription regulation, such as a promoter region. The rs2072634 CFB and rs4151670 
C2 gene variants are synonymous SNPs, thus the resulting proteins are not affected. The 
rs7746553  and  rs9332735  variants  are  located  in  C2  introns,  while  the  rs3020644, 
rs3130683 and rs644045 variants are located just upstream of  C2, in the 3‟ UTR. The 
rs1270942,  rs4151657  and  rs4151664  variants  are  all  located  in  CFB  introns,  and  any 
remaining  tag  SNPs  not  mentioned  here  were  not  significantly  associated  with  AMD 
phenotypes in this and/or prior studies. 
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Details of Associations 
Association of C2/CFB genetic variants with late AMD 
None of the three prior published studies of AMD and C2/CFB variants
134,  213,  240 have 
analysed the neovascular and atrophic AMD types together as a late AMD cohort, and 
compared them with all less severe cases of AMD. Though the analyses of Spencer et al.,
213 
discussed earlier, approached such  an experiment,  the definitions  of cases  and controls 
differed significantly from ours, with the non-AMD subjects included in the control group, 
and early AMD (by our definition) subjects found in both the case and control groups. 
Although finding evidence for the association of multiple tagging SNPs in C2/CFB with 
multiple AMD severity-associated phenotypes, the current study did not find evidence that 
common variants in C2/CFB were significantly associated with late AMD. This finding is 
in contrast to the findings of some previous studies.
213 This differing finding may be due to 
differences in study design, or because findings of the previous studies
213 were confounded 
by the presence of sub-categories of AMD within the „late‟ group. 
Association of C2/CFB genetic variants with other severity subphenotypes 
Significant associations were observed between C2/CFB variants and neovascular AMD, 
atrophic AMD, lesion size and composition in neovascular AMD and legal blindness in the 
current  study.  There  are  many  plausible  links  between  these  AMD  subphenotypes  and 
variance  of  the  C2/CFB  genes,  primarily  via  differential  activation  of  the  complement 
cascade.  A high function CFB variant could result in superfluous complement deposition 
in host tissues, leading to destruction of these tissues and generation of debris. This tissue 
destruction could theoretically lead to atrophy of the retinal tissues, as seen in atrophic 
AMD. Some complement proteins have been found in drusen, the deposits of debris that are 
a hallmark of AMD. The components of drusen have also been found to have a potential   
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role in the uP regulation of vascular endothelial growth factor,
274 which leads to choroidal 
neovascularisation, the chief symptom of neovascular AMD. 
Inter-relationship between C2/CFB and CFH genes 
It  has  been previously  noted that the combined risk conferred by multiple  genetic risk 
factors can be considerably greater than the sum of the individual risks.
208 We explored the 
existence of C2/CFB-CFH additive and epistatic interaction in light of their involvement in 
a common biological pathway implicated in AMD development.  
The associations of C2/CFB SNPs with AMD subphenotypes were largely independent of 
CFH  Y402H  variant.  All  previously  significant  associations  remained  significant  when 
CFH Y402H status was added as a covariate, and when the C2/CFB:CFH interaction term 
was  introduced.  There  were  only  two  significant  multiplicative  interactions  observed 
between C2/CFB variants and CFH Y402H, occurring with the rs4151670 and rs9332735 
variants. The interaction between the CFH Y402H variant and each of these variants was 
such that the strength of the association between the variants and age of diagnosis was 
significantly increased.  
CFH is a key regulator of the complement cascade, in particular the alternate pathway. CFH 
inhibits the levels of C3b to ensure that the rate of C3b deposition does not exceed the 
body‟s requirements for innate immune function. CFB is required for the conversion of 
C3b to C3bB in the alternate pathway, and competes with CFH at this point. It is possible 
that if any interaction or dependence is observed between CFB and CFH, it may be a result 
of this direct competition.  
It is theorised that people with a risk variant of the CFH gene produce a less active CFH 
protein, thus  reducing the inhibition  of the alternate pathway and allowing superfluous   
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deposition  of  C3b.
134  The  errant  deposition  of  C3b  could  thus  trigger  the  damage  and 
destruction  of  host  cells.  C2  is  involved  in  both  the  lectin  and  classical  pathways  of 
complement activation, while CFB is involved in the alternate pathway. It is possible that a 
less  active  CFB  variant  could  bind  C3b  without  converting  it  to  C3bB  properly,  thus 
reducing the potential for superfluous complement deposition resulting from ineffective 
CFH inhibition of the alternative pathway.  
There is evidence to support the role of CFB variance in AMD pathogenesis. Gold et al. 
found a strong association between reduced risk of AMD and the rs641153 SNP (R32Q).
134 
The resulting variant CFB protein containing glutamine at position 32 has been shown to 
have  reduced  haemolytic  activity  compared  with  the  more  common  Arg32  form.
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Furthermore, the location of the rs4151667 (L9H) SNP in the signal peptide of CFB could 
cause  modulation  of  CFB  secretion;  a  functional  consequence  not  yet  demonstrated 
directly.
134 
5.2 Strengths of Study 
The  current  study  possessed  a  variety  of  strengths,  aptly  facilitating  this  research  and 
becoming a valuable resource for future investigations. 
This study‟s all-AMD study population allowed a much keener focus on AMD severity 
than  would  be  possible  in  studies  with  non-AMD  controls.  Additionally,  the  study 
population was rich in neovascular AMD cases, which are of great clinical concern due to 
the acuteness and severity of this AMD type, and the available treatment possibilities. Early 
AMD is fairly common, usually mild, and currently untreatable; and the majority of early 
AMD cases do not progress to neovascular or atrophic AMD during the lifetime of the   
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individual.  Currently  there  are  useful  treatments  such  as  anti-VEGF  drugs  for  only 
neovascular  AMD,  and  the  efficacy  of  such  treatments  is  greatly  enhanced  when  used 
promptly after development of CNV, and would be a logical preventative measure to be 
used before CNV has a chance to develop. Pre-emptive diagnosis of neovascular AMD in 
early AMD cases and at-risk elderly individuals has the potential to prevent acute and 
severe vision loss from neovascular AMD by utilizing anti-VEGF and other therapies to 
their best advantage. This supports the idea that currently it would be more practical and 
beneficial to identify individuals at particular risk of developing neovascular AMD rather 
than those at risk of developing AMD generally. 
Other  strengths  of  the  current  study  included  the  large  study  population,  and  the 
comprehensive data collected. The availability of DNA, sera and a wide range of detailed 
phenotypic data documenting ophthalmological details, demographics and relevant lifestyle 
factors makes the WAMDS a versatile and valuable resource for investigating a great many 
hypotheses. The large sample sizes lend good statistical power, facilitating analysis and 
detection of more subtle effects. Furthermore, the occurrences of genetic variants in this 
study population can be compared to those of other AMD study populations, and likewise 
those of the general population. Such comparisons will be potentially more useful when the 
available reference populations (such as HapMap-CEU) become larger.  
5.3 Potential Limitations 
Various aspects of this study brought potential limitations to the analyses. Consideration of 
inherent limitations follows, and any allowances made for these factors are discussed.   
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5.3.1 Aetiological Loci Versus Linkage Disquilibrium 
Due to the situation of the C2 and CFB genes within the MHC III locus with many other 
inflammation related genes, it may be possible that observed associations are due to LD 
with adjacent loci. Gold et al.
134 addresses this concern with several pieces of evidence, one 
of which related to the strength of earlier observed relationships between MHC loci and 
AMD.
134 The statistical significance observed in the current study between C2/CFB loci 
and AMD exceeds that observed between MHC loci and AMD. 
5.3.3 Statistical Power 
Some aspects of this study were insufficiently powered due to low numbers and/or low 
minor allele frequencies. For example, the relatively small number of atrophic AMD cases 
meant  that  the  analyses  dealing  with  the  atrophic  AMD  outcome  were  underpowered. 
Likewise, nearly half of all tested variants  had  minor allele  frequencies under 0.1 (i.e. 
10%), reducing the ability to detect associations with these variants. 
5.3.4 Population Stratification 
A  limitation  of  this  study  is  that  the  population  consisted  of  predominantly  European 
Australians,  thus  the  results  are  potentially  only  relevant  to  European  populations.  To 
address  these  issues,  the  association  of  C2/CFB  variations  with  AMD  sub-phenotypes 
should  be  investigated  in  further  replication  studies  in  other  ethnic  groups,  with  larger 
population sizes.  
Design of population-based genetic association studies is often compromised by false or 
nonreplicable  findings.  Population  stratification  is  the  presence  in  one  population  of 
subgroups that differ in allele frequencies and LD pattern due to systematic differences in 
ancestry,
239 and is a well-recognised cause of spurious gene-disease associations.   
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The  WAMDS  population  is  predominantly  Caucasian.  The  low  proportion  of  non-
Caucasian  subjects  (2.3%,  excluding  missing  data)  in  this  study  makes  population 
stratification unlikely to be of concern. Nevertheless, the potentially confounding effect of 
population stratification was investigated in this study by performing sensitivity analyses. 
The  results  of  the  sensitivity  analyses  showed  that  population  stratification  was  not  a 
significant factor in the current study analyses.  
5.3.5 Multiple Testing 
Though many significant associations between C2/CFB variants and AMD subphenotypes 
were observed initially, only the minority of these remained significant after adjustment for 
multiple testing. These associations could be usefully explored in replication studies in a 
larger study with a more focussed set of variants. 
The  FDR  approach  was  employed  to  correct  for  multiple  testing  as  opposed  to  the 
traditional method of Bonferroni correction. It was considered the non-null situation to be 
more realistic than the global null hypothesis (assumed by Bonferroni correction), given 
that multiple SNPs appeared to confer susceptibility in the current study and that a plausible 
biological mechanism exists to explain the observations. 
Nine of the many statistically significant associations (excluding interaction and sensitivity 
tests)  remained  significant  (p≤0.05)  following  FDR  correction,  suggesting  that  these 
observed associations are unlikely to be false positives. 
5.3.6 Additional Limitations 
These study findings can only be generalised to Caucasian populations, for two reasons. 
Firstly, WAMDS consists of predominantly Caucasian-Australians. Secondly, the nineteen   
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C2/CFB LD-selected tag SNPs  were chosen using the  HapMap-CEU data, which were 
collected from a sample containing subjects with Caucasian ancestry. Ideally, the results 
should be interpreted within the context of a population with a similar demography to that 
from which the tag SNPs were derived.  
The questionnaires used for data collection were not validated, but were largely composed 
of questions from existing validated questionnaires. This potential limitation applies more 
heavily to some of the more experimental questions that did not yield data suitable for 
analysis,  rather  than  the  more  useful  and  popular  questions.  The  provision  of  the 
questionnaires  in  the  appendices  enables  independent  scrutiny  of  each  question  and 
comparison with existing validated questionaires. 
Additionally, there was potential selection bias favouring survival and AMD severity; both 
of these factors can be partially attributed to exclusive study recruitment within a prominent 
tertiary eye clinic.  
5.4 Future Directions 
First and foremost, these study findings should be validated in larger and well-characterised 
populations of AMD cases of mixed severity, and in other ethnic groups, ideally using the 
same study design, analytical method, phenotype definition and genetic markers. Consistent 
replication will provide insurance against errors and biases that can unavoidably afflict any 
individual  study,  and  amplify  confidence  that  observed  associations  reflect  genuine 
biological processes rather than methodological inadequacies. 
More research is also needed to determine which functional C2/CFB variants are chiefly 
responsible for the associations with AMD subphenotypes observed in this study. Evidence   
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of functional associations will not only provide biological corroboration and enhance the 
likelihood that the statistical associations observed are genuine, but also shed light on the 
critical biological processes that are involved in AMD development and progression.  
Additional  gene-gene  interactions  will  be  explored  as  more  genotyping  data  becomes 
available  and  novel  variants  are  elucidated.  The  observed  interactions  between  some 
C2/CFB  variants  and  the  CFH  Y402H  variant  (with  regard  to  prediction  of  age  of 
diagnosis)  suggest  it  may  be  worth  investigating  possible  interactions  with  other  CFH 
variants,  and  refining  these  multivariate  models  could  provide  a  useful  predictor  of 
diagnosis  age  which  includes  both  the  C2/CFB  and  CFH  variants.  Also,  the  observed 
C2/CFB associations could be tested for independence from, and interactions with the CRP 
gene.  
The WAMDS project is ongoing and constantly evolving to adapt to the demands of AMD 
research.  In  terms  of  refining  the  collection  of  quality  phenotypic  data,  the  patient 
questionnaire  has  been  redeveloped  to  target  key  environmental  risk  factors,  to  allow 
greater efficiency and quality in future data collection. Regular periods of review ensure 
that the study aims and design are relevant to current AMD research. 
This  study  has  potential  as  a  basis  for  expansion  and/or  specialisation.  Serum  samples 
collected as part of the study could be utilised for relevant biochemical analyses. Newly 
recruited subjects  could be tested for local  Chlamydia and similar infections  to  further 
investigate the theory that such infections may stimulate the development of AMD.
276 The 
possibilities  for  extending  the  use  of  this  study  grow  as  the  field  of  AMD  research 
progresses.    
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5.5 Conclusion 
We  report  significant  associations  between  C2/CFB  genetic  variants  and  risk  of  AMD 
subphenotypes in a Caucasian population. The exact mechanism by which the associated 
C2/CFB genetic variants alter AMD differentiation is unclear, and future research is needed 
to  elucidate  the  functional  significance  of  these  polymorphisms.  We  also  demonstrate 
several novel associations between C2/CFB variants and various AMD phenotypes. These 
findings are clinically important and should be confirmed in larger well-characterised study 
populations. 
This  study  was  designed  to  investigate  whether  SNPs  in  the  C2  and  CFB  genes  were 
associated  with  AMD  severity  and  progression  in  a  large,  well-characterised  Western 
Australian population. It represents the largest comprehensive association study of these 
genes  yet  undertaken.  The  study  population,  exclusively  consisting  of  AMD  cases  of 
varying severity, allowed for a focussed examination of AMD severity and progression.   
Also, it should be noted that age at study was an important covariate due to the potential for 
early AMD to progress to late AMD with increasing age.  
This research builds on the findings of Gold et al.
134 in supporting the evidence for the role 
of the C2/CFB genes in AMD pathogenesis. Previous studies have supported the theory 
that it is primarily the alternative complement pathway involved in AMD pathogenesis, and 
that any apparent relationship with the C2 gene (not a member of the alternative pathway) 
is due largely to high LD with regions of the adjacent CFB gene. However, due to the role 
of  C2 in  regulating the production of C3 (a critical  complement pathway species), the 
possibility that C2 may also have a direct role in AMD pathogenesis cannot be ruled out.   
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The results of this study results support the theory that inflammatory and immunological 
processes  such  as  the  complement  cascade  are  central  to  AMD  pathogenesis  and 
subsequent  progression.  These  data  offer  new  insight  and  stimulation  for  further 
investigation into the pathogenesis of AMD. Given the relatively large genetic component 
underlying AMD, a pharmacogenetic approach to the discovery of novel preventive and 
therapeutic measures for AMD would be rational. I hope the end result of this research 
ultimately  will  be  the  ability  to  detect  AMD  risk  in  individuals  before  the  symptoms 
develop, and to provide a treatment (such as an implant) that will neutralise the imbalances 
that would normally predispose the individual to develop AMD. The social and economic 
benefits would extend far beyond the primary benefit of sight to the individual.  
In conclusion, this study provides new evidence for the important role of the C2/CFB genes 
in AMD pathogenesis and natural history. My results suggest that variants in the C2 and 
CFB genes may be important determinants of AMD clinical severity and prognosis. The 
mechanism of action is proposed to be via differential activation within the complement 
cascade.  
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Appendix E: Univariate Results 
Table E. 1: Fisher's Exact test of association of C2/CFB variants with Atrophic AMD 
versus Early AMD 
SNP  Fisher's P value 
rs1048709  0.60 
rs1270942  0.91 
rs2072633  0.36 
rs2072634  0.51 
rs3020644  0.14 
rs3130683  0.11 
rs4151657  0.20 
rs4151664  0.29 
rs4151670  0.47 
rs4151672  1.00 
rs429608  1.00 
rs512559  0.62 
rs537160  0.84 
rs547154  0.41 
rs644045  0.38 
rs7746553  1.00 
rs9267673  0.73 
rs9332735  0.47 
rs9501161  1.00   
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Table E. 2: Fisher's Exact test of association of C2/CFB variants with Retinal 
Scarring in Neovascular AMD 
SNP  Fisher's P value 
rs1048709  0.10 
rs1270942  0.71 
rs2072633  0.20 
rs2072634  0.61 
rs3020644  0.38 
rs3130683  0.11 
rs4151657  0.65 
rs4151664  0.62 
rs4151670  0.63 
rs4151672  0.85 
rs429608  0.85 
rs512559  0.75 
rs537160  0.10 
rs547154  0.89 
rs644045  0.36 
rs7746553  0.46 
rs9267673  0.55 
rs9332735  1.00 
rs9501161  0.35 
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Table E. 3:  Fisher's Exact test of association of C2/CFB variants with Legal Blindness 
in Early AMD 
SNP  Fisher's P value 
rs1048709  0.75 
rs1270942  1.00 
rs2072633  0.43 
rs2072634  1.00 
rs3020644  0.23 
rs3130683  1.00 
rs4151657  0.22 
rs4151664  1.00 
rs4151670  1.00 
rs4151672  0.32 
rs429608  1.00 
rs512559  1.00 
rs537160  1.00 
rs547154  0.60 
rs644045  1.00 
rs7746553  0.68 
rs9267673  0.61 
rs9332735  1.00 
rs9501161  1.00 
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Table E. 4: Fisher's Exact test of association of C2/CFB variants with low vision in 
WAMDS subjects 
SNP  Fisher's P value 
rs1048709  0.73 
rs1270942  0.74 
rs2072633  0.86 
rs2072634  0.64 
rs3020644  0.38 
rs3130683  0.18 
rs4151657  0.64 
rs4151664  0.33 
rs4151670  0.57 
rs4151672  0.40 
rs429608  0.54 
rs512559  0.16 
rs537160  0.89 
rs547154  0.20 
rs644045  0.63 
rs7746553  0.56 
rs9267673  0.57 
rs9332735  0.44 
rs9501161  0.48 
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Table E. 5: Fisher's Exact test of association of C2/CFB variants with Low Vision in 
Late AMD 
SNP  Fisher's P value 
rs1048709  0.80 
rs1270942  0.18 
rs2072633  0.75 
rs2072634  0.33 
rs3020644  0.06 
rs3130683  0.44 
rs4151657  0.30 
rs4151664  0.52 
rs4151670  1.00 
rs4151672  0.42 
rs429608  0.67 
rs512559  0.63 
rs537160  0.64 
rs547154  0.75 
rs644045  0.09 
rs7746553  1.00 
rs9267673  0.49 
rs9332735  1.00 
rs9501161  0.65 
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Table E. 6: Fisher's Exact test of association of C2/CFB variants with Low Vision in 
Early AMD 
SNP  Fisher's P value 
rs1048709  0.86 
rs1270942  0.24 
rs2072633  0.41 
rs2072634  1.00 
rs3020644  0.19 
rs3130683  0.85 
rs4151657  0.19 
rs4151664  0.80 
rs4151670  1.00 
rs4151672  1.00 
rs429608  0.51 
rs512559  0.22 
rs537160  0.76 
rs547154  0.09 
rs644045  0.12 
rs7746553  0.34 
rs9267673  0.39 
rs9332735  0.70 
rs9501161  1.00   
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Table E. 7: Kruskal Wallis univariate test of association of better eye Snellen visual 
acuity with C2/CFB genotypes. 
SNP  Test Statistic H  P value 
rs1048709  0.52  0.77 
rs1270942  0.26  0.88 
rs2072633  0.04  0.98 
rs2072634  0.42  0.52 
rs3020644  0.73  0.70 
rs3130683  1.97  0.37 
rs4151657  0.32  0.85 
rs4151664  1.34  0.51 
rs4151670  0.26  0.61 
rs4151672  1.52  0.47 
rs429608  0.41  0.81 
rs512559  5.54  0.06 
rs537160  0.03  0.98 
rs547154  5.51  0.06 
rs644045  0.78  0.68 
rs7746553  1.96  0.38 
rs9267673  0.06  0.97 
rs9332735  0.47  0.49 
rs9501161  0.55  0.76   
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Appendix F: Multivariate Results 
Table F. 1: Estimated odds ratios (OR) of late AMD for C2/CFB genetic variants 
among WAMDS subjects (continued on next page) 
SNP  Genotypes 
Late AMD
a 
Q value 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.5  0.73 
GA  1.24 (0.85, 1.80) 
AA  1.25 (0.49, 3.18) 
rs1270942 
TT  1 
0.98  0.98 
TC  1.00 (0.67, 1.49) 
CC  1.13 (0.28, 4.51) 
rs2072633 
CC  1 
0.38  0.73 
CT  0.93 (0.63, 1.37) 
TT  1.29 (0.77, 2.17) 
rs2072634
b 
GG  1 
0.15  0.73  GA + AA  2.80 (0.60, 13.03) 
rs3020644 
AA  1 
0.4  0.73 
AG  0.81 (0.55, 1.19) 
GG  0.73 (0.45, 1.20) 
rs3130683
b 
TT  1 
0.43  0.73  TC + CC  1.17 (0.79, 1.74) 
rs4151657 
TT  1 
0.41  0.73 
TC  0.79 (0.55, 1.14) 
CC  0.79 (0.46, 1.38) 
rs4151664
b 
CC  1 
0.38  0.73  CT + TT  1.25 (0.76, 2.04) 
rs4151670
b 
CC  1 
0.36  0.73  CT + TT  1.59 (0.58, 4.33) 
rs4151672 
CC  1 
0.5  0.73 
CT  0.63 (0.28, 1.44) 
TT  0.52 (0.05, 5.87) 
aLate AMD adjusted for age at study, gender, pack-years of smoking, and alcohol consumption 
bDominant model used due to low minor allele frequency   
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Table F. 1: Estimated odds ratios (OR) of late AMD for C2/CFB genetic variants 
among WAMDS subjects (continued from previous page) 
SNP  Genotypes 
Late AMD
a 
Q value 
OR (95% CI)  LR P value 
rs429608 
GG  1 
0.65  0.85 
GA  0.82 (0.52, 1.29) 
AA  1.28 (0.25, 6.55) 
rs512559
b 
TT  1 
0.15  0.73 
TC + CC  0.61 (0.31, 1.19) 
GA  1.08 (0.75, 1.56) 
AA  1.43 (0.80, 2.55) 
rs537160 
GG  1 
0.48  0.73 
GA  1.08 (0.75, 1.56) 
AA  1.43 (0.80, 2.55) 
rs547154
b 
CC  1 
0.96  0.98  CA + AA  0.99 (0.59, 1.66) 
rs644045 
GG  1 
0.67  0.85 
GA  1.08 (0.76, 1.56) 
AA  1.29 (0.73, 2.30) 
rs7746553 
CC  1 
0.06  0.73 
CG  1.11 (0.75, 1.64) 
GG  4.63 (1.02, 21.01) 
rs9267673
b 
CC  1 
0.45  0.73  CT + TT  1.18 (0.77, 1.80) 
rs9332735
b 
GG  1 
0.89  0.98  GA+ AA  1.07 (0.40, 2.84) 
rs9501161 
GG  1 
0.77  0.91 
GA  1.18 (0.71, 1.95) 
AA  0.67 (0.06, 7.91) 
aLate AMD adjusted for age at study, gender, pack-years of smoking, and alcohol consumption 
bDominant model used due to low minor allele frequency    
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Table F. 2 Estimated odds ratios of neovascular AMD versus early AMD for C2/CFB 
genetic variants (continued on next page) 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.33  0.52 
GA  1.30 (0.89, 1.90) 
AA  1.40 (0.55, 3.56) 
rs1270942 
TT  1 
0.95  0.99 
TC  1.00 (0.67, 1.51) 
CC  1.25 (0.32, 4.98) 
rs2072633 
CC  1 
0.29  0.52 
CT  0.99 (0.66, 1.46) 
TT  1.42 (0.84, 2.40) 
rs207263
b 
GG  1 
0.13  0.52  GA + AA  2.95 (0.63, 13.82) 
rs3020644 
AA  1 
0.16  0.52 
AG  0.75 (0.51, 1.10) 
GG  0.64 (0.39, 1.06) 
rs3130683
b 
TT  1 
0.26  0.52  TC + CC  1.26 (0.84, 1.88) 
rs4151657 
TT  1 
0.18  0.52 
TC  0.74 (0.51, 1.07) 
CC  0.67 (0.38, 1.18) 
rs4151664
b 
CC  1 
0.26  0.52  CT + TT  1.33 (0.80, 2.18) 
rs4151670
b 
CC  1 
0.32  0.52  CT + TT  1.65 (0.60, 4.53) 
rs4151672 
CC  1 
0.49  0.67 
CT  0.61 (0.26, 1.41) 
TT  0.61 (0.05, 6.85) 
aNeovascular AMD adjusted for age at study, gender, pack-years of smoking, and alcohol 
bDominant model used due to low minor allele frequency   
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Table F. 2 Estimated odds ratios of neovascular AMD versus early AMD for C2/CFB 
genetic variants (continued from previous page) 
SNP  Genotypes 
Neovascular AMD
a 
Q value 
OR (95% CI)  LR P value 
rs429608 
GG  1 
0.54  0.68 
GA  0.79 (0.50, 1.25) 
AA  1.44 (0.28, 7.33) 
rs512559
b 
TT  1 
0.14  0.52  TC + CC  0.59 (0.30, 1.18) 
rs537160 
GG  1 
0.33  0.52 
GA  1.13 (0.78, 1.64) 
AA  1.55 (0.86, 2.78) 
rs547154
b 
CC  1 
0.99  0.99  CA + AA  1.00 (0.59, 1.71) 
rs644045 
GG  1 
0.47  0.67 
GA  1.14 (0.79, 1.64) 
AA  1.42 (0.80, 2.55) 
rs7746553 
CC  1 
0.03  0.52 
CG  1.18 ( 0.79, 1.74) 
GG  5.14 (1.14, 23.25) 
rs9267673
b 
CC  1 
0.33  0.52  CT + TT  1.24 (0.80, 1.90) 
rs9332735
b 
GG  1 
0.84  0.94  GA+ AA  1.11 (0.41, 2.97) 
rs9501161 
GG  1 
0.69  0.82 
GA  1.24 (0.74, 2.05) 
AA  0.80 (0.07, 9.36) 
aNeovascular AMD adjusted for age at study, gender, pack-years of smoking, and alcohol 
bDominant model used due to low minor allele frequency 
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Table F. 3: Estimated odds ratios of atrophic AMD for C2/CFB genetic variants 
versus Early AMD (continues on next page) 
SNP  Genotypes 
Atrophic AMD
a 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.62  GA  0.74 (0.36, 1.52) 
AA  0.54 (0.06, 5.15) 
rs1270942
b 
TT  1 
0.52 
TC + CC  1.25 (0.63, 2.49) 
rs2072633 
CC  1 
0.66  CT  0.75 (0.38, 1.46) 
TT  0.72 (0.28, 1.88) 
rs2072634
† 
GG  1 
0.86 
GA + AA  1.27 (0.99, 16.34) 
rs3020644 
AA  1 
0.13  AG  2.13 (0.95, 4.77) 
GG  2.15 (0.83, 5.56) 
rs3130683
b 
TT  1 
0.16 
TC + CC  0.56 (0.24, 1.31) 
rs4151657 
TT  1 
0.19  TC  1.64 (0.79, 3.39) 
CC  2.32 (0.90, 6.02) 
rs4151664
b 
CC  1 
0.36 
CT + TT  1.29 (0.68, 2.47) 
rs4151670
b 
CC  1 
0.87 
CT + TT  1.22 (0.12, 12.47) 
aAtrophic AMD adjusted for age at study and smoking status  
bDominant model used due to low minor allele frequency   
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Table F. 3: Estimated odds ratios of atrophic AMD for C2/CFB genetic variants 
versus Early AMD (continued from previous page) 
SNP  Genotypes 
Atrophic AMD
a 
OR (95% CI)  LR P value 
rs4151672
b 
CC  1 
0.35 
CT + TT  0.49 (0.10, 2.41) 
rs429608
b 
GG  1 
0.92 
GA + AA  1.04 (0.48, 2.27) 
rs512559
b 
TT  1 
0.4 
TC + CC  0.61 (0.18, 2.03) 
rs537160 
GG  1 
0.96  GA  0.92 (0.48, 1.75) 
AA  0.91 (0.30, 2.79) 
rs547154
b 
CC  1 
0.54 
CA + AA  0.73 (0.27, 2.02) 
rs644045 
GG  1 
0.6  GA  0.89 (0.47, 1.69) 
AA  0.56 (0.17, 1.84) 
rs7746553
b 
CC  1 
0.29 
CG + GG  0.67 (0.32, 1.42) 
rs9267673
b 
CC  1 
0.56 
CT + TT  0.78 (0.33, 1.85) 
rs9332735
b 
GG  1 
0.93 
GA+ AA  1.11 (0.11, 10.81) 
rs9501161
b 
GG  1 
0.24 
GA + AA  0.56 (0.21, 1.53) 
aAtrophic AMD adjusted for age at study and smoking status  
bDominant model used due to low minor allele frequency 
   
  264 
Table F. 4: Estimated odds ratios of legal blindness for C2/CFB genetic variants 
among late AMD WAMDS subjects under codominant models (continued on next 
page) 
SNP  Genotypes 
Legal Blindness
a 
LR P value  Q value 
OR (95% CI) 
rs1048709 
GG  1 
0.19  0.70 
GA  0.72 (0.47, 1.12) 
AA  0.52 (0.18, 1.54) 
rs1270942 
TT  1 
0.57  0.72 
TC  0.79 (0.49, 1.29) 
CC  0.66 (0.14, 3.19) 
rs2072633 
CC  1 
0.42  0.70 
CT  1.01 (0.65, 1.56) 
TT  0.71 (0.39, 1.29) 
rs2072634
b 
GG  1 
0.35  0.70  GA + AA  1.80 (0.55, 5.87) 
rs3020644 
AA  1 
0.7  0.78 
AG  1.03 (0.68, 1.58) 
GG  0.81 (0.44, 1.48) 
rs3130683 
TT  1 
0.32  0.70 
TC  0.70 (0.43, 1.13) 
CC  0.92 (0.25, 3.35) 
rs4151657 
TT  1 
0.55  0.72 
TC  1.03 (0.68, 1.55) 
CC  0.71 (0.35, 1.44) 
rs4151664 
CC  1 
0.33  0.70 
CT  1.27 (0.74, 2.21) 
TT  3.57 (0.56, 22.61) 
rs4151670
b 
CC  1 
0.44  0.70  CT + TT  0.57 (0.13, 2.59) 
rs4151672
b 
CC  1 
0.78  0.82  CT + TT  0.88 (0.35, 2.22) 
 
 
aLegal blindness adjusted for age at study  
bDominant model used due to low minor allele frequency   
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Table F. 4: Estimated odds ratios of legal blindness for C2/CFB genetic variants 
among late AMD WAMDS subjects under codominant models (continued from 
previous page) 
aLegal blindness adjusted for age at study  
bDominant model used due to low minor allele frequency 
SNP  Genotypes 
Legal Blindness
a 
LR P value  Q value 
OR (95% CI) 
rs429608 
GG  1 
0.38  0.70 
GA  1.09 (0.64, 1.86) 
AA  2.61 (0.71, 9.69) 
rs512559
b 
TT  1 
0.99  0.99  TC + CC  1.00 (0.45, 2.26) 
rs537160 
GG  1 
0.15  0.70 
GA  0.95 (0.63, 1.44) 
AA  0.53 (0.27, 1.05) 
rs547154 
CC  1 
0.07  0.67 
CA  1.00 (0.52, 1.91) 
AA  11.72 (1.18, 116.31) 
rs644045 
GG  1 
0.34  0.70 
GA  0.75 (0.49, 1.13) 
AA  0.75 (0.39, 1.42) 
rs7746553 
CC  1 
0.03  0.57 
CG  1.53 (1.01, 2.32) 
GG  2.98 (1.07, 8.32) 
rs9267673 
CC  1 
0.32  0.70 
CT  1.36 (0.85, 2.17) 
TT  2.25 (0.42, 12.01) 
rs9332735
b 
GG  1 
0.5  0.72  GA+ AA  0.61 (0.13, 2.79) 
rs9501161 
GG  1 
0.66  0.78 
GA  1.27 (0.77, 2.09) 
AA  1.07 (0.11, 10.59) 
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Table F. 5: Estimated odds ratios of low vision for C2/CFB genetic variants among 
WAMDS subjects under codominant models (continued on next page) 
SNP  Genotypes 
Low Vision
a 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.64 
GA  1.11 (0.80, 1.53) 
AA  1.37 (0.63, 2.96) 
rs1270942 
TT  1 
0.88 
TC  1.02 (0.71, 1.45) 
CC  1.36 (0.41, 4.59) 
rs2072633 
CC  1 
0.52 
CT  0.93 (0.66, 1.31) 
TT  1.18 (0.76, 1.84) 
rs2072634
b  GG  1 
0.38  GA + AA  0.63 (0.22, 1.80) 
rs3020644 
AA  1 
0.09 
AG  1.12 (0.80, 1.57) 
GG  0.71 (0.46, 1.10) 
rs3130683 
TT  1 
0.4 
TC  1.19 (0.84, 1.68) 
CC  1.94 (0.55, 6.86) 
rs4151657 
TT  1 
0.41 
TC  0.95 (0.69, 1.30) 
CC  0.72 (0.44, 1.18) 
rs4151664 
CC  1 
0.15 
CT  1.24 (0.80, 1.93) 
TT  6.50 (0.65, 65.00) 
rs4151670
b  CC  1 
0.72  CT + TT  1.18 (0.49, 2.84) 
rs4151672
b  CC  1 
0.22  CT + TT  0.63 (0.30, 1.32) 
aLow vision adjusted for age at study and pack-years of smoking  
bDominant model used due to low minor allele frequency   
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Table F. 5: Estimated odds ratios of low vision for C2/CFB genetic variants among 
WAMDS subjects under codominant models (continued from previous page) 
SNP  Genotypes 
Low Vision
a 
OR (95% CI)  LR P value 
rs429608 
GG  1 
0.26 
GA  1.00 (0.67, 1.51) 
AA  0.29 (0.06, 1.45) 
rs512559
b  TT  1 
0.98  TC + CC  1.01 (0.53, 1.92) 
rs537160 
GG  1 
0.96 
GA  1.01 (0.74, 1.40) 
AA  1.07 (0.65, 1.75) 
rs547154 
CC  1 
0.85 
CA  0.95 (0.59, 1.54) 
AA  1.86 (0.17, 20.64) 
rs644045 
GG  1 
0.28 
GA  1.13 (0.82, 1.56) 
AA  1.50 (0.91, 2.49) 
rs7746553 
CC  1 
0.59 
CG  1.00 (0.72, 1.40) 
GG  1.67 (0.63, 4.41) 
rs9267673 
CC  1 
0.53 
CT  1.07 (0.73, 1.56) 
TT  2.59 (0.47, 14.17) 
rs9332735
b  GG  1 
0.96  GA+ AA  0.98 (0.40, 2.41) 
rs9501161 
GG  1 
0.9 
GA  1.05 (0.69, 1.61) 
AA  1.66 (0.14, 19.09) 
aLow vision adjusted for age at study and pack-years of smoking  
bDominant model used due to low minor allele frequency   
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Table F. 6: Estimated odds ratios of low vision for C2/CFB genetic variants among 
late AMD WAMDS subjects under codominant models (continued on next page) 
SNP  Genotypes 
Low Vision
a 
LR P value  Q value 
OR (95% CI) 
rs1048709 
GG  1 
0.64  0.87 
GA  1.04 (0.74, 1.46) 
AA  1.43 (0.67, 3.06) 
rs1270942 
TT  1 
0.32  0.87 
TC  1.25 (0.85, 1.82) 
CC  2.07 (0.52, 8.22) 
rs2072633 
CC  1 
0.63  0.87 
CT  1.08 (0.75, 1.54) 
TT  1.25 (0.79, 1.98) 
rs2072634
b 
GG  1 
0.49  0.87  GA + AA  0.69 (0.24, 1.99) 
rs3020644 
AA  1 
0.05  0.57 
AG  0.99 (0.70, 1.40) 
GG  0.59 (0.37, 0.94) 
rs3130683 
TT  1 
0.19  0.87 
TC  1.23 (0.85, 1.78) 
CC  2.27 (0.78, 6.57) 
rs4151657 
TT  1 
0.16  0.87 
TC  0.89 (0.64, 1.25) 
CC  0.60 (0.35, 1.01) 
rs4151664 
CC  1 
0.28  0.87 
CT  1.14 (0.72, 1.79) 
TT  4.64 (0.50, 43.24) 
rs4151670
b 
CC  1 
0.82  0.87  CT + TT  1.12 (0.42, 2.99) 
rs4151672
b 
CC  1 
0.24  0.87  CT + TT  0.64 (0.31, 1.35) 
aLow vision adjusted for age at study and prior CNV treatment 
bDominant model used due to low minor allele frequency   
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Table F. 6: Estimated odds ratios of low vision for C2/CFB genetic variants among 
late AMD WAMDS subjects under codominant models (continued from previous 
page) 
SNP  Genotypes 
Low Vision
a 
LR P value  Q value 
OR (95% CI) 
rs429608 
GG  1 
0.61  0.87 
GA  1.00 (0.65, 1.53) 
AA  0.52 (0.14, 1.92) 
rs512559
b 
TT  1 
0.81  0.87  TC + CC  1.09 (0.56, 2.10) 
rs537160 
GG  1 
0.68  0.87 
GA  1.14 (0.81, 1.60) 
AA  1.18 (0.73, 1.93) 
rs547154 
CC  1 
0.73  0.87 
CA  1.01 (0.61, 1.68) 
AA  2.41 (0.24, 23.94) 
rs644045 
GG  1 
0.06  0.57 
GA  1.25 (0.90, 1.75) 
AA  1.82 (1.09, 3.05) 
rs7746553 
CC  1 
0.61  0.87 
CG  1.02 (0.72, 1.44) 
GG  1.60 (0.63, 4.03) 
rs9267673 
CC  1 
0.4  0.87 
CT  0.88 (0.60, 1.31) 
TT  2.42 (0.53, 11.12) 
rs9332735
b 
GG  1 
0.97  0.97  GA+ AA  1.02 (0.36, 2.87) 
rs9501161 
GG  1 
0.79  0.87 
GA  1.07 (0.70, 1.63) 
AA  1.99 (0.20, 19.67) 
aLow vision adjusted for age at study and prior CNV treatment  
bDominant model used due to low minor allele frequency    
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Table F. 7: Estimated odds ratios of low vision for C2/CFB genetic variants among 
Early AMD WAMDS subjects under codominant models (continued on next page) 
SNP  Genotypes 
Low Vision
a 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.69 
GA  1.49 (0.60, 3.67) 
AA  1.16 (0.11, 11.71) 
rs1270942
b  TT  1 
0.9  TC + CC  0.94 (0.34, 2.54) 
rs2072633 
CC  1 
0.98 
CT  1.03 (0.41, 2.58) 
TT  1.14 (0.32, 4.02) 
rs2072634
b  GG  1 
c  GA + AA  c 
rs3020644 
AA  1 
0.85 
AG  1.32 (0.49, 3.56) 
GG  1.12 (0.34, 3.71) 
rs3130683
b  TT  1 
0.29  TC + CC  1.68 (0.65, 4.35) 
rs4151657 
TT  1 
0.56 
TC  1.64 (0.64, 4.21) 
CC  1.15 (0.30, 4.38) 
rs4151664
b  CC  1 
0.5  CT + TT  1.54 (0.45, 5.34) 
rs4151670
b  CC  1 
c  CT + TT  c 
rs4151672
b  CC  1 
0.69  CT + TT  0.71 (0.13, 4.01) 
aLow vision adjusted for age at study, alcohol consumption, NSAID use and smoking status  
bDominant model used due to low minor allele frequency   
cA model was unable to be fitted due to low frequency of the minor allele   
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Table F. 7: Estimated odds ratios of low vision for C2/CFB genetic variants among 
Early AMD WAMDS subjects under codominant models (continued from previous 
page) 
SNP  Genotypes 
Low Vision
a 
OR (95% CI)  LR P value 
rs429608
b 
GG  1 
0.19  GA + AA  0.46 (0.13, 1.57) 
rs512559
b  TT  1 
0.1  TC + CC  0.21 (0.02, 1.90) 
rs537160 
GG  1 
0.8 
GA  1.33 (0.55, 3.21) 
AA  1.33 (0.31, 5.75) 
rs547154
b 
CC  1 
0.05  CA + AA  0.17 (0.02, 1.44) 
rs644045 
GG  1 
0.96 
GA  0.91 (0.38, 2.19) 
AA  1.11 (0.26, 4.67) 
rs7746553
b  CC  1 
0.93  CG + GG  0.96 (0.37, 2.46) 
rs9267673
b  CC  1 
0.22  CT + TT  1.90 (0.69, 5.18) 
rs9332735
b  GG  1 
c  GA+ AA  c 
rs9501161
b  GG  1 
0.13  GA + AA  0.35 (0.08, 1.54) 
aLow vision adjusted for age at study, alcohol consumption, NSAID use and smoking status  
bDominant model used due to low minor allele frequency   
cA model was unable to be fitted due to low frequency of the minor allele 
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Table F. 8: Estimated odds ratios of retinal detachment for C2/CFB genetic variants 
among neovascular AMD WAMDS subjects under codominant models (continued on 
next page) 
SNP  Genotypes 
Retinal Detachment
a 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.97 
GA  1.05 (0.70, 1.57) 
AA  0.98 (0.40, 2.42) 
rs1270942 
TT  1 
0.42 
TC  0.80 (0.51, 1.25) 
CC  0.48 (0.09, 2.46) 
rs2072633 
CC  1 
0.33 
CT  0.75 (0.49, 1.15) 
TT  0.71 (0.41, 1.23) 
rs2072634
b  GG  1 
0.26  GA + AA  0.49 (0.13, 1.83) 
rs3020644 
AA  1 
0.59 
AG  1.17 (0.77, 1.76) 
GG  0.91 (0.53, 1.56) 
rs3130683 
TT  1 
0.54 
TC  1.06 (0.69, 1.62) 
CC  0.46 (0.10, 2.18) 
rs4151657 
TT  1 
0.76 
TC  1.14 (0.77, 1.70) 
CC  0.97 (0.52, 1.80) 
rs4151664 
CC  1 
0.99 
CT  0.99 (0.58, 1.70) 
TT  1.13 (0.18, 7.17) 
rs4151670
b  CC  1 
0.21  CT + TT  0.46 (0.12, 1.68) 
rs4151672
b 
CC  1 
0.06  CT + TT  2.41 (0.98, 5.93) 
aRetinal detachment adjusted for prior CNV treatment and alcohol consumption 
bDominant model used due to low minor allele frequency   
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Table F. 8: Estimated odds ratios of retinal detachment for C2/CFB genetic variants 
among neovascular AMD WAMDS subjects under codominant models (continued 
from previous page) 
SNP  Genotypes 
Retinal Detachment
a 
OR (95% CI)  LR P value 
rs429608
b 
GG  1 
0.39  GA + AA  1.25 (0.75, 2.09) 
rs512559
b  TT  1 
0.29  TC + CC  0.60 (0.23, 1.58) 
rs537160 
GG  1 
0.91 
GA  0.92 (0.61, 1.37) 
AA  0.98 (0.55, 1.75) 
rs547154
b 
CC  1 
0.07  CA + AA  0.55 (0.28, 1.07) 
rs644045 
GG  1 
0.35 
GA  0.85 (0.57, 1.27) 
AA  0.64 (0.33, 1.21) 
rs7746553 
CC  1 
0.9 
CG  0.92 (0.61, 1.39) 
GG  0.88 (0.32, 2.44) 
rs9267673 
CC  1 
0.78 
CT  0.89 (0.56, 1.42) 
TT  0.65 (0.12, 3.52) 
rs9332735
b  GG  1 
0.15  GA+ AA  0.36 (0.08, 1.68) 
rs9501161
b  GG  1 
0.16  GA +AA  1.43 (0.88, 2.32) 
aRetinal detachment adjusted for prior CNV treatment and alcohol consumption 
bDominant model used due to low minor allele frequency   
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Table F. 9: Estimated odds ratios of retinal scarring for C2/CFB genetic variants 
among neovascular AMD WAMDS subjects under codominant models (continued on 
next page) 
SNP  Genotypes 
Retinal Scar Tissue
a 
OR (95% CI)  LR P value 
rs1048709 
GG  1 
0.51 
GA  0.79 (0.53, 1.18) 
AA  0.87 ( 0.35, 2.19) 
rs1270942 
TT  1 
0.74 
TC  1.11 (0.72, 1.74) 
CC  1.56 (0.40, 6.08) 
rs2072633 
CC  1 
0.46 
CT  0.83 (0.53, 1.28) 
TT  0.71 (0.41, 1.23) 
rs2072634
b  GG  1 
0.47  GA + AA  1.53 (0.48, 4.85) 
rs3020644 
AA  1 
0.51 
AG  1.08 (0.72, 1.64) 
GG  0.80 (0.47, 1.36) 
rs3130683 
TT  1 
0.21 
TC  0.72 (0.47, 1.11) 
CC  0.47 (0.11, 1.96) 
rs4151657 
TT  1 
0.79 
TC  1.15 (0.77, 1.71) 
CC  1.04 (0.57, 1.90) 
rs4151664 
CC  1 
0.46 
CT  1.43 (0.81, 2.51) 
TT  0.83 (0.11, 6.23) 
rs4151670
b  CC  1 
0.91  CT + TT  1.06 (0.37, 3.05) 
rs4151672 
CC  1 
0.87 
CT  0.78 (0.29, 2.16) 
TT  1.37 (0.08, 22.60) 
aRetinal scar tissue adjusted for gender, cholesterol medication and pack years of smoking 
bDominant model used due to low minor allele frequency   
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Table F. 9: Estimated odds ratios of retinal scarring for C2/CFB genetic variants 
among neovascular AMD WAMDS subjects under codominant models (continued 
from previous page) 
SNP  Genotypes 
Retinal Scar Tissue
a 
OR (95% CI)  LR P value 
rs429608 
GG  1 
0.58 
GA  1.31 (0.77, 2.24) 
AA  0.76 (0.12, 4.86) 
rs512559
b  TT  1 
0.14  TC + CC  2.08 (0.79, 5.47) 
rs537160 
GG  1 
0.37 
GA  0.79 (0.53, 1.19) 
AA  0.69 (0.38, 1.24) 
rs547154 
CC  1 
0.68 
CA  1.32 (0.71, 2.45) 
AA  0.96 (0.051, 17.78) 
rs644045 
GG  1 
0.38 
GA  0.80 (0.53, 1.19) 
AA  1.12 (0.61, 2.07) 
rs7746553 
CC  1 
0.8 
CG  1.11 (0.73, 1.69) 
GG  1.30 (0.47, 3.59) 
rs9267673 
CC  1 
0.52 
CT  1.32 (0.82, 2.13) 
TT  0.94 (0.18, 4.85) 
rs9332735
b  GG  1 
0.67  GA+ AA  0.78 (0.25, 2.44) 
rs9501161
b  GG  1 
0.75  GA + AA  0.92 (0.55, 1.53) 
aRetinal scar tissue adjusted for gender, cholesterol medication and pack years of smoking 
bDominant model used due to low minor allele frequency 
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